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HEAD AND NECK SQUAMOUS CELL CARCINOMA 
 
Epidemiology  
Head and neck cancer consists of a heterogeneous group of lesions that arise in the 
upper aerodigestive tract, which includes the oral cavity, pharynx (nasopharynx 
oropharynx and hypopharynx) and larynx (Figure 1) [1]. The majority of these 
neoplasms (90 percent) are head and neck squamous cell carcinomas (HNSCC) that 
develop in the squamous layer of the mucosal lining. HNSCC develops in the middle-
aged population, with the highest incidence in the sixth decade of life. Even though 
our knowledge about HNSCC has increased significantly, the survival rate has 
improved modestly during the last 20 years [2]. 
The incidence of HNSCC varies globally. Although the precise reasons are not 
known, this variation likely reflects worldwide ethnic, cultural and socio-economical 
differences [3]. Exemplary is the incidence of nasopharyngeal cancer (NPC), which is 
highest in Southeast Asia, whereas, in Western countries the oral cavity, the pharynx 
and the larynx are the most preferential sites [4;5]. All together, there are 
approximately 500,000 new cases of HNSCC worldwide [4]. In the Netherlands 
approximately 2,400 cases are yearly diagnosed. Particularly in females, the 
incidence of HNSCC in the Netherlands is still rising, presumably related to an 
increase in tobacco-smoking, one of the major risk factors of HNSCC (see also 
below). Vice versa, in the United States a decrease in tobacco-smoking seems to 
cause a reduction of the incidence of HNSCC [6], except for tonsillar cancer of which 
the occurrence is increasing particularly among men.  
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Figure 1. The upper aerodigestive tract  
 
Risk Factors 
 
Tobacco smoking and Alcohol 
The major risk factors for the development of HNSCC are life-style factors, most 
notably tobacco smoking and alcohol consumption [7]. Tobacco smoking and alcohol 
consumption are independent risk factors, but have a synergistic effect when 
combined [8-12]. The relative risk appears to be related to the time of exposure [13]. 
Nicotine and tar are not the only harmful ingredients; over 4,000 chemicals have 
been identified in cigarette smoke. Carcinogens from tobacco smoking, for example 
benz-(a)-pyrene and nitrosamines, are known to produce the precise types of 
guanine nucleotide transversions causing mutations in cancer genes that are 
involved in HNSCC development [13-15].  
Together with tobacco, alcohol is the most abundantly consumed noxious compound 
worldwide [16]. There is convincing evidence that acetaldehyde, the first metabolite 
produced during alcohol degradation, is responsible for the carcinogenic effect of 
ethanol on the upper aerodigestive tract due to its multiple mutagenic effects on DNA 
[17;18]. Ethanol may also stimulate carcinogenesis by inhibiting DNA methylation 
and by interacting with retinoid metabolism [19;20]. Another source of potent 
carcinogens originates from chewing tobaccos or betel nuts, but these habits are rare 
in Western countries [21].  
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Human papillomavirus 
In recent years human papillomavirus (HPV) was found to be involved in a subset of 
HNSCC [22;23], and sexual transmission is suggested to cause the infection [24-27]. 
In cervical carcinomas HPV is found in nearly all cases [28] and its causal 
involvement is widely accepted [29], but the situation in HNSCC is less clear.  
HPV is a DNA virus with a genome of approximately 7.9 kilobase pairs in size, with 
more than 100 subtypes identified. Only 14 types are oncogenic, referred to as high-
risk types (hrHPV). HrHPV produces two oncoproteins, encoded by the E6 and E7 
genes, that inactivate the p53 and pRb proteins, respectively, allowing cell cycle 
entry and a DNA synthesis environment needed for viral replication. HPV16-E6 
interacts besides p53 with a large number of other cellular proteins [33]. The direct 
targeting of the p53 protein via E6AP by HPV16-E6 for proteasome-mediated 
degradation is well characterized, but the direct binding to proteins with a PDZ-
binding motif like Scribble, MAGI-1,2,3, MUPP1 and Dlg, is less investigated. These 
proteins are mainly involved in cell signaling, cell adhesion and possibly tumor 
suppressor activity [30-32]. HPV-E7 interacts besides pRb, also with its family 
members p107 and p130. HPV-E7 further interacts with other proteins such as 
HDACs 1, 2, 3, 8, the cyclin-dependent kinase inhibitors p21CIP1 and p27kip1, and 
histone acetylase p300 [33]. The intensive research on the role of HPV in cervical 
carcinomas has instigated studies on the prevention or treatment of HPV–induced 
cancers using preventive and therapeutic vaccines [34]. Particularly the preventive 
vaccination seems very successful in reducing HPV16 infection in young women 
[35;36].  
The reported prevalence of high-risk HPV DNA in HNSCC tumor specimens varies 
tremendously between studies ranging from 0 to 100% [27;37]. The most commonly 
detected HPV-type in HNSCC is HPV16, which has been demonstrated in 90-95% of 
all HPV-positive HNSCC, followed by HPV18 and HPV33. Part of the variation in 
HPV prevalence can be explained by differences with regard to the location of the 
tumor, i.e. it is relatively low in the oral cavity and high in the tonsil [22;23;38;39]. 
More importantly, variations in the type of tissue material studied and the HPV 
detection methods used, seem to have a major impact on the discrepancy in reported 
prevalence rates [22;37;40]. Frequently PCR methods are employed that detect HPV 
DNA. A major problem with these assays is that they are extremely sensitive causing 
false positive results. Sample to sample contaminations and transient infections 
might all cause positive HPV DNA assays, while they do not reflect a true oncogenic 
infection. Based on this problem we focused previously on the detection of HPV E6 
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and E7 transcripts, and showed that of 24 HPV DNA positive cases only 12 reflected 
an oncogenic infection as determined by E6 RT-PCR [41]. This approach was 
substantiated by the recent finding that tumors containing transcriptionally active 
HPV are genetically different from those that do not contain HPV and that arose most 
likely as a result from exposure to environmental carcinogens [23]. Tumors with 
transcriptionally active HPV did not show any TP53 mutation and displayed very 
limited allelic losses at 3p, 9p and 17p. In contrast, in tumors not containing HPV a 
TP53 mutation had occurred in 75% of the cases and very frequent allelic losses 
were found [23]. These results suggest that an infection with HPV is an early event in 
HNSCC development that persists throughout the entire period of cancer 
progression. Moreover, the disruption of the pRb and p53 pathways by HPV 
oncoproteins is reflected in a unique genotype of the resulting tumors. Although 
indirectly, these data support the view that particularly tumor with transcriptionally 
active HPV are a separate entity, an observation in line with the known biological 
properties of the virus in cervical carcinogenesis. There is evidence suggesting that 
patients with HPV-positive HNSCC have a more favourable prognosis, than those 
with HPV-negative HNSCC [40;42-44]. However, in a recent meta-analysis showed 
this was still not clear. A major problem in this respect is that there is no consensus 
on how HPV should be detected. 
 
Genetic predispostion 
Defects in DNA repair processes are associated with a high HNSCC cancer risk [45]. 
One example is Fanconi Anemia (FA). Patients suffering from FA, as a result of a 
defect in one of the FANC genes, have a very high risk to develop oral and 
oropharyngeal carcinoma at early age [46]. Some studies have shown that HNSCC 
shows a familial clustering, indicative for a susceptibility to HNSCC with a genetic 
basis [47;48]. The search for cancer-predisposing genes is ongoing, with functional 
tests and large scale genome-wide association studies as tools [47]. It is very likely 
that a combination of certain alleles of these cancer predisposing genes determines 
the risk for cancer.  
 
CHAPTER 1 
 
12 
Clinical and histopathological staging 
Head and neck squamous cell carcinomas are classified according to the TNM 
system of the ‘International Union Against Cancer’ (UICC) [50]. The TNM anatomical 
staging is based on the assessment of three components: the extent of the primary 
tumor (T), the absence or presence and extent of regional lymph node metastases 
(N), and the absence or presence of distant metastases (M). Two classifications are 
used: (a) clinical classification (pre-treatment clinical classification), based on 
evidence acquired before treatment, e.g. from physical examination, imaging, 
endoscopy, biopsy and ultrasound-guided fine needle aspiration cytology 
(USgFNAC), and (b) pathological classification (post-surgical histopathological 
classification), based on histopathological examination of the resection specimen. 
Based on the TNM classification, a clinical stage is used to group tumors with 
comparable clinical prognosis. Patients are classified into four clinical stages I-IV. 
Stages I and II represent early stages of the disease, with relative small tumors and 
no lymph node metastases. Stages III and IV represent more advanced stages of 
HNSCC with larger tumors that have spread to regional lymph nodes or secondary 
organs. For HNSCC patients TNM staging is strongly associated with survival 
although individual patients with similar TNM stage may differ significantly in clinical 
outcome and response to specific treatment. This indicates room for an improved 
staging system, one that is perhaps based on molecular characteristics, to more 
accurately predict disease progression and treatment response. 
 
Treatment and prognosis 
In general, one-third of the HNSCC patients presents with early stage (I and II) 
disease, while two-third presents with advanced disease (stage III and IV) [51]. The 
vast majority of patients with early stage HNSCC can be cured with single modality 
treatment (surgery or radiotherapy) focussed only at the tumor site. Patients with 
advanced stages are mostly treated with a combination of surgery and (chemo-
)radiotherapy or increasingly with combined chemo-radiation, but the prognosis 
remains relatively modest or poor.  
Despite major improvements in surgical techniques and radiotherapy in HNSCC 
treatment, the long term survival of HNSCC patients has only moderately improved 
during the last 20 years [2]. An important reason for this lack of progress is the 
relatively high locoregional recurrence rates observed in these patients. Local 
recurrences occur in about 10 to 30% of the cases, even when the surgical margins 
are histologically tumor-free [52]. Moreover, 10 to 20% of the patients develop 
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regional recurrences and 15 to 25% distant metastases [53]. Finally, HNSCC patients 
frequently develop second primary tumors (SPT) in the upper aerodigestive tract [54]. 
These SPT develop on average with a constant rate of 2 to 3% per year [55].  
Disease staging is strongly associated with survival, but tumors with similar TNM 
stage may differ significantly in response to treatment. Currently, systemic therapy 
including chemotherapy and molecularly targeted agents, like the epidermal growth 
factor receptor inhibitors, angiogenesis inhibitors and other molecularly targeted 
agents, has been successfully integrated into curative treatment of locoregionally 
advanced HNSCC [56]. One shortcoming is that the majority of the clinical trails are 
based on an ‘one size fits all’ approach and treatment is not tailored to the patient. 
Although many clinical-pathological variables and molecular markers (e.q.EGFR 
expression and HPV) are of prognostic value, wide heterogeneity in clinical outcomes 
is seen, implicating the necessity of standardization of established and additional 
biomarkers that will guide treatment decisions. Advances in basic research and 
applications of genomic profiling are expected to provide powerful methods for the 
individualisation of treatment approaches in HNSCC patients.  
 
HNSCC carcinogenesis 
It is generally accepted that HNSCC develops by an accumulation of genetic 
alterations. These genetic alterations result in inactivation of tumour suppressor 
genes and activation of proto-oncogenes by deletions, point mutations, promoter 
methylation, or gene amplification. These genetic changes have been identified in 
HNSCC by a variety of methods, including conventional cytogenetic karyotyping, loss 
of heterozygosity (LOH) analysis [57] and comparative genomic hybridization (CGH) 
[58;59]. HNSCC develops through a number of precursor stages. Most premalignant 
changes can be recognized histologically as dysplasia in the mucosal epithelium 
graded as mild, moderate and severe. By genetic analysis of these histologically 
defined preneoplastic changes and invasive tumours Califano et al. presented the 
first genetic progression model for HNSCC [60] This model was adapted and 
simplified by Braakhuis et al. [61] (Figure 2). 
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Allelic loss of the chromosomal regions 3p, 9p21 and 17p13 are considered to be 
altered at an early phase in HNSCC carcinogenesis, as they are found in 60–80% of 
the preneoplastic lesions and invasive HNSCC [61-65]. Amplification of chromosomal 
region 11q13 is found with a lower frequency in preneoplastic lesions, but is present 
in 70% of primary HNSCC tumors. Some alterations of chromosomal regions are 
identified as prognosticator of outcome in HNSCC, including amplification at 11q13, 
gain of 12q24, and losses at 5q11, 6q14, and 21q11 [66]. 
Many potential cancer genes are suggested to be localized at the frequently altered 
chromosomal regions. The gene locus found in chromosome 9p21 encodes two 
different transcripts, p16Ink4A and p14ARF, which are responsible for G1 cell cycle 
regulation and MDM2 mediated degradation of p53, respectively. P16 is often 
inactivated in HNSCC through homozygous deletion, by promoter methylation, and 
less commonly by point mutations [67]. On 3p it is difficult to pinpoint a potential 
cancer gene, since in most cases a large part or whole chromosomal p-arm is lost, 
making characterization of the specific locus responsible for the tumour suppressor 
phenotype almost impossible. One candidate tumor suppressor gene at this 
chromosomal area is FHIT, which has been found to be inactivated by exonic 
deletions in many tumour types, including a small percentage of HNSCC [68;69]. The 
TP53 gene is located on the short arm of chromosome 17 (17p13) and is important 
for maintaining genomic stability. Mutation of TP53, often accompanied with allelic 
loss of 17p13, is the most common genetic event in human tumors, including head 
and neck cancer [70-72]. Inactivation of p53 leads to a loss of the G1/S phase cell 
 
Figure 2. HNSCC progression model. Braakhuis et al. suggested an adapted progression model for 
cancer in the head and neck. A stem cell acquires one or more genetic alterations and forms a patch, a 
small cluster of less than 200 cells in diameter that can be detected by p53 immunostaining. Eventually 
the stem cell escapes normal growth control. A precursor lesion arises and laterally displaces the 
normal mucosa. Additional genetic hits give rise to different subclones within a field and eventually a 
subclone evolves into invasive cancer [61].  
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cycle checkpoint and as a result cells continue dividing without pausing to repair DNA 
damage [73]. Besides increasing the risk for developing HNSCC, inactivation of p53 
makes the tumor less sensitive to radiotherapy and chemopreventive strategies 
[74;75]. P63, a p53 homologue located on 3q28 with oncogenic properties is 
frequently amplified in HNSCC [76]. Mutation of TP53 can lead to overexpression 
and accumulation of truncated p53 within the cells, making detection of the mutated 
form with immunostaining possible. Sequence analysis and immunostaining on 
dysplastic lesions have shown that the gene is often mutated before the invasive 
cancer develops, making it an early marker for progression.  
In addition, amplification of 11q13 is linked with overexpression of Cyclin D1 and has 
been associated with an increased rate of lymph node metastases and overall poor 
prognosis [77;78]. Cyclin D1 induces phosphorylation of Rb, thus enabling 
progression from G1 to S phase.  
Other potential cancer genes in HNSCC are DCC and SSCRO. DCC, located on 
18q21, is commonly deleted in colorectal cancer and is inactivated in HNSCC by 
hypermethylation of its promoter [79;80]. SSCRO, also known as DCUN1D1, is 
located on 3q26.3 and often amplified in HNSCC. Amplification and overexpression 
of SCCRO correlates with poor clinical outcome and the oncogenic potential of 
SCCRO is underscored by its ability to transform fibroblasts (NIH-3T3 cells) in vitro 
and in vivo [81]. Finally, overexpression of epidermal growth factor receptor (EGFR) 
and its ligands is an important feature of HNSCC cancer with up to 80% of HNSCC 
showing elevated EGFR mRNA levels compared to normal mucosa [81;82].  
Taken together, the current findings provide evidence that many genetic alterations 
are necessary to drive the progression from a normal cell to a cancer cell. To pinpoint 
the causative genes located in the altered chromosomal regions is hampered 
severely by a number of reasons. First, the majority of the HNSCC have a 
chromosomal instability phenotype, resulting in gains and losses of large parts or 
even whole chromosomes. As a consequence, many DNA changes or differentially 
expressed genes may be considered as a result and not a cause of carcinogenesis. 
It is therefore of utmost importance to discriminate the carcinogenic ‘driving’ from the 
‘passenger’ genetic events [83]. Second, the data provided is based on the findings 
with ‘low resolution methods’ as LOH analysis, multiplex ligation-dependent probe 
amplification (MLPA) or conventional CGH that do not allow to identification of causal 
genes. 
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Micro Array Comparative genomic hybridization 
The recent completion of the Human Genome Project combined with polymerase 
chain reaction (PCR)-based genomic evaluation techniques has contributed 
tremendously to the analysis of chromosomal aberration in solid tumors [84]. Lately, 
much knowledge is gained about chromosomal copy number changes or allelic 
imbalance in HNSCC, using low resolution techniques focussing on pre-selected 
genomic regions like LOH and MLPA analysis. A revolution in cancer genetics was 
the development of conventional CGH, as it allowed the genome wide analysis of 
genetic changes with a 5 Megabase (Mb) resolution. CGH is based on hybridization 
of equal amounts of tumor and normal reference DNA labelled with different 
fluorescent compounds to metaphase spreads. By quantitative fluorescent 
microscopy the numerical changes can be determined and summarized. Both the 
resolution and speed of genome-wide analysis of genetic profiles has been improved 
immensely by the introduction of microarray-based analysis (maCGH). The technique 
is explained in Figure 3. The first arrays consisted of large-insert genomic clones, 
such as BACs (Bacterial Artificial Chromosomes) or PACs (P-1 derived Artificial 
Chromosomes), yielding an average resolution of 1 Mb [85;86]. The use of BAC 
clones with known genomic positions allowed direct identification of numerical 
changes throughout the genome. Nowadays, high resolution tiling arrays exist, 
containing more than 30,000 overlapping BAC clones [87].  
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Figure 3. Principle of array CGH. This figure shows the steps in BAC array CGH. (A) BAC clones are 
selected from a physical map of the genome. (B) DNA samples are extracted from selected BAC clones 
and their identity is confirmed by DNA fingerprinting or sequence analysis. (C) A multi-step amplification 
process generates sufficient material from each clone for array spotting. Each clone is spotted in 
replicate onto a solid support. (D) Reference DNA and test DNA are differentially labeled with cyanine 3 
and cyanine 5 respectively. (E) The two labeled products are combined and hybridized onto the spotted 
slide. (F) Images from hybridized slides are obtained by scanning in two channels. Signal intensity ratios 
from individual spots can be displayed as a simple plot (G) or by using more complex software such as 
Imagene, which can display copy number alterations throughout the whole genome [88]. 
 
In addition to BAC arrays, oligonucleotide arrays (oligo arrays) have been developed. 
Oligo arrays have major advantages over BAC arrays, as their manufacturing is 
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cheaper, since BAC-DNA isolation and PCR amplification are not necessary [89-91]. 
In addition, they can be custom-made with a much higher resolution and are 
commercially available. Since the introduction of array CGH, many studies reported 
DNA copy number aberrations in HNSCC and frequent gains and losses of almost 
every chromosome have been described [59;92-94]. Unfortunately, most of the data 
is descriptive as most studies comprise small numbers of patients and data is not 
related to prognostic factors or clinical outcome.  
 
Functional analysis of cancer genes and their pathways.  
Based on epidemiological data and in vitro transformation experiments, it has been 
estimated that four to six genetic events are required in humans to transform a 
normal cell into a malignant cell [95;96]. As delineated above, HNSCC 
carcinogenesis is mainly driven by a few genetic events that involve the impairment 
of the P53 and the pRb pathway, two pathways that are involved in cell cycle 
regulation and apoptosis [97]. Yet, in some HNSCC these pathways seem not to be 
disrupted and other genes may be involved. However, the genetic instability of 
tumors is a factor of importance. Many DNA changes or differentially expressed 
genes could be considered as a consequence and not a cause of carcinogenesis. To 
discriminate the carcinogenic ‘driving’ from the ‘passenger’ genetic events, functional 
characterization of candidate genes in vivo or in vitro is therefore essential to 
elucidate causative involvement.  
 
In vivo models 
Mouse models play an important role in understanding the mechanisms of human 
carcinogenesis and have accelerated the search for finding new molecular targets for 
cancer therapy. However, suitable transgenic and knock-out mouse models for 
HNSCC are still not available. Some initial successes have been reported [98], but 
the models show a low rate of tumorigenesis and are late at development, hampering 
efficient investigation. Moreover it is a major task to generate them and for this 
reason not suitable for the investigation of candidate genes. Initial functional data 
obtained in in vitro models should be available before a mouse model is worth the 
effort.  
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In vitro models 
Cell lines have frequently been used as a tool for the investigation of pathways 
involved in HNSCC [99]. Unlike tumors, cell lines are generally clonal and therefore it 
is much easier to examine their underlying genetic abnormalities [100]. However the 
majority of the cancer cell lines are extracted from invasive carcinomas that may 
have already acquired numerous mutations and genetic changes, which hampers the 
investigation of early phenotypic changes. Moreover, the process of adapting to 
culture likely selects for pheno- and genotypes important for in vitro culture, causing 
artifacts [101;102].  
A more compelling way to characterize novel cancer genes, would be to investigate 
the transforming ability of these genes in normal cells [103;104]. The introduction of 
viral oncogenes in combination with long term in vitro cultivation allowed the 
outgrowth of rare immortalized clones [105-107]. More interestingly are the modern 
approaches in which specific cancer-associated pathways are manipulated using 
genetic modifications. These models have been used to study the malignant 
transformation of human fibroblasts in vitro [1]. Similar in vitro models have been 
exploited using primary oral mucosa cells, which demonstrated that an immortal 
phenotype can be achieved by introduction of a combination of Cyclin D1 
overexpression and p53 inactivation [108], or deficient p16 expression, in 
combination with ectopic expression of the telomerase catalytic subunit, hTERT 
[109]. Unfortunately, the use of primary cells as in vitro model has important 
limitations. First of all, experimental transformation of primary human oral 
keratinocytes is very difficult due to the rapid premature senescence of oral 
keratinocytes in culture [110]. Due to the limited lifespan of primary cells, these types 
of studies must be carried out at a small scale and in a short time-frame. It is 
therefore difficult if not impossible to reproduce experiments, as individual primary 
cultures contain a too low number of cells to accomplish this. Secondly, primary 
cultures consist of mixtures of various types of cells as stem cells, transit amplifying 
cells and differentiated cells that cannot be identified separately in culture while the 
cellular origin might have major impact on the obtained phenotypes. Finally, large 
genetic screens will not be possible in primary cultures [111-113]. Above reasons 
show that there is a clear need for a reproducible and robust in vitro model of oral 
squamous cells.  
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Aim and outline of this thesis 
Improvements in the long-term survival of HNSCC can be achieved if the generic 
signalling pathways involved in malignant transformation are elucidated, and when 
tumors can be classified in subgroups with a comparable prognosis, treatment 
response and therapy choice. At present two different subgroups of HNSCC can be 
discriminated on the basis of the etiological factor involved. In one group the human 
papillomavirus (HPV) is the causative factor, while in the other group predominantly 
smoking and alcohol consumption seems to play a role. These subgroups are 
genetically and clinically distinct, suggesting that a different route of carcinogenesis 
has been followed. A remaining question is the choice of a suitable assay to detect 
an high-risk HPV infection which is necessary to assess the exact prevalence of 
HPV-positive HNSCC and allow a reliable classification.  
Based on descriptive genetic data and experimental models, convincing evidence is 
present that alterations in the genes TP53, p16INK4A as well as CCND1 are causative, 
suggesting an important role for the p53 and pRb pathways. This is supported by the 
notion that in HPV-infected tumors these same pathways are inactivated by the viral 
oncogenes E6 and E7. Many other potential genes and signalling pathways have 
been indicated, including involvement of the genes DCC, SSCRO and FHIT, but the 
evidence is less compelling. Moreover, even for the well established cancer genes, 
TP53, p16INK4A and CCND1, many questions have remained such as: 1) in what 
order does the abrogation of the p53- and pRb-pathways take place, 2) is there an 
additional effect of combined p16INK4A and CCND1 abrogation, etcetera. 
Furthermore, what is the driving molecular event in the 40% of the HNSCC that are 
TP53 wild type? As described above, the latter question may be partly explained by 
the presence of HPV in a subgroup of these TP53 wild-type tumors. However, still 
approximately 30% of the tumors are apparently TP53 wild type and negative for 
HPV. Are other genes in the p53 pathway altered in these tumors, or are we dealing 
with a separate carcinogenic route? 
Besides these issues on the established (viral) cancer genes we are facing three 
major problems that hamper head and neck cancer research. First, the chromosomal 
regions harbouring potential cancer genes have been identified by low resolution 
methods such as microsatellite PCR or conventional CGH analysis, and these data is 
not stratified for the presence of HPV or biologically relevant outcome parameters, 
such as development of lymph node metastases, distant metastases or second field 
tumors. Second, the genetic instability of tumors is a significant problem, because 
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many DNA changes comprise large parts or whole chromosomal arms harbouring 
thousands of genes. Third, there are no models to test in particular the genes 
causing the earliest changes in carcinogenesis. The only models available at present 
are established HNSCC cell lines that do not allow analysis of phenotypes of early 
carcinogenesis such as immortalization, anoikis, and others.  
In this thesis the use of high-density genome wide profiling of HNSCC by microarray 
comparative genomic hybridization (maCGH) and development of algorithms to 
decipher these data is described. Moreover, a number of approaches and assays to 
distinguish different patient groups have been developed and evaluated. In addition 
an in vitro model was established using conditionally immortalized primary oral 
squamous keratinocytes, which is not only suited for functional analysis of candidate 
cancer genes but also allows high throughput functional screening to identify these.  
In Chapter 2, we address the question on the discrepancy in literature about the 
HPV prevalence in HNSCC, and evaluate relevant assays that are applicable for 
detection on archival formalin-fixed paraffin-embedded specimen. In Chapter 3 [114] 
a bioinformatic tool is described that allows comparative analysis using CGH data. In 
Chapter 4 both the maCGH platform as the developed bioinformatic tools are 
exploited to detect the genome wide genetic alterations that are in common and 
those that differ between tumors caused by HPV infection and tumors caused by 
other etiological factors such as alcohol consumption and tobacco smoking. In 
Chapter 5 we exploited a novel algorithm to classify HNSCC on basis of genome 
wide chromosomal aberrations, and showed that within the group of HPV-negative 
HNSCC at least two, possibly three genetically distinct subgroups of tumors exist 
associated with both etiological, clinical and molecular characteristics. In Chapter 6 
the genetic data of HPV-positive and HPV-negative tumors was compared with that 
of HPV-positive cervical squamous cell carcinomas. Both genetic changes 
associated with HPV infection as well as changes associated with the tissue origin 
could be distinguished, an observation that will help to focus the attention on the 
most relevant chromosomal locations harbouring cancer genes.  
Additionally, to solve the critical lack of relevant models to study the earliest cancer-
associated phenotypes, we generated an in vitro transformation model using 
conditionally immortalized primary oral squamous keratinocytes. The establishment, 
validation and application of this model to answer a number of questions on the role 
of the p53 and pRb pathways in HNSCC are described in Chapter 7.  
In Chapter 8 a general discussion of the results presented in this thesis is provided. 
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ABSTRACT 
Human papillomavirus type 16 (HPV16) plays a role in the development of a 
subgroup of head and neck squamous cell carcinomas (HNSCC). However, 
uncertainty exists about the true impact of HPV in this tumor type as conflicting 
reports have been published with prevalence rates from 0 to 100%. We aimed to find 
a detection algorithm of a biologically and thus clinically meaningful infection, 
applicable for high-throughput screening of frozen and formalin-fixed paraffin 
embedded (FFPE) specimens. 
By considering detection of HPV E6 oncogene expression in frozen biopsies as gold 
standard for a meaningful HPV infection, the value of several assays was evaluated 
on FFPE tumor specimens and sera of 48 HNSCC patients. The following assays 
were evaluated on FFPE tissue samples: HPV DNA general primer (GP)5+/6+ PCR, 
viral load analysis, HPV16 DNA FISH detection, HPV16 E6 mRNA RT-PCR, p16 
immunostaining, and on corresponding serum samples detection of antibodies 
against the HPV16 proteins L1, E6 and E7. Comparing single assays on FFPE tissue 
samples detection of E6 expression by RT-PCR was superior, but application 
remains at present limited to HPV16 detection. Most suitable algorithm with 100% 
sensitivity and specificity appeared p16 immunostaining followed by GP5+/6+ PCR 
on the p16-positive cases. 
We show that clinically meaningful viral HPV infections can be more reliably 
measured in FFPE HNSCC samples in a standard and high throughput manner, 
paving the way for prognostic and experimental vaccination studies, regarding not 
only HNSCC, but possibly also cancer types with HPV involvement in subgroups 
such as penile and anal cancer. 
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INTRODUCTION 
Tobacco smoking and alcohol consumption are the main risk factors in the etiology of 
head and neck squamous cell carcinomas (HNSCC). In addition, over the last 15 
years, infection with high-risk human papillomavirus (HPV) types has also been 
etiologically linked with a subset of HNSCCs [1-7] and sexual transmission is 
suggested to cause the infection [5;8;9]. 
High risk HPV type 16 (HPV16) has been identified in approximately 90% of HPV-
positive HNSCC, and HPV18, -31 and -33 in the remaining cases [10]. These high 
risk viruses play a role in the carcinogenic process by producing two oncoproteins 
encoded by the viral E6 and E7 genes. These oncoproteins directly inactivate p53 
and pRb, respectively, and promote cell cycle entry and DNA synthesis as well as 
blockade of apoptosis, cellular conditions favoring viral replication [11]. 
At present, the causal role of HPV in cervical carcinomas, has been well established. 
High-risk HPV DNA is detected in almost all cervical carcinomas [12-14] and this 
finding has instigated studies on the prevention or treatment of HPV infections using 
vaccines [15]. As for etiology of HNSCC, the importance of HPV infection is more 
controversial, mainly because no unanimously accepted detection method exists. 
The reported prevalences of high-risk HPV DNA tremendously vary per study from 0 
to 100% [10;16]. Part of the variation in HPV prevalence can be explained by 
differences with regard to the location of the tumor, i.e. it is relatively low in the oral 
cavity and high in the tonsil [1;4;7] More importantly, variations in the type of tissue 
material studied and the HPV detection methods used, likely have a major impact on 
the discrepancy in reported prevalence rates. The most widely applied detection 
methods are based on PCR amplification of viral DNA. However, these methods are 
extremely sensitive and can even detect a few DNA copies per sample, which might 
yield false-positive results [4;10;17]. Moreover, HPV-DNA presence does not per se 
indicate viral involvement in the carcinogenic process and may reflect a transient 
infection that does not carry any risk of neoplastic transformation [18]. It is our 
opinion that the lack of agreement of what to consider a HPV-involvement is for a 
large part the cause of confusion in the HNSCC literature. As an example, some 
studies reported an association between HPV infection and improved survival [4;19-
21] whereas other studies failed to show this [22-24]. 
Recently, we demonstrated HPV DNA by PCR in 24/143 (16.7%) frozen oral and 
oropharyngeal tumors, but could confirm viral involvement by E6/E7 expression 
analysis in only 12/24 (50%) of these samples [22]. This observation shows that 
presence of HPV DNA solely does not necessarily mean that the virus is biologically 
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active in these tumors. In addition, it was found that tumors containing 
transcriptionally active HPV can be genetically distinguished as a specific subgroup 
[1], strongly supporting the hypothesis that HPV only plays a carcinogenic role when 
viral oncogenes are expressed. This group of tumors with transcriptionally active 
HPV showed absence of TP53 mutations and a limited number of genetic 
abnormalities, whereas their counterparts without transcriptionally active HPV 
showed TP53 mutations in 75% of cases and many genomic abnormalities 
[1;2;25;26]. Given this concept, measurement of E6/E7 expression seems to be the 
most reliable way to detect a biologically relevant association between HPV and 
malignancy, but a precondition to measure E6/E7 mRNA expression in a user-
friendly reliable manner, is the availability of frozen material. A method feasible for 
more accessible routinely collected material, such as formalin-fixed, paraffin-
embedded (FFPE) tissue is still missing. 
Commonly used HPV detection methods for FFPE tissue are known from studies on 
cervical cancer, and include, besides HPV consensus PCR methods, type-specific 
HPV-DNA detection by Fluorescence In Situ Hybridization (FISH) [27] and real-time 
PCR assays, the latter allowing viral load analysis [28;29]. Also the use of surrogate 
biomarkers such as p16 immunostaining can be considered for studying FFPE 
specimens of HNSCC [7;21;30]. Alternatively, detection of serum antibodies [31] 
directed against HPV epitopes might be an option when serum has been collected. 
In this study we aimed to find a reliable and easily implementable test algorithm to 
assess a directly carcinogenesis-related HPV involvement in both frozen and FFPE 
tumor specimens of HNSCC patients.  
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MATERIAL AND METHODS 
Patients, tissue samples and group definitions 
For this study we used tumor specimens and serum samples of 48 patients who 
underwent surgical treatment for HNSCC at the VU University Medical Center. The 
study was approved by the Institutional Review Board, and informed consent was 
obtained from all patients. Regarding the tumors a dual work-up was followed: a part 
of the tumorous tissue was snap-frozen in liquid nitrogen and stored for research 
purposes [32]. The remaining part of each tumor was processed for routine 
histopathology and the tissue detection methods that are the subject of this study 
were performed on this routinely processed material. 
Group classification. The frozen tumor specimen were analyzed for the presence of 
HPV-DNA and E6/E7 mRNA as described previously [1;2]. All HPV DNA-positive 
carcinomas contained high risk HPV16. For this study we considered presence of 
HPV16 E6/E7 mRNA in the frozen specimens as ‘gold standard’ reflecting direct viral 
involvement in carcinogenesis and this was used as selection criterion for the case 
group. Among 24 HPV16 DNA-positive tumors, 12 (50%) samples were positive for 
E6 and E7 transcripts and were considered true HPV-positive [1;2] and further 
referred to as HPV D+/R+ (DNA+/RNA+). The group of twelve HPV16 DNA-positive, 
but E6/E7 mRNA-negative tumors was also included in the comparative analysis as 
an as yet undefined group regarding the HPV status, and was further referred to as 
the HPV D+/R- group. A third HPV-negative (DNA-/RNA-) control group of 24 tumors 
were selected in such a way that a similar distribution over the groups was ensured 
for clinical parameters that might in theory confound the analysis (i.e., age, gender, 
tumor site and stage, tobacco and alcohol consumption, and histology). After 
analysis, the HPV D+/R- group showed in general negative test results and together 
with the negative E6-expression in frozen tissue, this group was scored as being 
HPV-negative and was included as such in the calculation of sensitivity and 
specificity.  
 
Preparation of paraffin sections and isolation of nucleic acids 
Paraffin sections were prepared according to the sandwich method: the first and last 
section were stained by haematoxylin and eosin to check for tumor presence and to 
guide microdissection. One 4 µm section was used for FISH analysis and one 5 µm 
section for p16 immunohistochemical staining. Routinely 10-20 sections were used 
for microdissection of the neoplastic cells for viral load analysis. From 10-20 
subsequent sections RNA and DNA was isolated simultaneously for GP5+/6+ PCR 
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and HPV16 E6* RT-PCR (see below). To avoid cross-contamination, a new 
microtome blade was used each time a new case was sectioned, aerosyl tips were 
used for all pipetting steps, and separate laboratories were used for pre- and post-
PCR handling. 
 
Detection of High Risk HPV DNA by GP5+/6+-PCR 
Detection of high risk HPV was performed by general primer GP5+/6+-PCR on 50 ng 
of DNA, quantified by the Quant-It Picogreen dsDNA assay kit (Invitrogen, Breda, 
The Netherlands), followed by reverse line blot genotyping [33;34]. Serial dilutions of 
DNA isolated from cervical carcinoma cell line SiHa (ATCC; HTB35; 1–2 integrated 
HPV16 copies), and reactions without template were run in parallel as controls. 
 
Viral load analysis 
Quantification of HPV16 DNA copy numbers per cell was performed by real-time 
PCR using the LightCycler® technology (Roche Molecular Biochemicals, Mannheim, 
Germany) as described previously [35], except that for PCR detection of both HPV16 
and beta-globin other primers were employed to shorten the amplicon lengths to 114 
and 111 base pairs, respectively (Table 1). Based on the assumption that at least 
one viral copy is needed per cell for clonal expansion, tumors with > 0.5 copies per 
cell were scored as positive, allowing some normal tissue contamination in the 
microdissected tumor samples. 
Table 1. Primer and probe sequences used for viral load and E6*I expression analysis. 
Assay (amplicon 
length in basepairs) 
Target 
  
Sequence 5’ → 3’ Primer location in  
genome sequence 
Viral load analysis 
(114) 
HPV16 E7 
(K02718)† 
 
fw: GAGGAGGAGGATGAAATAGATGGT 
re: TTGTACGCACAACCGAAGC 
dp: CAAAAGGTTACAATATTGTAATGGGCTCT 
ap: CCGGTTCTGCTTGTCCAGCTGG 
658-681 (24)‡ 
772-753 (19)‡ 
735-706 (30)‡ 
703-682 (22)‡ 
Viral load Analysis 
(111) 
Human β-
globin§ 
(U01317)† 
fw: GGAGAAGTCTGCCGTTACTGC 
re: TTGGTCTCCTTAAACCTGTCTTGT 
dp: CCAGGGCCTCACCACCAACTTC 
ap: CCACGTTCACCTTGCCCCACAG 
62207-62227 (21)‡ 
62318-62295 (24)‡ 
62275-62254 (22)‡ 
62251-62230 (22)‡ 
E6*I expression 
analysis (86) 
HPV16 E6 
(K02718)† 
 
fw: TTACTGCGACGTGAGGTGTA 
re: GGAATCTTTGCTTTTTGTCC¶ 
pr: AAGCCACTGTGTCCTGAAGAAAAGCAA 
212-226^409-413║(20)‡ 
479-460 (19)‡ 
425-451 (26)‡ 
E6*I expression 
analysis (100) 
BGUS* 
(NT007758.11)† 
fw: GAAAATATGTGGTTGGAGAGCTCATT 
re: CCGAGTGAAGATCCCCTTTTTA 
tp: CCAGCACTCTCGTCGGTGACTGTTCA 
3462209-3462184 (26)‡ 
3458871-3458850 (22)‡ 
3458876-3458902 (26)‡ 
Abbreviations used: fw, forward primer; re, reverse primer; dp, donor probe (3’end labelled with 
fluorescein); ap, acceptor probe (3’end phosphorylated, for HPV16 5’end labelled with LightCycler-Red-
640 and for β-globin 5’end labelled with LightCycler-Red-705); pr, Enzyme-Immuno-Assay (EIA)-probe; 
tp, TaqMan-probe (5’end labelled with FAM and 3’end labelled TAMRA), †Genbank accession number, 
‡Length in basepairs, § This gene is located at chromosome 11, * This gene is located at chromosome 7, 
║HPV16 E6*I is spliced between genome position 226 and 409, ¶ HPV16 E6 reverse primer is 5’-
biotinylated. 
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Detection of HPV16/18 DNA by FISH 
FISH was performed on paraffin-embedded tissue sections as described previously 
[7]. Controls included hybridizations on FFPE sections of known HPV16- and 18-
positive human cervical carcinoma cell lines (CaSki [ATCC; CRL1550; 500 integrated 
HPV16 copies], HeLa [ATCC; CCL2; 20–50 integrated HPV 18 copies] and SiHa 
[ATCC; HTB35; 1–2 integrated HPV16 copies]) as well as hybridizations on tissue 
sections of cervical lesions with proven integration or episomal presence (replication) 
of HPV genomic DNA to guarantee probe specificity, sensitivity and interpretation 
accuracy [36]. Negative controls consisted of HPV PCR- and FISH-negative cell lines 
and tissue sections and hybridizations omitting the viral probe. Evaluation of nuclear 
hybridization signals was performed by three investigators according to the criteria 
described by Cooper et al. [37] without information on the HPV-status of the samples. 
Both staining intensity (0 to 3) and punctate and/or diffuse signals throughout the 
nucleus indicating integrated and episomal HPV DNA, respectively, were evaluated. 
The level of inter-observer agreement was determined by calculating Cohen’s kappa 
values [38]. A definitive consensus score was determined by mutual agreement in a 
separate session. 
 
Immunohistochemical staining of p16 
For p16INK4a or short p16 (the protein encoded by CDKN2A) immunohistochemistry 
the CINtecTM Histology Kit (DakoCytomation B.V., Heverlee, Belgium) was used. 
For every case analyzed, an extra tissue section was stained with a mouse IgG, as a 
negative control. Staining intensity as a result of this mouse antibody was considered 
background and all samples with staining intensity above that background were 
scored as positive. An extra tissue section of an HPV-positive tumor with high p16 
expression was included as positive control. Both the staining intensity (graded 0-3 
proportional to staining intensity) and the percentage of the tumor cells positively 
stained per slide were assessed independently by three investigators. The level of 
inter-observer agreement was determined by calculating Cohen’s kappa values. A 
definitive consensus score was determined by mutual agreement in a separate 
session. The eventual decision if tumor was analyzed was made after consultation of 
an experienced pathologist (CJLMM). 
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Detection of antibodies against the proteins HPV16 L1, E6 and E7 
Antibodies against L1, E6 and E7 of HPV16 were measured in a sandwich ELISA 
using a glutathione S-transferase capture method with native recombinant L1-tag, 
E6-tag and E7-tag proteins [39;40]. All sera were measured at least twice and the 
median of the absorbance values was taken as the final read out. 
 
Detection of HPV16 E6*I mRNA on paraffin embedded tissue 
We developed an RT-PCR assay to detect the most abundant splice variant within 
the HPV16 E6 open reading frame, namely E6*I, in FFPE specimen [41;42]. For 
further details about the primer and assay design: see Supplementary Information. 
Primer sequences are listed in Table 1. 
PCR products were detected using an enzyme immunoassay (EIA) as described 
previously [43] with a HPV16 E6*I specific probe (Table 1) according to a method 
that was described previously [33]. Samples were scored positive when the EIA 
signal was above the threshold value of three times the average of the EIA signals of 
four negative PCR controls. RNA from cells of the HPV16 containing SiHa cell line, 
that were formalin-fixed and embedded in paraffin, was run in parallel as positive 
control. For each clinical sample a parallel RT-PCR without reverse transcriptase 
was used as a control for possible amplification of contaminating HPV16 DNA. RNA 
integrity as assayed by detection of ß-glucuronidase transcripts.  
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RESULTS 
All results are summarized in Table 2. Three groups of carcinomas have been tested, 
divided according to the HPV DNA and E6/E7 mRNA status as determined in frozen 
tissue [22]. In general, all tests scored positive in the carcinomas of the D+/R+ group 
and negative in the D-/R- group. The D+/R- group showed in most cases negative 
test results and was also negative for E6/E7-expression in frozen tissue. For these 
reasons this group was scored as being HPV-negative and was included as such in 
the calculation of sensitivity and specificity.  
 
 
 
Of all PCR-based detection methods in FFPE specimen, only E6* mRNA detection 
showed both a sensitivity and specificity of 100%. Typical examples are shown in 
Figure 1. FISH analysis showed to be very specific, but was less sensitive: In 10 out 
of 12 HPV D+/R+ tumors HPV16 DNA was detected. In all positive tumors a 
punctuated hybridization pattern was observed consistent with viral DNA integration, 
although some tumors in addition showed patterns suggestive of the presence of 
episomal viral DNA as well (Figure 2). Three samples could not be analyzed, 
because of a high background. Between the three investigators, there was total 
agreement on FISH scoring in 43 of the 45 cases (96%). When the inter-observer 
agreement was analyzed, an average kappa score of 0.85 was observed. This can 
be interpreted as a very good strength of agreement [38].  
 
Figure 1. The results of three HNSCC of which RNA and DNA was isolated from paraffin embedded 
specimen. As a positive control, SiHA cells were formalin fixed and paraffin embedded, followed by 
exact the same isolation method as used for the tumors [22;34]. The first two tumors show E6*I 
expression, the third tumor not, exactly matching the data obtained from the corresponding frozen tumor 
samples. The amplimer of the full length E6 transcript (248 bp) was not detected in paraffin embedded 
tissue. The negative control contains all reagent components except DNA/RNA. For more details on the 
assay and the performance on frozen and FFPE samples see supplementary information.  
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All HPV D+/R+ tumors showed expression of p16 by immunohistochemistry. One 
sample could not be analyzed as the tissue section appeared not to contain 
neoplastic cells anymore. Between the three investigators, there was full agreement 
on p16-IHC scoring, with respect to positive staining intensity (graded 0-3 
proportional to staining intensity) in 34 of the 44 cases (77%), with an average kappa 
score of 0.81. This can be interpreted as a very good strength of inter-observer 
agreement [38]. Figure 3 shows typical examples of tumors with different staining 
intensities. We measured HPV16 L1, E6 and E7 antibody levels above the cut-off 
values in the serum of patients in the HPV D+/R+ group, the HPV D+/R- and the 
HPV-negative group (Table 2). Regarding the E6 antibodies, a statistically significant 
difference (P<0.05, Fisher’s exact test) was observed between the HPV D+/R+ group 
and the HPV D+/R- group as well as the HPV-negative group. The significant 
difference is based on the number of samples that were above the cut-off level, 
defined as specified in the legend of Table 2. 
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Figure 2. Typical examples of HPV16 FISH on sections of paraffin embedded HNSCC specimens. All 
three tumors were positive for HPV DNA and E6/E7 expression. The images A and B show punctuate 
nuclear FISH signals indicating HPV16 DNA integrated into the host genome. Image C shows an area 
with diffuse nuclear FISH staining indicative for episomal HPV16 DNA. 
 
  
Figure 3. Representative examples of p16 immunostaining on three tumors of the HPV D+/R+ group (A-
C) and one of the HPV-negative group (D). A = Tumor 1 (table 2) with 100% of the cells stained with 
high intensity in both nucleus and cytoplasm; B = Tumor 5 (table 2) with approximately 50% of the cells 
positively stained with high intensity; C = Tumor 11 (table 2) with 100% of the cells stained, but with a 
lower intensity; D = Tumor 26 (table 2) negative for p16 immunostaining. 
CHAPTER 2 
 
 
40 
Table 2. Different Methods for Detecting Clinically Relevant HPV Infections in Paraffin embedded Head 
and Neck Carcinomas and Patient Sera 
p16 IHC1 
 
Sera2 
 
 Tumor Site Intensity Percentage GP5+/6+
E6*I 
mRNA3
Viral 
load4 FISH5 16L1 16E6 16E7
 
1 OC 3 90 + + 87.0 2 NA NA NA 
2 OP NE NE + + 0.2 0 383 1906 1821
3 OP 2 90 + + 4.5 3 400 1583 56 
4 OP 3 80 + + 8.0 2 1509 85 22 
5 OP 3 50 + + 156.6 2 255 1746 43 
6 OP 2 90 + + 2.1 2 717 1772 1674
7 OP 3 80 + + 316.3 2 3 1203 1065
8 OC 3 90 + + 1.3 2 71 1319 1084
9 OC 3 80 + + 10.1 2 55 316 17 
10 OC 2 90 + + 1.6 2 61 1835 1721
11 OC 1 90 + + 5.3 0 93 89 27 
HPV DNA- and 
RNA - positive 
group6 (D+/R+) 
12 OC 2 60 + + 41.0 2 451 159 24 
13 OP NE NE - - NE NE 96 138 39 
14 OC 0 0 - - 0 0 38 87 32 
15 OC 0 0 - - 0 0 0 18 1 
16 OC 1 10 - - 0 0 81 59 33 
17 OP 2 40 - - 0 NE NA NA NA 
18 OC 1 10 - - 0 0 135 86 21 
19 OC 3 90 - - 0 0 43 45 27 
20 OC NE NE - - 0 0 29 68 22 
21 OC 0 0 - - 0 0 42 63 103
22 OC 0 0 - - 0 0 86 145 29 
23 OC 0 0 + - 0 0 26 164 39 
HPV DNA-
positive, but 
RNA-negative 
group7 (D+/R-) 
24 OC 0 0 - - 0 0 39 71 7 
25 OP 1 10 - - 0 0 22 13 -6 
26 OP 0 0 - - 0 0 NA NA NA 
27 OP NE NE - - 0 0 68 85 27 
28 OC 0 0 - - 0 0 NA NA NA 
29 OC 0 0 - - 0 0 NA NA NA 
30 OP 0 0 - - 0 NE 40 29 13 
31 OP 0 0 - - 0 0 27 92 16 
32 OP 1 10 - - 0 0 NA NA NA 
33 OP 0 0 - - 0 0 NA NA NA 
34 OC 0 0 - - 0 0 173 145 76 
35 OC 0 0 - - 0 0 90 169 33 
36 OC 0 0 + - 0 0 96 354 90 
37 OC 0 0 - - 0 0 NA NA NA 
38 OC 0 0 + - 0 0 200 57 20 
39 OC 0 0 - - 0 0 NA NA NA 
40 OP 0 0 - - 0 0 99 81 48 
41 OP 0 0 - - 0 0 99 79 33 
42 OC 3 90 - - 0 0 NA NA NA 
43 OC 0 0 - - 0.6 0 NA NA NA 
44 OC 0 0 - - 0 0 29 70 15 
45 OC 0 0 - - 0 0 NA NA NA 
HPV-negative 
group8 (D-/R-) 
46 OC 0 0 - - 0 0 53 87 25 
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47 OC 0 0 - - 0 0 NA NA NA 
48 OP 0 0 + - 0 0 NA NA NA 
Sensitivity9   11/11 (100%) 12/12 
(100%) 
12/12 
(100%)
11/12 
(92%)
10/12 
(83%) 
10/11 (91%) 
Specificity10   26/33 (79%) 32/36 
(89%) 
36/36 
(100%)
34/35 
(97%)
33/33 
(100%) 
7/23 (30%) 
Different methods for detecting clinically relevant HPV infections in paraffin embedded head and neck 
carcinomas and patient sera. 
Tumors are grouped on basis of the presence of HPV DNA and HPV E6/E7 transcripts as determined in 
the frozen samples (gold standard); #HPV DNA- and E6/E7 RNA-positive (D+/R+), ##HPV DNA-positive, 
but E6/E7 RNA-negative (D+/R-), and ###HPV-negative (D-/R-). † p16 IHC staining intensity: 0-3 and the 
percentage of tumor cells positively stained. ‡ (+) = Positive or (-) negative respectively for E6*I 
expressing according to the criteria as described in the material and methods. § Viral DNA copy number 
per cell ║ FISH staining intensity 0-3 was scored according to Cooper et al. [37]. ¶ The cut-off value to 
define HPV-antibody-positive sera was calculated separately for each antigen as the median of the 
specific absorbance values of control sera from individuals who did not have cancer plus three standard 
deviations excluding positive outliers, as described elsewhere [47]. The samples were scored positive 
when the optical density (OD)-value was above the following levels: 16L1: 100; 16E6: 150 and 16E7: 60 
and are in bold. OC = Oral cavity. OP = Oropharynx. NE = Not evaluable. Some tumors could not be 
analyzed reliably, as the tissue section did not contain enough neoplastic cells. NA= Not available for 
serologic detection of HPV16 L1, E6 and E7 antibodies. **Sensitivity: Relative number of positive 
samples detected in the HPV D+/R+ group. *Specificity: Relative number of negative samples detected 
in the HPV DNA+/R- and HPV-negative group together. Sera results: positivity was scored when any of 
the three markers was scored positive. 
 
Since all single methods showed limitations with respect to sensitivity and specificity, 
and E6* mRNA detection is not yet available for HPV-types other than 16, 
combinations of high throughput methods were considered. Our results showed that 
when p16 immunochemistry is followed by GP5+/6+-PCR on the p16-positive cases, 
100% sensitivity and specificity might be reached (Figure 4). 
 
Figure 4. Proposed flowchart for high throughput identification of HNSCC with a clinically relevant HPV 
infection on paraffin-embedded tissue sections with 100% sensitivity and specificity. 
 
CHAPTER 2 
 
 
42 
DISCUSSION 
The reported large variation of HPV prevalence in HNSCC has complicated 
understanding of the role of HPV in this tumor type [4;10;16;17] The high sensitivity 
of the widely used PCR methods for HPV-DNA amplification is a likely explanation for 
this variation, and a HPV DNA-positive assay may not always reflect biologically 
meaningful viral involvement [18]. Recent findings point out that the only way to 
support a conclusive viral involvement is measuring levels of E6/E7 RNA, thus far 
necessitating frozen tissue material [1;2;26;32]. We aimed to find a sensitive and 
specific high throughput HPV detection algorithm for FFPE specimen.  
The D+/R- group was included with an unknown definitive HPV status and the 
present results were interpreted to be additional arguments to consider this group of 
tumors HPV negative and to include this as such in the test performance 
assessment. This decision was motivated initially by the argument that E6 RT-PCR 
was negative in frozen tissue. All other data supported this decision: most tests 
showed negative results, these tumors showed genetic profiles indistinguishable from 
HPV negative tumors [1;2], and the GP5+/6+-PCR signal intensities in the frozen 
tissues, the starting situation, were just above background. Regarding this last item, 
details on how this relatively low level was detected and interpreted has been 
mentioned in a previous report [22]. Nevertheless, we consider samples that are 
positive for the DNA assay but negative for the E6/E7 assay as false positive. The 
presence of HPV DNA in these cases is not relevant for the carcinogenic process. 
This is supported by all other assays that we performed. How the presence of HPV 
DNA should be explained is not easy to answer. HPV DNA could be present in the 
saliva or mucosa without influencing the physiology of the host. It has to be stressed 
that no matter how this virus ended up in these samples, no viral oncogene 
expression was detected, making it unlikely that the virus is biologically active in 
carcinogenesis. The E6*I mRNA detection designed for FFPE material showed a 
hundred percent sensitivity and specificity and seems very well applicable for large 
retrospective studies, i.e. the readout is performed by PCR-EIA resulting in a 
basically dichotomous output. This assay also does not require laborious 
microdissection. A limitation is that the HPV-type should be known, and similar 
assays for types other than 16 need to be developed. Nevertheless, this novel assay 
may already solve current clinical controversies about HPV involvement [44;45]. 
All methods based on PCR amplification of viral DNA showed limitations with respect 
to sensitivity and specificity. As expected, the GP5+/6+ PCR assay detected HPV in 
all tumors of the D+/R+ group. However, only a single case was GP5+/6+-PCR 
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positive in the D+/R- group, while the corresponding frozen samples were all positive, 
although with relative low values [22], demonstrating that HPV is more readily 
detectable in frozen tumor tissue than in paraffin embedded tissue, which is not 
unexpected. PCR amplification is more efficient on frozen than on FFPE material, 
since it is known that the fixation procedure leads to DNA fragments that are often 
shorter than 200 bp [46]. In the group of 24 tumors that were HPV-negative on basis 
of the frozen biopsy, three corresponding FFPE tumor samples were GP5+/6+ PCR 
positive. An explanation for this phenomenon might be related for instance to tumor 
heterogeneity and sampling error. The pieces that were selected for cryopreservation 
were often small biopsies, while the FFPE samples encompassed transsectional cuts 
through the whole tumor. It has to be emphasized that the E6/E7 mRNA expression 
remained negative in these samples, indicating that the virus was not biologically 
active and it demonstrates that PCR-based HPV DNA detection methods can lead to 
falsely positive results in terms of biologically active HPV detection. 
Quantitative assessment of the viral copy number per cell might improve specificity, 
but resulted in one false negative observation, and it is very labor-intensive as the 
neoplastic cells need to be enriched by microdissection [17]. 
FISH allows for the direct visualization of down to 1 copy of viral DNA per cell and in 
addition the discrimination between integrated and replicative (episomal) HPV as a 
punctuated or diffuse hybridization signal, respectively [47]. It is unclear why FISH 
was unable to identify the virus in the D+/R+ cases two and eleven. The viral load 
values were relatively low in these cases, suggesting a low viral copy number. In a 
second instance, sample 11 was repeated on a different section and came out 
positive. This outcome was not included in the results as we decided to present the 
first unbiased results. Thus, to increase sensitivity of FISH one could think of testing 
multiple sections to minimize a possible sampling error. The sensitivity of FISH was 
85% (10/12), but the specificity was optimal (100%) in our data set. 
Another potentially interesting method, exploiting a surrogate marker to identify 
clinically relevant HPV infections, is detection of antibodies to E6 and E7 in sera, 
chosen for its easy applicability and used in several large clinical studies with cervical 
cancer patients [48-50]. We exploited the potential value of serology and were able to 
analyze serum samples of most of the patients. There was indeed a significant 
difference between the HPV D+/R+-group and the HPV D+/R- group, in particular for 
antibodies against HPV16 E6. Highest sensitivity was reached with positive serology 
with any of the three antibodies (91%), but the specificity was then limited (74%). 
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A second method using a surrogate marker is p16 over-expression as it is strongly 
related to active HPV infection based on the concept that functional inactivation of Rb 
by E7 induces p16 up-regulation. P16 immunohistochemistry is a relatively 
standardized technique and easy applicable on FFPE samples. Analysis of p16 over-
expression can have clinical value [21] and although we and other investigators 
found an association with viral oncogene activity [7;51], p16 overexpression is 
certainly not limited to HPV D+/R+ samples only. Some cases in the HPV D+/R- and 
the HPV-negative group showed very high p16-expression and these were further 
analyzed in detail for the possibility that we failed to detect the virus by GP5+/6+ 
PCR due to viral integration into the host genome in the L1 gene. This was 
performed by type-specific HPV DNA PCR using primers in the E6/E7 region that 
also enables detection of all high-risk HPV types when integrated. However, these 
assays did not yield positive results, indicating that these cases should be considered 
as truly false-positive cases for p16 immunostaining. 
As we found that each single assay seems to meet limitations, which is in line with 
observations of others [52], we decided to investigate algorithms based on the 
combination of assays. We could extract an algorithm with a satisfactory 
performance and allowing high-throughput analysis (Figure 4). P16-immunstaining is 
upfront and when positive staining is observed GP5+/6+ PCR is used for 
confirmation. In our series the sensitivity and specificity of this approach is 100%. 
P16 immunohistochemistry can easily be combined with standard histology when a 
hematoxylin/eosin (HE)-stained tissue section is prepared for examination by a 
pathologist. Preselection by p16-staining reduces the workload and the combination 
gives a dramatic decrease of the number of false-positive observations by either of 
these assays. Based on the test outcome and the easy applicability we judge this as 
a reliable algorithm for HPV detection in FFPE specimen. One possible limitation of 
this algorithm is that both assays may yield a false-positive result in the same 
sample. However, based on the presently available data the chance that this occurs 
is around 2%. It should be emphasized that the proposed algorithm should be 
validated in subsequent studies, particularly in multi-center designs. Our data clearly 
show that HPV DNA detection by PCR only overestimates the number of samples 
with a clinically relevant infection. 
In conclusion, we propose an algorithm for detecting a clinically relevant HPV 
infection, applicable for high-throughput analysis of paraffin embedded material, 
using a combination of p16 immunohistochemistry and GP5+/6+ PCR. This algorithm 
may provide the opportunity to assess the role of HPV in large retrospective studies, 
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and could be helpful to select patients who may benefit from immunotherapeutic 
strategies. 
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SUPPLEMENTARY INFORMATION 
Detection of HPV16 E6*I mRNA on paraffin embedded tissue 
Because of the potential value of measuring HPV-oncogene expression in FFPE 
specimens, we set out to develop an RT-PCR assay to detect the most abundant 
splice variant within the HPV16 E6 open reading frame, namely E6*I [41;42]. Last 
few years it has become increasingly clear that RNA can be isolated from paraffin 
material and analyzed by RT-PCR [22;47]. DNA and RNA can be isolated 
simultaneously from paraffin sections using proteinase K digestion, followed by 
phenol extraction and ethanol precipitation as described previously.[34] Based on our 
own experience RT-PCR on the RNA in these preparations works well and reliably, 
but only when the amplicons are approximately 100 bp (data not shown) and when 
the primers have been designed to prevent PCR amplification of the co-isolated DNA 
templates. The latter issue is in particular a problem for HPV genes as the open 
reading frames are usually unspliced transcripts from the viral genome. There is an 
important exception for a splice variant of the E6 gene, named E6*I. This splice 
variant misses 162 base pairs of the full length transcript. In an attempt to solve the 
problem of unwanted HPV DNA amplification, one of the primers was designed over 
the splice-site location of the E6*I splice variant of the E6 gene. A schematic view of 
the primer and probe design is shown in supplementary Figure 1. The primer set was 
analysed on a mixture of RNA and DNA isolated from frozen samples of CaSki and 
SiHa HPV16-positive cervical cancer cell line with high and low viral copy number 
(CaSki [ATCC; CRL1550; 500 integrated HPV16 copies] and SiHa [ATCC; HTB35; 
1–2 integrated HPV16 copies]). The detection limit was determined by running a 
serial dilution of RNA isolated from SiHa cells in a background of normal human 
RNA. In total 100 pg of SiHa RNA (20 cells) in a background of 100 nanograms 
normal human RNA (20,000 cells) was still detectable (Data not shown). The results 
found with frozen and FFPE samples of these cell lines are shown in supplementary 
Figure 2 and explained in the legend. 
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Supplementary Figure 1. Schematic view of primer and probe design for E6*I mRNA detection. The 
genomic sequence of HPV 16 is shown from basepair 200 to 500. Exons sequences are in CAPITAL 
letters, intron sequences are in italics. The forward primer is spanning the splice-site specific for the E6*I 
transcript with exactly 10 bases located on each different exon. Homology of at least 5 bases at the 3’-
end of the forward primer is indicated above the intron sequence. 
 
Despite positioning of one of the primers over the splice site, the primer set did not 
detect E6*I only, but also the full-length E6 transcript and consequently also viral 
DNA in both cell lines (Figure 2). This is likely caused by a large sequence homology 
of 5 bases at the 3’-end of the forward primer to the 5’ beginning of the intron 
sequence (supplementary Figure 1). In an attempt to reduce this unwanted 
amplification of unspliced E6 and viral DNA we evaluated two other primers located 
two and four base pairs further over the splice-site, but these gave no improvement. 
The type of the material analysed (frozen or FFPE) strongly influences the amplimers 
found. In RNA of frozen samples both the 248 (full length E6) and 86 bp (E6*I) base 
pairs fragment are seen. In FFPE samples only the E6*I amplimer (86 bp) is 
detectable. Moreover, also the contaminating DNA in the RNA preparations still gives 
rise to amplification of the 248 bp fragment, and we introduced RNAse-free DNAse 
treatment in the isolation procedure to avoid this further. 
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Supplementary Figure 2. Validation of the new primer set designed for detection of E6*I mRNA in 
FFPE specimen. The Figure shows the PCR amplimer separated on an agarose gel and the 
corresponding EIA results, obtained from CaSki and SiHA RNA/DNA with different combinations of 
DNAse treatment and Reverse Transciptase. C = CaSki DNA/RNA; S = SiHa DNA/RNA; (-) = Negative 
control; The -DNAse/ -RT reaction represents a PCR reaction without DNAse treatment and reverse 
transcriptase, and shows viral DNA amplification (248 bp). CaSki contains a much higher viral copy 
number compared to SiHa, which results in a more intense amplimer band of 248 basepairs compared 
to SiHa. The -DNAse/ +RT represents a PCR reaction without DNAse, but with reverse transcriptase 
and shows the amplification of the E6*I mRNA at 86 basepairs, the full-length E6 transcript and viral 
DNA of 248 base pairs. 
The +DNAse/ -RT represents the reaction with DNAse, but without reverse transcriptase and shows that 
viral DNA amplification was completely abolished. The +DNAse/ +RT shows the reaction with DNAse 
treatment and reverse transcriptase. Only the E6*1 (86 bp) and full length E6 mRNA (248 bp) were 
detected in frozen material. In FFPE only the small fragment of 86 bp of E6*I is detected. The specificity 
of the generated amplimer was checked with the use of a specific probe in an EIA setting. 
 
The quality and quantity of the RNA preparation of the tumor samples was tested by 
quantitative RT-PCR (TaqMan, Applied Biosystems, The Netherlands) for the 
housekeeping gene BGUS (β-glucuronidase). Primers are listed in table 1 and PCR 
conditions were as described previously [53]. The standard assay for the FFPE was 
as follows. A minimum of 1 ng (relative to BGUS expression of cell line UM-SCC-
22A) of extracted tumor RNA was used for E6*I cDNA synthesis. To eradicate the 
unwanted amplification of co-isolated DNA we pre-treated the sample with 0.5 U RQ1 
DNAse (Promega, Leiden, The Netherlands). In a reaction without reverse 
transcriptase this treatment is checked. The reverse transcriptase reaction was 
performed with 20 pmol biotinylated HPV16 E6*I reverse primer (Table 1). PCR 
analysis of the cDNAs was performed in 50 μl containing 50 mM KCl, 10 mM Tris HCl 
pH 8.3, 200 μM of each dNTP, 1.5 mM MgCl2, 1 unit Taq polymerase, and 25 pmol of 
the forward and reverse primer (Table 1). Cycling conditions were 4 min at 95°C, 
followed by 40 cycles of 30 seconds at 95°C, 60 seconds at 55°C and 90 seconds at 
72°C followed by 4 minutes of elongation at 72°C. 
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SUMMARY 
We compute P-values, based on the Wilcoxon test with ties, to compare two 
conditions with array comparative genomic hybridization data, and we provide a 
simple interface to export and plot these P-values.  
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Array comparative genomic hybridization (array CGH) is applied to the detection of 
genomic abnormalities in cancer and inheritable DNA copy number aberrations that 
cause genetic disorders. It is a high-resolution, high-throughput technique that allows 
for genome-wide measurement of chromosomal DNA copy number changes and 
determination of the associated breakpoints along the chromosomes [1].  
Software such as aCGHsmooth [2] and similar programs [3] enables the visualization 
and identification of aberrated chromosomal regions by individual separately. CGH-
Miner [4] has additional features to summarize alteration information over groups. We 
developed CGHMultiArray to integrate array CGH data over individuals by computing 
P-values per clone and visualizing these to find generic patterns. The program deals 
with the most common situation: comparison of two conditions.  
When considering a suitable statistic to measure generic DNA copy number changes 
among individuals, we have to consider the nature of array CGH data. Although 
technical errors may disperse the data somewhat, the data in reality represent 
discrete levels of genetic aberrations. The normal DNA copy number of mammalian 
clones is two: one from both the paternal and maternal chromosomes. In particular 
diseases, such as cancer, changes in the DNA copy number with respect to the 
‘normal’ value may occur as a ‘deletion’ (at least one copy is lost) or a ‘gain’ (at least 
one additional copy is present). These non-normal levels may be further detailed, 
e.g. by including ‘amplification’, which is a high level of copy number gains.  
The granularity of (discretized) CGH data makes the t-statistic, or variations thereof, 
unsuitable. Moreover, the discrete levels possess a natural ordering, which rules out 
the Fisher exact test. The Wilcoxon test makes explicit use of both features. 
However, the data naturally contain many ties, i.e. sets of equal observations. The 
distribution of the Wilcoxon statistic, and consequently the P-values, depends on the 
tie structure [5]. Hence, it has to be re-computed for each new case.  
Define the Wilcoxon statistic W as the sum of the mid-ranks assigned to the smallest 
sample. The observed value of W is denoted by w. The two-sided P-value is then 
defined by  
2P(W ≤ w)if w ≤ E(W), and 2P(W ≥ w) otherwise, where probabilities and expected 
values are computed under the null hypothesis of equally likely permutations of the 
mid-ranks. Since the number of tests is of the order of thousands, one needs a fast 
calculation method. Moreover, asymptotic theory is often not applicable, because the 
number of biological replicates per condition is small and the presence of ties 
worsens the accuracy of asymptotic approximations. For example, when both sample 
sizes equal eight, cases with asymptotic P-value approximations in the range 
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0.0001–0.05 correspond to 2–3 times larger exact (true) P-values, which leads to 
more than a doubling of the number of false calls when using the approximations.  
Therefore, a fast algorithm to compute exact P-values is needed. The relevance of 
such algorithms to solve bioinformatics problems was recently shown by Bejerano et 
al. [6]. We developed the split-up algorithm [7], which suits the requirements well: it is 
fast, exact and deals with ties. The algorithm represents the probability distribution of 
the test statistic under the null hypothesis (‘no change between two conditions’) as a 
generating function. Baglivo et al. [8] showed that generating functions are powerful 
tools to represent null distributions of discrete test statistics. We used the generating 
function introduced by Streitberg and Röhmel [9]. This generating function is a 
polynomial in product form, expansion of which would reveal the entire null 
distribution, but this may be time consuming. The split-up algorithm splits the product 
into two parts and requires the expansion of these two smaller parts, which are 
several orders of magnitude faster than full expansion. Then, these two results are 
efficiently combined to compute the P-value. CGHMultiArray is written in 
Mathematica [10]. The basic algorithm is also available as R code and as an 
executable. To make the algorithm easily accessible, we provide a web 
implementation too.  
The website provides a tool to convert smoothed log2-ratios from other software to 
input data for CGHMultiArray. First, it transforms observed array CGH log2 values to 
discretized data: ‘1’ for gains, ‘−1’ for losses and ‘0’ for normals. It allows for the 
introduction of extra levels for amplifications or double deletions. Next, it counts 
occurrences of all levels for both conditions.  
The input for CGHMultiArray then consists of a simple text file, the rows of which 
represent clones in the chromosomal order. When ℓ is the number of levels used 
(three in this example), the first (second) ℓ columns represent counts of the number of 
control (treatment) samples attaining level j, j= 1, ..., ℓ. Optional columns may provide 
name, chromosomal information and base pair position information, which allows for 
separate P-value plots by chromosome. The algorithm stores all count 
configurations, so P-value computations for clones with the same configuration are 
not repeated. More details are provided in the manual. Note that when one would like 
to use only ℓ = 2 levels, e.g. for comparing gains, the Wilcoxon statistic with tie 
correction is equivalent to the hypergeometric statistic.  
We have used CGHMultiArray to analyze the genomic changes of two groups of 12 
head and neck tumors. Illustrative data shown here (also available on the website) 
are identical to the real data except for permutations of chromosomes. 
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CGHMultiArray generates an exportable list of univariate P-values, a DNA view of 
these (Fig. 1) and, optionally, a view by chromosome (data not shown). These views 
are useful to identify regions with unusually many differential aberrations. One may 
wish to perform a multiple testing correction to the P-values afterwards, such as the 
Benjamini and Yekutieli [11] FDR rule. In this case, one may want to focus on a 
limited number of clones or consider chromosomal regions instead of separate 
clones. An implementation for the latter option is provided on the website.  
 
 
 
Figure 1. DNA view of P-values by position for an illustrative dataset 
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ABSTRACT 
Oncogene expressing human papillomavirus type 16 (HPV16) is found in a subset of 
head and neck squamous cell carcinomas (HNSCC). HPV16 drives carcinogenesis 
by inactivating p53 and pRb with the viral oncoproteins E6 and E7, paralleled by a 
low level of mutations in TP53 and allelic loss at 3p, 9p and 17p, genetic changes 
frequently found in HNSCCs of non-viral etiology. We hypothesize that two pathways 
to HNSCC exist: one determined by HPV16 and one by environmental carcinogens. 
To define the critical genetic events in these two pathways, we now present a 
detailed genome analysis of HNSCC with and without HPV16 involvement by 
employing high resolution micro-array comparative genomic hybridization. Four 
regions showed alterations in HPV-negative tumors that were absent in HPV-positive 
tumors: losses at 3p11.2-26.3, 5q11.2-35.2, 9p21.1-24, and gains/amplifications at 
11q12.1-13.4. Also, HPV16-negative tumors demonstrated loss at 18q12.1-23, in 
contrast to gain in HPV16-positive tumors. Seven regions were altered at high 
frequency (>33%) in both groups: gains at 3q22.2-qter, 5p15.2-pter, 8p11.2-qter, 
9q22-34.1, 20p-20q and losses at 11q14.1-qter and 13q11-33. These data show that 
HNSCC arising by environmental carcinogens are characterized by genetic 
alterations that differ from those observed in HPV16-induced HNSCC, and most 
likely occur early in carcinogenesis. A number of genetic changes are shared in both 
tumor groups and can be considered crucial in the later stages of HNSCC 
progression.  
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INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) comprises about 5% of all newly 
diagnosed cancer cases in the Northern and Western European countries and the 
United States, and is the fifth most common cancer worldwide [1]. Despite advances 
in local tumor control, the five-year survival rates of approximately 50% have only 
moderately improved during the last 20 years, and identification of the cancer genes 
causally involved in carcinogenesis seems crucial to enable development of new 
therapeutic agents aimed at improving survival. HNSCC arises by the accumulation 
of genetic and epigenetic changes in oncogenes, tumor suppressor genes and/or 
DNA stability genes [2]. Using cytogenetics, loss of heterozygosity (LOH) analysis, 
and comparative genomic hybridization (CGH), over 20 recurrent chromosomal 
alterations have been found in invasive HNSCCs, including losses at 3p, 9p and 17p, 
and gains at 3q26 and 11q13 [3-7]. The relatively high frequencies of these 
chromosomal aberrations, which occur usually in over 30% of carcinomas, or the 
association with prognosis, argue for a role in head and neck carcinogenesis. 
HNSCC arises by a chemical etiology encompassing well-established causative life 
style related agents, like tobacco smoking and alcohol abuse. Recently, the role of 
the human papillomavirus (HPV) in head and neck carcinogenesis as a separate 
etiologic factor has been firmly established [8-10]. Human papillomaviruses are 
epitheliotropic DNA viruses with a genome of approximately 8 kb. More than 100 
subtypes are distinguished at present, and some subtypes have been assigned as 
high-risk types, as they are the main causative factors in the development of cervical 
cancer [11]. The virus produces two oncoproteins, encoded by the E6 and E7 genes, 
which inactivate the p53 and pRb proteins, respectively, providing cell cycle entry 
and DNA synthesis needed for viral replication. It was recently shown that tumors 
containing oncogene expressing HPV are genetically different from those that do not 
contain HPV and arose most likely as a result from exposure to environmental 
carcinogens. Tumors with oncogene expressing HPV (in particular HPV16) did not 
show any TP53 mutation and very limited allelic losses at 3p, 9p and 17p, while in 
75% of tumors not containing HPV a TP53 mutation had occurred and very frequent 
allelic loss was found [12]. These results suggest that an infection with HPV is an 
early event in HNSCC development that persists throughout the entire period of 
cancer progression. Moreover, the disruption of the pRb and p53 pathways by the 
viral oncoproteins is reflected in a unique genotype of tumors with oncogene 
expressing HPV. 
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These two different genetic pathways caused by chemical carcinogens and HPV 
leading to one single tumor type form a unique opportunity to detect the relevant 
genetic events in head and neck cancer. We now present for the first time a detailed 
and comprehensive genetic analysis of HNSCCs of different etiology. With a genome 
wide high-resolution method we determined the chromosomal regions that show 
different alterations between tumors with and without oncogene expressing HPV, and 
those that are shared, and combined the data to propose an integrated HNSCC 
progression model.  
 
RESULTS 
CGH profiles of HPV-positive and HPV-negative tumors 
Twelve tumors that were HPV DNA-positive with E6/E7 expression and twelve HPV-
negative tumors were selected from a previously published cohort of 143 tumors that 
had been analyzed for HPV and TP53 mutations [12], and maCGH was carried out. 
The two groups of tumors did not differ statistically with regard to patient age at 
diagnosis or tumor site (Table 1). The consumption of alcohol and tobacco was also 
not different between the groups (details in Table 1).  
The maCGH profiles were smoothed to define the regions that show copy number 
changes. The significance of the data was checked by calculating the 99% 
confidence interval on the log2 ratios of non-altered chromosomes for each sample. 
All values indicated as gain or loss by the smoothing algorithm exceeded the 99% 
confidence interval level, an indication for the reliability of the dataset. The total 
number of BAC-clones showing an alteration varied considerably between tumors: 
from 886 to 3,969 clones for HPV-negative tumors, and from 256 to 2,831 BAC 
clones for HPV-positive tumors. The frequency plot of alterations per BAC-clone of 
chromosome 1 to 22 is shown in Fig. 1. On average, the HPV-positive tumors 
showed a significantly (p=0.04, normal scores two-sample rank test) lower total 
number of alterations, as compared with HPV-negative tumors, i.e., 28% versus 44% 
of the BAC-clones studied, respectively. One HPV-positive tumor showed a 
remarkably low number of copy number changes (alterations for only 256 BAC 
clones), showing only gain of a small region of 11q and an extra copy of 
chromosome 20.  
GENETIC ALTERATIONS IN HEAD AND NECK CANCER 
 
 
 63 
 
Table 1. Patient and tumor characteristics in relation to HPV status of the tumor.  
Characteristic Case group 
HPV-positive* 
(n=12) 
 Control group 
HPV-negative* 
(n=12) 
Difference between 
cases and controls 
 No. %  No. % P† 
       
Sex       
      Male 9 75  8 67 1.0 
      Female 3 25  4 33  
       
Age at diagnosis, 
years 
      
      40-50  4 33  2 17 0.59 
      51-60  4 33  6 50  
      61-75 4 33  4 33  
       
Tobacco use       
      Never 1 9  2 17 0.59 
      Former 4 33  2 17  
      Current 7 58  8 66  
       
Total amount of 
tobacco consumed, 
pack years 
      
< 10 1 9  3 25 0.20 
≥10 to <40 9 75  4 33  
≥40 2 17  5 42  
       
Alcohol use       
      Never 1 9  3 25 0.22 
     Former 3 17  0 0  
     Current 9 75  9 75  
       
Tumor site       
     Oral cavity 6 50  6 50 1.0 
     Oropharynx 6 50  6 50  
            Tonsil 5 42  4 33 1.0§ 
            Nontonsil 1 9  2 17  
       
TP53 gene mutation       
     yes 0 0  10 83 <0.001 
     No 12 100  2 17  
*HPV-positive: positive for HPV DNA and expression of E6/E7; HPV-negative: negative for HPV DNA. 
†For the 2 x 2 comparison the Fisher’s exact test was used; for the other comparisons the Chi-square 
test was applied. A P-value <0.05 was considered to reflect a significant difference. 
§The frequency of tonsillar cancers was compared with cancer at all other sites 
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Figure 1. The frequency plot of DNA copy number changes at chromosome 1 to 22 is shown as 
determined on 12 HPV-positive and 12 HPV-negative HNSCCs. Cumulative results per chromosomal 
regions (based on 3,995 BAC clones) for each tumor group are presented. Loss or gain/amplification 
are indicated in gray and black, respectively. Differential chromosomal regions (p>0.02) between the 
groups are indicated by diagonally striped rectangles. Chromosomal regions with alterations in common 
are indicated by horizontally striped rectangles. 
 
 
Genetic alterations different between HPV-positive and HPV-negative tumors 
We analyzed the chromosomal regions that showed significant differences between 
the HPV-positive and HPV-negative tumors. Significantly (p<0.05) differential genetic 
alterations were found in nine regions (Table 2). Each significant chromosomal 
region consisted of spatially consecutive BAC clones and all regions encompassed in 
total 505 (12.6%) of the 3,969 clones analyzed. All significant regions spanned large 
parts of chromosomes or contained an entire chromosomal arm. The smallest 
different region just spanned four megabases and was located on chromosome 
11q12.1 - 11q13.4. For some chromosomal regions the significance was based on a 
small number of tumors with opposite alterations. For example, the region 1p31.1 - 
13.1 showed gains in two HPV-positive cases compared to losses in four cases of 
the HPV-negative group. In this example the opposite value (-1 vs. +1) of losses 
versus gains largely determined the significance. We therefore calculated the false 
discovery rate (FDR) on our data to adjust for multiple testing. FDR correction is 
likely to be conservative considering the relatively small number of cases, but several 
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differentially altered regions at various chromosomes remained highly significant, as 
indicated by relatively low FDR-values. The FDR value of 0.3 as for region 1p31.1 - 
13.1 indicates that the relevance of this finding should be interpreted with caution, 
and we therefore focused particularly on the regions with p values < 0.05 and low 
FDR values. 
 
 
Based on FDR correction five chromosomal areas were identified that displayed a 
very pronounced difference of alterations between the groups fulfilling the 
significance criterion (p<0.05). Four of these chromosomal regions were altered in a 
relatively large number of HPV-negative tumors, while hardly changed in the HPV-
positive group. First, loss of 3p11.2–26.3 was observed in more than 10 HPV-
negative cases, whereas in HPV-positive cases once a gain and twice a loss were 
found. Region 5q11.2–35.2 was lost in 8 cases of the HPV-negative group, whereas 
the 5q-arm was lost in just one case and gained in one case in the HPV-positive 
group. In addition, loss of 9p24-9p21.1 was seen in six cases of the HPV-negative 
group while this was not observed in the HPV-positive cases. Most striking 
observation was the gain or amplification of the 11q12.1–11q13.4 region in ten cases 
of the HPV-negative group while this gain was completely absent in the HPV-positive 
group. Furthermore, the difference of the region 18q12.1-18q23 was remarkable as it 
was lost in seven HPV-negative tumors and gained in five HPV-positive tumors 
(Table 2).  
 
Table 2. Chromosomal areas that are significantly different between HPV-positive and HPV-negative 
HNSCC 
HPV-positive (N) HPV-negative (N) 
Difference between
HPV-positive and 
-negative Region Size 
(Mbase) 
Gain Ampl Loss Gain Ampl Loss P-value FDR 
1p13.1 - 31.1 39 2 0 0 0 0 4 0.032 0.30 
3p11.2 – 26.3 87 1 0 2 0 0 10 0.001 0.03 
5q11.2 – 35.2 126 1 0 1 0 0 8 0.002 0.03 
7p14.3 - 21.3 22 1 0 1 6 0 0 0.046 0.30 
7q13.22 – 21.11 13 1 0 1 7 0 0 0.019 0.27 
9p21.1 - 24 34 2 0 0 3 0 6 0.014* 0.14* 
11q12.1 – 13.4 14 1 1 1 4 6 0 0.003 0.06 
18q12.1 – 23 52 5 0 1 0 0 7 0.004 0.07 
21p - 21q 62 2 0 0 1 0 5 0.026 0.30 
NOTE: Frequency of chromosomal regions with significantly different (P≤0.05; see Materials and 
Methods for the statistical test) alterations between HPV-positive and HPV-negative tumors are 
depicted. Amplifications were scored, when the 2-log value of the peak exceeded 1. Most significant 
regions, based on the criteria of p<0.05 and a relatively low FDR value are indicated in bold. Ampl. = 
Amplification. FDR = False Discovery Rate *Significance of the region 9p21.1 – 24 was reached only 
when the data were dichotomized in ‘losses’ and ‘no-losses’.  
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Genetic alterations common HPV-positive and HPV-negative tumors. 
Besides differential changes between HPV-negative and HPV-positive tumors also 
seven genomic regions were found with a high frequency of common gains and 
losses. Regions that showed common gains in more than 4 of 12 cases in each 
group were on chromosome arms 3q, 5p, 8p, 8q, 9q, 20p and 20q (Table 3). Regions 
that showed common chromosomal losses in more than 4 of 12 cases in each group 
were detected on chromosome arms 11q and 13q (Table 3). 
 
Table 3. Regions with frequent chromosomal alterations common in HPV-positive and HPV-negative 
HNSCC 
Region Size (Mbases) Alteration HPV(-) 
N (%) 
HPV(+) 
N (%) 
3q22.2-qter 98 Gain 9 (75) 7 (58) 
5p15.2-pter 36 Gain 6 (50) 4 (33) 
8p11.2-qter 111 Gain 10 (83) 7 (58) 
9q22-34.1 49 Gain 6 (50) 6 (50) 
11q14.1-qter 54 Loss 8 (66) 8 (66) 
13q11-33 95 Loss 6 (50) 7 (58) 
20p – 20q 47 Gain 6 (50) 5 (42) 
NOTE: Genetic alterations common among HPV-positive and HPV-negative HNSCC. A region was 
scored as being altered when at least 4 out of 12 tumors in both groups showed alteration. 
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DISCUSSION 
The role of HPV as an important carcinogenic agent in a subset of HNSCCs has 
been well-established at present. Very recently Braakhuis et al. [12] suggested, 
based on the analysis of HPV status, TP53 mutation and loss of heterozygosity 
(LOH), that two genetic routes of multi-step head and neck carcinogenesis exist. 
According to their hypothesis the first and most frequent route results from chemical 
carcinogen exposure and is characterized by frequent TP53 mutations and allelic 
loss of large chromosomal regions at 3p, 9p, and 17p, which are considered early 
events in HNSCC development [9;13-18]. The second route is associated with active 
HPV infection and characterized by lack of TP53 mutations and a low level of allelic 
loss. These data were interpreted as proof for the concept that HPV16 is actively 
involved in the early steps of the development of a subgroup of HNSCC and that the 
virus remains active during the entire carcinogenic process [12;19]. We now show 
the common and differential genetic alterations between the two groups of tumors. 
Four chromosomal regions showed more alterations in HPV-negative tumors (either 
gains or losses) than in HPV-positive tumors (hardly any or no changes): loss at 
3p11.2-26.3, 5q11.2-35.2, 9p21.1-24, and gain/ amplification at 11q12.1-13.4. Since 
there is evidence that an active HPV infection occurs early in cervical and HNSCC 
carcinogenesis [11;12], the genetic alterations that have been found presently in the 
HPV-negative tumors only, are likely to reflect the early carcinogenesis. These 
alterations can be considered an alternative for the biological effects of the viral 
oncogenes E6 and E7. The frequent gain/amplification at 11q13 and the frequent 
loss at the region 9p21 in HPV-negative tumors, while showing no alteration in HPV-
positive tumors seem biologically plausible in this respect. The most likely candidate 
oncogene at the highly significantly amplified region 11q13 is CCND1 (Cyclin D1), a 
component of the CDK/Cyclin complex that phosphorylates pRb causing S-phase 
entry. In addition, the region 9p21 encompasses the tumor suppressor gene 
CDKN2A (p16), an important inhibitor of the CDK/Cyclin complex preventing S-phase 
entry, that is often altered in HNSCC. In HPV-infected tumors the pRb pathway is 
disrupted by the oncoprotein E7 while apparently in HPV-negative tumors the 
pathway is impaired by mutation or loss of p16 and/or amplification of CCND1. In the 
present study 5/12 tumors showed both loss at 9p21 and gain/ amplification at 
11q13, suggesting that in some cases it seems necessary to alter two components of 
the pRb pathway to be at least functionally equivalent to pRb binding by HPV E7. 
This hypothesis needs to be proven by in vitro or mouse models. 
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In contrast to the biologically plausible findings concerning the pRb pathway, we did 
not observe a difference at a region we also expected to find, namely, the region 
17p13, encompassing the tumor suppressor gene TP53. The viral oncogene E6 
binds and inactivates p53, while in tumors without HPV involvement TP53 gene is 
mostly inactivated by mutation, often accompanied with allelic loss [12;20-22]. In a 
previous study, we showed that a significant difference in allelic loss frequency at 
17p was observed between HPV-positive and HPV-negative tumors as determined 
by microsatellite markers [12]. In the HPV-negative HNSCC frequent TP53 mutations 
and allelic loss at 17p was found, while absent in the HPV-positive tumors. With 
maCGH we found frequent copy number gains at this locus in the HPV-negative 
group, while expecting copy number losses. This paradox can be explained by the 
fact that using microsatellite markers allelic imbalance is measured, either gain or 
loss of an allele. In the present maCGH analysis a mixture of gains and losses was 
observed in the HPV-negative tumors, making it impossible to detect the difference.  
Some of the loci that show significant differences between HPV-positive and HPV-
negative tumors have been reported in other studies that focused on the identification 
of genetic events associated with prognosis of HNSCC. Loss of 3p and gain or 
amplification of 11q13 were previously identified by Bockmuhl et al. [3] as alterations, 
associated with poor clinical outcome. Also in the study of Wreesmann et al. [7], 
amplification of 11q13 and deletion of 5q11-15 amongst other changes were shown 
to have a prognostic value in HNSCC. These results are in line with previous 
observations that HPV-positive tumors have in general a better prognosis [10]. An 
intrinsic problem with these approaches, however, remains that genetic changes that 
are specifically linked to clinical failures, may only reflect late progression and do not 
allow identification of chromosomal loci that play a role in the earlier phase of 
carcinogenesis. Moreover, the different outcomes, distant metastasis, locoregional 
recurrence as result of residual cancer cells or second field tumors [22;24], are very 
different biologically entities and most likely associated with different genetic 
changes. 
The majority of loci presented here showed losses or gains in HPV-negative tumors 
and no apparent changes in HPV-positive tumors. There appeared to be one 
exception. Chromosomal region 18q12.1-23 was lost in 7 of 12 (58%) HPV-negative 
tumors, but appeared to be gained in 5 of 12 (41%) HPV-positive tumors. SMAD4 
has been proposed as a candidate cancer gene at 18q21.1, as deletion and mutation 
of this gene in a subset of HNSCC was observed [25;26]. Whether this or another 
gene is involved in HPV-induced HNSCC remains to be determined. 
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Besides differences, both tumor groups were shown to share several altered regions. 
Gains at 3q22.2-qter, 5p15.2-pter, 8p11.2-8qter, 9q22-34.1, 20p-20q, and loss of 
11q14.1-qter (telomeric from the 11q13 amplicon) and 13q11-33 were detected in 
often more than 50% of the tumors in both groups. These can be considered genetic 
changes that are important in head and neck carcinogenesis as they frequently occur 
independent from the etiological factors causing these tumors. The question can be 
asked how these common alterations should be placed in the time-frame of HNSCC 
multistep carcinogenesis. The most likely option is that these common alterations 
occur late in progression.  
The results of the present study are consistent with and provide further evidence for 
the hypothesis that HNSCCs develop by two different etiologies: one driven by 
exposure to environmental carcinogens (i.e. tobacco and alcohol) without HPV 
involvement and the other involving infection with oncogene expressing HPV16 
[10;27;28]. However, we now also provide evidence that the two carcinogenic routes 
– one with HPV and one without HPV involvement – partly overlap. As stated above, 
this finding may implicate that these common alterations are necessary events in 
HNSCC, irrespective the etiological factor. It can not be excluded, however, that the 
overlapping genetic events are related to the exposure to cigarette smoke. Most of 
our HPV-positive patients have smoked or are current smokers, making this group 
not different from the normal HNSCC patient population in that respect. Our present 
results show that although the two carcinogenic routes, virus and exposure to 
environmental carcinogens, differ in multiple ways, particularly related to the early 
genetic events and the activity of the known viral oncogenes E6 and E7, the late 
genetic events are common. The results of the present study indicate that to describe 
the development of HNSCC an integrated genetic progression model needs to be 
considered. This model presented in Fig. 2 builds upon the previous existing models 
but now includes the HPV route and the different and common genetic events [9;18]. 
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Figure 2. A genetic progression model of multi-step head and neck carcinogenesis is proposed. The 
two etiological factors, smoking and HPV16 are incorporated into the “patch-field-cancer” model that in 
essence has previously been published [9]. In this model the development of a field with genetically 
altered cells play a central role. In the initial phase a “patch” develops, a clonal unit in which the stem 
cell and its daughter cells acquire a genetic alteration. Some evidence point to an alteration in 
p53/MDM2 pathway as a likely first event. This pathway is disrupted by a mutation of TP53 in case of 
smoking as a causative factor, or alternatively, by the HPV effect of E6, that results in a degradation of 
p53. The conversion of a patch into a field is the next step in this progression model, and this field 
expands at the expense of normal epithelium. An important event in the field phase is the impairment of 
the p16/CDK/pRb pathway [22]. In case of smoking this pathway is disrupted by inactivating CDKN2A, 
the gene encoding p16, by mutation, chromosomal loss or promoter hypermethylation. Alternatively, this 
pathway can be impaired by E7, a protein that is produced by HPV. Next, clonal divergence leads to the 
development of one or more tumors within the contiguous field of preneoplastic cells. Considering the 
two etiological factors, the common and differential chromosomal events possibly involved in the 
progression from field to carcinoma are shown. At this moment it is difficult to point out the pathways 
that are involved in this stage of carcinogenesis. CCND1 (Cyclin D1) is likely involved in smoking-related 
HNSCC, since the 11q13 region is found to be highly significantly amplified; cyclin D1 is part of the 
p16/CDK/pRb pathway, a component of the CDK/Cyclin complex that phosphorylates pRb causing S-
phase entry. 
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MATERIAL AND METHODS 
 
Patients and tumor specimens 
We obtained tumor specimens from 143 consecutive patients who underwent 
surgical treatment for a tumor in the head and neck region at the VU University 
Medical Center. Primary tumor samples were immediately snap-frozen in liquid 
nitrogen and stored at –80 oC. In twelve tumors HPV16 DNA and E6/E7 mRNA 
expression was determined. This was considered to reflect direct viral involvement 
and was used as selection criterion for the case group [12]. The HPV-positive case 
group was compared with a HPV DNA-negative control group of 12 HNSCC, in part 
(10/12) similar as the group previously published [12]. Cases and controls were 
stratified according to tumor site (oral cavity or oropharynx), as well as degree of 
differentiation and further selected in such a way that a similar distribution over the 
groups was ensured for those clinical parameters that might in theory confound the 
analysis (i.e., age, sex, smoking and drinking behavior and TNM-stage). The Fisher’s 
exact test and chi-square test were used to asses the statistical significance of 
frequency distributions between case and control groups (Table 1). The study was 
approved by the Institutional Review Board of the VU University Medical Center, and 
written informed consent was obtained from all patients. 
Information on patient tobacco and alcohol use was obtained from the medical files. 
Patients were classified as never, former (at least one year of tobacco abstinence), 
or current daily tobacco smokers as well as never, former, or current alcohol drinkers.  
  
Detection of high-risk HPV DNA and E6/E7 transcripts  
Frozen tumor samples were used for HPV analysis and for all tumor samples 
microdissection was performed to enrich for tumor tissue. DNA and RNA was 
extracted as described previously [22]. Detection of the presence of HPV16 DNA and 
expression of the oncogenes E6 and E7 was performed as previously described [12].  
 
Micro-array Comparative Genomic Hybridization 
Arrays of Bacterial Artificial Chromosomes (BACs) were prepared from the 1 Mb 
resolution Sanger BAC set (http://www.ensembl.org/Homo_sapiens/index.html), and 
the OncoBAC set (http://informa.bio.caltech.edu/Bac_onc.html), and in house clones 
of interest, supplemented with clones from the Children’s Hospital Oakland Research 
Institute (CHORI), amounting to a total of 5,659 clones with known chromosomal 
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positions. DNA of BAC clones was isolated according to published protocols 
available on the web (http://bacpac.chori.org/dnaprep.htm). 
Amplification of BAC clone DNA was performed by ligation-mediated polymerase 
chain reaction (PCR) according to Snijders et al. [23], followed by purification with 
Montage PCR µ96 filter plates (Millipore BV, Amsterdam, the Netherlands). This DNA 
was spotted at a concentration of 10 µg/µL in 150mM sodium phosphate buffer, 
pH8.5) on CodeLinkTM microscopic glass slides (Amersham Bioscience, 
Roosendaal, the Netherlands), using a Spot Array 72 robot (Perkin Elmer Life 
Sciences, Zaventum, Belgium). The printed glass slides were further processed 
according to instructions of the manufacturer. 
Test DNA, extracted as described previously [22] and reference genomic DNA 
isolated from randomized blood donors (300 ng of each) were labeled with a random 
primer elongation kit (Invitrogen, Breda, The Netherlands) in a 50 µL reaction with 
Cy3 dCTP and Cy5 dCTP (Perkin Elmer Life Sciences). Non-incorporated 
nucleotides were removed using ProbeQuant G-50 Micro Columns (Amersham 
Biosciences). Labeled DNA was mixed with Cot-1 DNA (Invitrogen) and precipitated 
with ethanol. DNA was dissolved in 190 µl hybridization mix with a final composition 
of 50% formamide, 10% dextran sulphate, 2x SCC, 4% SDS, and 1.3 mg yeast 
tRNA. The hybridization solution was heated to 73 °C for 10-15 minutes to denature 
the DNA, and then incubated at 37 °C for one hour to allow blocking of repetitive 
sequences. The array-slides were prehybridized with hybridization mix containing 
650 µg salmon sperm DNA without probe at 37 °C in a hybridization station 
(Hybstation 12; Perkin Elmer Life Sciences) for one hour. Subsequently slides were 
hybridized for 48 hour at 37°C. After hybridization, slides were washed six times in 
50% formamide, 2x SCC, pH 7.0, at 45 °C, and twice in PN buffer (0.1 M sodium 
phosphate, 0.1% nonidet P40, pH 8.0) at room temperature, twice with 0.2x SCC and 
twice with 0.1x SCC. Slides were scanned with Scan Array Express (Perkin Elmer 
Life Sciences). 
 
Image acquisition and data analysis 
Image analysis was carried out with ImageneTM software (BioDiscovery, El 
Segundo, California, USA). Spots with non-homogeneous fluorescence were 
automatically flagged and excluded from further analysis. Mean log2 ratios of the 
triplicate Cy3 and Cy5 signals of each spot were calculated in a spreadsheet (Excel 
2000, Microsoft Corp, Amsterdam, The Netherlands) after subtraction of the mean 
local background. BAC clones with a standard deviation above 0.2 over the triplicate 
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values were excluded from further analysis. Normalization per array was carried out 
using the modus of the log2 ratios of all unflagged clones. The clones were ordered 
by position in the genome according to the UCSC draft genome sequence (“freeze” 
July 2003, http://www.sanger.ac.uk). With a “smoothing” algorithm the gains (>0) and 
losses (<0) were defined over chromosome 1 to 22 on basis of the log2 values [29]. 
The smoothing algorithm “aCGH-Smooth” uses a heuristic algorithm, based on the 
assumption that the experimental noise in the data is generated by a Gaussian 
process. It identifies breakpoints and smooths the observed array CGH values 
between consecutive breakpoints to a suitable common value. All log2 ratios 
exceeding 1.0 were considered to indicate amplifications. Chromosome X-clones 
were discarded from further analysis, since all tumor samples were hybridized to 
reference DNA of the opposite gender. Only data of BACs were included in the 
analysis when at least 20/24 tumors showed a value. After the exclusion procedures 
a total number of 3,969 clones could eventually be analyzed per each array.  
To perform this analysis, the “smoothed”-log2 ratios were converted to categorized 
data of `+1` for chromosomal gains, `-1` for chromosomal losses and `0` if no change 
was determined. To identify the differential chromosomal loci between the two tumor 
groups these smoothed data were used for the Wilcoxon rank sum test with ties, 
which was implemented in two web-based applications: “CGHMultiArray” and 
“CGHMultiArrayRegion” test (www.win.tue.nl/~markvdw/CGHMultiArray.html), 
especially developed for differential genetic analyses using CGH micro-array data 
[30]. Both tests take the discrete nature of the smoothed data into account. The first, 
“CGHMultiArray”, computes P-values per clone, and the second, 
“CGHMultiArrayRegion” test defines regions of adjacent and identical alterations 
which are then considered as one testing entity. This reduces the multiplicity problem 
severely and allows adaptation of the usual Benjamini-Hochberg FDR type 
corrections. For more information we refer to the supplementary information at 
http://webmathematica.win.tue.nl/mark/cghregion/index.html. 
We noted that the analysis could be disturbed by opposite events that occurred only 
in a few tumors. These events can be considered accidental and therefore we also 
performed the statistical analysis by comparing two groups by adjusting either all 
gains or all losses to ‘no change’ (from ‘+1’ to ‘0’ or from ‘-1’ to ‘0’, respectively). 
CHAPTER 4 
 
 
74 
 
ACKNOWLEDGMENTS 
We thank the mapping core and map finishing groups of the Wellcome Trust Sanger 
Institute for initial BAC clone supply and verification. We are indebted to M Tijssen, 
PP Eijk, E Hopmans and P van den IJssel for printing slides and technical 
assistance. 
  
 
GENETIC ALTERATIONS IN HEAD AND NECK CANCER 
 
 
 75 
REFERENCES  
 1.  Pisani, P., Bray, F., Parkin, D.M. (2002) Estimates of the World-Wide Prevalence of Cancer for 25 
Sites in the Adult Population. Int J Cancer, 97, 72-81. 
 2.  Vogelstein, B. and Kinzler, K.W. (2004) Cancer genes and the pathways they control. Nat Med, 
10, 789-99. 
 3.  Bockmuhl, U., Schluns, K., Kuchler, I., Petersen, S., Petersen, I. (2000) Genetic Imbalances With 
Impact on Survival in Head and Neck Cancer Patients. Am JPathol, 157, 369-75. 
 4.  Gollin, S.M. (2001) Chromosomal alterations in squamous cell carcinomas of the head and neck: 
window to the biology of disease. Head Neck, 23, 238-53. 
 5.  Beder, L.B., Gunduz, M., Ouchida, M., Fukushima, K., Gunduz, E., Ito, S., et al. (2003) Genome-
Wide Analyses on Loss of Heterozygosity in Head and Neck Squamous Cell Carcinomas. Lab 
Invest, 83, 99-105. 
 6.  Tsao, A.S., Kim, E.S., Hong, W.K. (2004) Chemoprevention of cancer. CA Cancer J Clin, 54, 
150-80.  
 7.  Wreesmann, V.B., Shi, W., Thaler, H.T., Poluri, A., Kraus, D.H., Pfister, D., et al. (2004) 
Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and 
neck. J Clin Oncol, 22, 3965-72.  
 8.  Dahlgren, L., Mellin, H., Wangsa, D., Heselmeyer-Haddad, K., Bjornestal, L., Lindholm, J., et al. 
(2003) Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern 
of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer, 107, 
244-9.  
 9.  Braakhuis, B.J., Leemans, C.R.,  Brakenhoff, R.H. (2004) A genetic progression model of oral 
cancer: current evidence and clinical implications. J Oral Pathol Med, 33, 317-22. 
 10.  Gillison, M.L., Koch, W.M., Capone, R.B., Spafford, M., Westra, W.H., Wu, L., et al. (2000) 
Evidence for a causal association between human papillomavirus and a subset of head and neck 
cancers. J Natl Cancer Inst, 92, 709-20. 
 11.  zur Hausen, H. (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat 
Rev Cancer, 2, 342-50. 
 12.  Braakhuis, B.J.M., Snijders, P.J.F., Keune, W.J.H., Meijer, C.J.L.M., Ruijter-Schippers, H.J., 
Leemans, C.R., et al. (2004) Genetic patterns in head and neck cancers that contain or lack 
transcriptionally active human papillomavirus. J Natl Cancer Inst, 96, 998-1006. 
 13.  van der Riet, P., Nawroz, H., Hruban, R.H., Corio, R., Tokino, K., Koch, W., et al. (1994) Frequent 
loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res, 54, 1156-
8. 
 14.  Mao, L., Lee, J.S., Fan, Y.H., Ro, J.Y., Batsakis, J.G., Lippman, S., et al. (1996) Frequent 
microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their 
value in cancer risk assessment. Nat Med, 2, 682-5. 
 15.  Partridge, M., Pateromichelakis, S., Phillips, E., Emilion, G.G., A'Hern, R.P., Langdon, J.D. (2000) 
A case-control study confirms that microsatellite assay can identify patients at risk of developing 
oral squamous cell carcinoma within a field of cancerization. Cancer Res, 60, 3893-8. 
 16.  Rosin, M.P., Cheng, X., Poh, C., Lam, W.L., Huang, Y., Lovas, J., et al. (2000) Use of allelic loss 
to predict malignant risk for low-grade oral epithelial dysplasia.  Clin Cancer Res, 6, 357-62. 
 17.  Tabor, M.P., Braakhuis, B.J., van der Wal, J.E., van Diest, P.J., Leemans, C.R., Brakenhoff, R.H., 
et al. (2003) Comparative molecular and histological grading of epithelial dysplasia of the oral 
cavity and the oropharynx. J Pathol, 199, 354-60. 
 
CHAPTER 4 
 
 
76 
 18.  Califano, J., Vanderriet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., et al. (1996) 
Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization. 
Cancer Research, 56, 2488-92. 
 19.  Mao, L. and Hong, W.K. (2004) How Does Human Papillomavirus Contribute to Head and Neck 
Cancer Development? Journal of the National Cancer Institute, 96, 978-80. 
 20.  Ahomadegbe, J.C., Barrois, M., Fogel, S., Le Bihan, M.L., Douc-Rasy, S., Duvillard, P., et al. 
(1995) High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck 
primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein 
overexpression in normal epithelium and in early non-invasive lesions. Oncogene, 10, 1217-27. 
 21.  Erber, R., Conradt, C., Homann, N., Enders, C., Finckh, M., Dietz, A., et al. (1998) TP53 DNA 
contact mutations are selectively associated with allelic loss and have a strong clinical impact in 
head and neck cancer. Oncogene, 16, 1671-9. 
 22.  Tabor, M.P., Brakenhoff, R.H., van Houten, V.M., Kummer, J.A., Snel, M.H., Snijders, P.J.F., et 
al. (2001) Persistence of genetically altered fields in head and neck cancer patients: biological 
and clinical implications. Clin Cancer Res, 7, 1523-32. 
 23.  Snijders, A.M., Nowak, N., Segraves, R., Blackwood, S., Brown, N., Conroy, J., et al. (2001) 
Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet, 29, 
263-4. 
 24.  Tabor, M.P., Brakenhoff, R.H., Ruijter-Schippers, H.J., Kummer, J.A., Leemans, C.R., Braakhuis, 
B.J.M. (2004) Genetically altered fields as origin of locally recurrent head and neck cancer: a 
retrospective study. Clin Cancer Res, 10, 3607-13..  
 25.  Hahn, S.A., Schutte, M., Hoque, A.T., Moskaluk, C.A., da Costa, L.T., Rozenblum, E., et al. 
(1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271, 
350-3. 
 26.  Kim, S.K., Fan, Y.H., Papadimitrakopoulou, V., Clayman, G., Hittelman, W.N., Hong, W.K., et al. 
(1996) Dpc4, a Candidate Tumor Suppressor Gene, Is Altered Infrequently in Head and Neck 
Squamous Cell Carcinoma. Cancer Research, 56, 2519-21. 
 27.  Herrero, R., Castellsague, X., Pawlita, M., Lissowska, J., Kee, F., Balaram, P., et al. (2003) 
Human papillomavirus and oral cancer: the International Agency for Research on Cancer 
multicenter study. J Natl Cancer Inst, 95, 1772-83. 
 28.  van Houten, V.M., Snijders, P.J.F., van den Brekel, M.W., Kummer, J.A., Meijer, C.J.L.M., van 
Leeuwen, B., et al. (2001) Biological evidence that human papillomaviruses are etiologically 
involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer, 93, 232-5. 
 29.  Jong, K., Marchiori, E., Meijer, G., Van Der Vaart, A., Ylstra, B. (2004 ) Breakpoint Identification 
and Smoothing of Array Comparative Genomic Hybridization Data. Bioinformatics, 20, 3636-7. 
 30.  van de Wiel, M.A., Smeets, S.J., Brakenhoff, R.H., Ylstra, B. (2005) CGHMultiArray: exact P-
values for multi-array comparative genomic hybridization data. Bioinformatics, 21, 3193-4. 
 
 CHAPTER 5 
 
Genetic classification of oral and oropharyngeal 
carcinomas identifies subgroups with a different 
prognosis 
 
 
Cellular Oncology (2009); in press 
 
 
 
 
Serge J. Smeets* 
Ruud H. Brakenhoff* 
Bauke Ylstra 
Wessel N. van Wieringen 
Mark A. van de Wiel 
C. René Leemans 
Boudewijn J. M. Braakhuis 
*These authors contributed equally  
CHAPTER 5 
 
 
78 
 
ABSTRACT 
The common risk factors for oral and oropharyngeal cancer are tobacco smoking and 
alcohol consumption, and recently the human papillomavirus (HPV) was shown to be 
involved in a subgroup. HPV-positive and -negative carcinomas can be distinguished 
on basis of their genetic profiles. Aim of this study was to investigate patterns of 
chromosomal aberrations of HPV-negative oral and oropharyngeal squamous cell 
carcinomas (OOSCC) in order to improve stratification of patients regarding outcome. 
Thirty-nine OOSCCs were classified on basis of their genetic pattern determined by 
array comparative genomic hybridization (aCGH). Resulting groups were related to 
patient and tumor characteristics using the Fisher’s exact test and in addition to 
survival with the Kaplan-Meier and log rank tests. Classification distinguished three 
groups, one characterized by hardly any chromosomal aberration (N=8), and another 
by a relatively high level (N=26), and one with a very high level (N=5) of 
chromosomal aberrations. This classification was significantly (p=0.003) associated 
with survival, with the best survival in the genetically ‘silent’ group and the worst 
survival in the most aberrant group. The silent profile was significantly (p<0.05) 
associated with wild-type TP53, an absence of alcohol consumption and a female 
gender. These carcinomas were negative for microsatellite instability. This 
classification of OOSCC was confirmed in an independent set of 89 oral carcinomas. 
In conclusion: The discovery of these new classes of oral and oropharyngeal cancer 
with unique genetic and clinical characteristics has important consequences for 
future basic and clinical studies. 
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INTRODUCTION 
Oral and oropharyngeal squamous cell carcinomas (OOSCC) develop in the mucosal 
linings of the oral cavity and oropharynx and constitute with hypopharyngeal and 
laryngeal carcinomas the group of head and neck squamous cell carcinomas. 
Despite significant advances in loco-regional control, long-term survival of OOSCC 
patients has only moderately improved during the last 20 years. The identification of 
biological markers will be essential to make headway in detecting this malignancy at 
an early stage and developing novel therapies. 
The major and classical risk factors for OOSCC are exposure to tobacco and alcohol, 
but it has recently become clear that also an infection with human papillomavirus 16 
(HPV16) plays an important role in a subgroup of these tumors. There is convincing 
evidence that HPV–infected tumors form a completely distinct group. These tumors 
differ from non-infected tumors with respect to risk factors [13], absence of a TP53 
mutations [38,42], a low level of allelic losses [5] and mRNA expression profiles [30]. 
This distinct pathological entity may be the reason for a better response rate and 
survival [11,43].  
Genetic analysis of cancers with array comparative genomic hybridization (aCGH) 
makes it nowadays possible to analyze DNA copy number variations with high 
resolution [12]. With aCGH it could be shown that HPV-infected tumors are also 
distinct from non-infected OOSCC regarding DNA copy number changes [31].  
We hypothesized that other subgroups of non-HPV-involved carcinomas exist that 
differ regarding their pattern of genetic alterations and that this might have 
consequences for prognosis. Previously, it was shown that breast cancers and 
leukemia could be divided into prognostic relevant subgroups using expression array 
analysis [18,40]. These classifications are based on algorithms using the T-statistics 
as expression data are normally distributed. Only recently, cluster algorithms like 
WECCA, tailor-made for ordered aCGH data sets, became available [7,41]. The 
present study aims to identify distinct groups of non-HPV OOSCC by means of 
aCGH analysis and unsupervised cluster analysis. Different genetic groups were 
identified and could be linked to clinical parameters.  
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MATERIAL AND METHODS 
 
Patients and tumor specimens 
We obtained tumor specimens from 39 patients who underwent surgical treatment for 
a carcinoma in the oral cavity or oropharynx at the VU University Medical Center. 
This group was randomly selected from our tissue collection that contains snap-
frozen carcinomas, gathered during the period from 1997 to 2001. To exclude the 
presence of HPV, detection of viral DNA and expression analysis of the oncogenes 
E6 and E7 was performed as previously described [31,38]. The mutational status of 
TP53 of these carcinomas was determined in the evolutionarily conserved regions, 
exons 5 to 9 [39]. When no mutations were found in these exons, the remaining 
coding exons 2, 3, 4, 10 and 11 were sequenced in addition. Mutations were also 
classified in disruptive or non-disruptive mutations, according to the criteria used by 
Poeta et al. [27]. In brief, these criteria are based on the location of the mutation and 
the type of predicted amino acid alteration. For all studies microdissection was 
performed to enrich for carcinoma tissue. The study had been approved by the 
Institutional Review Board of the VU University Medical Center, and written informed 
consent was obtained from all patients. Staging was performed according to the 
classification of the International Union Against Cancer (UICC) [33] and information 
on patient tobacco and alcohol use was obtained from the medical files. Patients 
were classified as never, current or former tobacco smokers. Pack-years were taken 
as a measure of cumulative tobacco consumption. It is calculated by multiplying the 
number of packs of cigarettes smoked per day by the number of years the person 
has smoked. Patients were classified as never, current or former alcohol drinkers. 
Unit-years were taken as a measure of cumulative alcohol consumption and were 
calculated as the number of years drinking multiplied by the number of units per day. 
A unit is defined as one alcoholic beverage (equivalent to approximately 15 mL of 
alcohol). 
 
Array Comparative Genomic Hybridization 
Test DNA (300 ng), extracted as described previously [39] and reference genomic 
DNA (300 ng) isolated from a random panel of blood donors were labeled with a 
random primer elongation kit (Invitrogen, Breda, The Netherlands). Arrays of 
Bacterial Artificial Chromosomes (BACs) were prepared and hybridized as described 
previously [31].  
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Image acquisition and data analysis 
Image analysis, the exclusion of bad spots and the calculation of the mean log2 
ratios of triplicate Cy3 and Cy5 signals were performed as previously described [31]. 
The data discussed in this publication have been deposited in NCBIs Gene 
Expression Omnibus (GEO), and are accessible through GEO series accession 
number GSE11929. 
Chromosome X-clones were discarded from further analysis, since all tumor samples 
were hybridized to reference DNA of the opposite gender. Data of a BAC was only 
included in the analysis when at least 80% of the tumors showed a value for that 
particular BAC. A total number of 4,062 clones could be analyzed for all samples. 
The log2 ratios are segmented by means of ‘DNAcopy’ [25], and called by means of 
‘CGHcall’ [36]. The calling results in the so-called call probabilities, a probability 
vector for each feature on the array: a probability of a loss, a probability of ‘no-
aberration’, and a probability of a gain. The maximum probability indicates the most 
likely aberration. The use of call probabilities in down-stream analyses prevents the 
loss of information associated with the use of calls. Finally, genomically adjacent 
features not separated by a breakpoint have the same call probability signature over 
the samples. Therefore, the data are reduced to the unique, non-spurious call 
probability signatures by means of ‘CGHregions’ [37]. 
The samples are clustered by means of a modified version of WECCA [41]. WECCA 
is a hierarchical clustering method tailor-made for called aCGH data. The modified 
version accommodates the use of call probabilities instead of calls. The use of the 
call probabilities in the unsupervised analysis will give a more subtle picture of the 
similarities and differences between the samples. The modified version of WECCA 
defines the distance between two features as the absolute difference between the 
cumulative call probability distributions. The distance between the call probability 
profiles of two samples is then defined as the average of these differences over all 
features. In the construction of the dendrogram we used Ward's linkage as it yields 
compact and well-separated clusters. Chromosomal breakpoints were calculated 
from the segmented data. 
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Differences between groups as for frequencies of patient and tumor characteristics 
were performed with the 2 x 2 and 2 x3 Fisher’s exact test. Continuous variables 
were compared with the Mann-Whitney (two groups) or the Kruskal-Wallis (three 
groups) test. Survival characteristics were determined according to the Kaplan-Meier 
method and survival curves were compared with the log-rank test. All tests were two-
sided and differences were considered to be significant if the P-value was below 
0.05. 
 
Micro Satellite Instability (MSI)  
MSI was detected using a MSI analysis system (Promega corporation, Madison, 
USA), according to instructions of the manufacturer. In short, this system uses 
fluorescently labeled primers (marker panel) for co-amplification of seven markers for 
analysis of the MSI-high (MSI-H) phenotype, including five nearly monomorphic 
mononucleotide repeat markers (BAT-25, BAT-26, MON0-27, NR-21 and NR-24) and 
two highly polymorphic pentanucleotide repeat markers (Penta C and Penta D). 
These markers are recommended by the National Cancer Institute (NCI) workshop 
for identifying MSI-type colorectal cancer [35]. Amplified fragments were detected by 
a sequence analyzer (model 3100 from Applied Biosystems BV, Nieuwerkerk a/d 
IJssel, Netherlands).  
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 Table 1. Patient and tumor characteristics in relation to genetic classification 
Group  Difference (p-values) 
Characteristic 1 2a 2b  1 vs. 2 1 vs. 2a vs. 2b 
Number 8 26 5    
       
Age (in years)     0.772 0.930 
Average 58.6 59.0 61.4    
Range 43-81 38-76 42-79    
       
Gender     0.235 0.021 
Female 6 14 0    
Male 2 12 5    
       
Tumor Site     0.652 0.554 
Oropharynx 1 7 2    
Oral cavity 7 19 3    
       
Pathological tumor Stage       
I +II 6 13 3  0.426 0.567 
III + IV 2 12 2    
Unknown 0 1 0    
       
Pathological nodal stage       
N- 2 10 2  0.683 0.781 
N+ 6 15 3    
       
Smoking§       
Current + former 5 22 5  0.302 0.524 
Never 2 4 0    
Unknown 1 0 0    
Pack-years     0.644 0.680 
Average 37 31 39    
Range. 0-84 0-65 23-61    
       
Alcohol‡       
Current + former 2 20 5  0.014 0.014 
Never 5 6 0    
Unknown 1 0 0    
Unit-years     0.199 0.230 
Average 103.57 136.0 138.0    
Range. 0-405 0-450 120-244    
       
TP53       
Mutated 1 15 2  0.049 0.076 
Wild-type 7 11 3    
       
Disruptive mutation 0 11 2  0.035 0.061 
Non-Disruptive/Wild-type 8 15 3    
       
Average number of 
breakpoints     <0.001 <0.001 
Average 2.8 30.0 52.8    
Range 0-6 12-49 31-80    
Characteristics of the three groups as classified with WECCA (Figure 1) are listed. Group1 tumors show 
the lowest and group 2b the highest level of aberrations. P values are two-sided and for the 2 x 2 and 2 
x3 frequency comparisons the Fisher’s exact test was used and for the mean comparisons, the Mann-
Whitney or the Kruskal-Wallis test. Significant differences (P<0.05) are shown in bold. § Patients were 
classified as never, current or former tobacco smokers. Pack-years were taken as a measure of 
cumulative tobacco consumption. It is calculated by multiplying the number of packs of cigarettes 
smoked per day by the number of years the person has smoked. ‡ Patients were classified as never, 
current or former alcohol drinkers. Unit-years were taken as a measure of cumulative alcohol 
consumption and were calculated as the number of years drinking multiplied by the number of units per 
day. A unit is defined as one alcoholic beverage (equivalent to approximately 15 mL of alcohol). 
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RESULTS 
To investigate whether classification on the basis of genetic aberrations is possible, 
we performed aCGH on 39 OOSCC and analyzed the data. Unsupervised clustering 
enabled the discovery of two distinct groups at the top of the tree (Figure 1). Group 1 
consisted of 8 tumors that showed a significantly lower level of chromosomal 
aberrations, when compared to the other group, labeled 2 (average number of 
chromosomal breakpoints 2.8 and 33.7 respectively: Table 1). The few changes that 
were observed in group 1 were never shared by two or more tumors of that group. 
Group 2 was characterized by a higher level of chromosomal aberrations. 
Aberrations that were present in this group in more than 50% of the tumors, were 
gains at chromosome 3q, 7q, 8q and 11q13 and losses at chromosome 3p, 5q, 
11q23 and 18q (Figure 1). Regions that showed numerical changes in even more 
than 80% of carcinomas; loss at 3p (total p-arm), gain at 3q26.2-qter (29 Mb) and 
gain at 8q24.13-q24.21 (3 Mb). Typical examples of a CGH profile of tumors of 
groups 1 and 2 are shown in Figure 2. 
Looking further down the tree it appeared that group 2 consists of two further 
subgroups; one (2a) of 26 tumors with a relatively high level of aberrations (average 
number breakpoints of 30.0) and another (2b) of five tumors with an even higher level 
of aberrations (average number of breakpoints 52.8).  
Comparison of the clinical parameters between the identified groups revealed that 
group 1 (with infrequent aberrations), significantly differed from groups 2a and 2b, as 
it was characterized by the absence of alcohol consumption, female gender and wild 
type TP53 in the carcinoma (Table 1). Regarding the mutational status in TP53, the 
differences between group 1 and 2 were more pronounced when the mutations were 
classified as disruptive vs. non-disruptive and wild-type (Table 1). A remarkable 
feature of group 2b was the gender dysbalance, as only males were observed in this 
group.  
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Figure 1. WECCA heatmap of 39 OOSCCs without HPV involvement. At the top of the tree two tumor 
groups can be distinguished: a group consisting of 8 OOSCC with in general genetically silent profiles and 
another group of 31 tumor with many genetic aberrations. In group2 downwards, two subgroups (a and b) 
can be distinguished with 2b as the group with the most genetic aberrations. The x-axis represents tumor 
numbers and the y-axis chromosome numbers. 
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Figure 2. Typical examples of an aCGH profile of each group. Group 1) Represents a tumor with a 
silent profile and wild-type TP53, showing just a few aberrations. Group 2) Shows a typical profile of a 
tumor of group 2 showing many aberrations, e.g. with gains at 3q, chromosome 8, 11q13, 17q, 
chromosome 20, and losses at 3p, 11q23 and 13q.  
 
Analysis of overall survival between the groups revealed a significant difference 
between the groups (log rank test with a p-value of 0.003), with the best survival in 
group 1 and the worst survival in group 2b (figure 3). We next investigated 
classification after including the dataset of 12 HPV-positive OOSCC from a previous 
study [31]. Seven out of twelve HPV-positive OOSCC appeared to cluster as a 
separate group within group 2a. Five HPV-positive tumors belonged to group 1 in 
which hardly any numerical change was observed (see supplementary Figure 1). 
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Figure 3. Kaplan-Meyer curves 
of clusters 1, 2a and 2b. 
Cumulative survival is shown in 
relation to time in months. Group 
1 (N=8) are OOSCC with hardly 
any chromosomal aberrations; 
group 2 contains the OOSCC 
with a relatively high level of 
chromosomal aberrations, 
divided in b (N=5) with the 
highest and a (N=26) with a 
lower level of aberrations. Log-
rank analysis yielded a p-value 
of 0.004. 
 
It was tried to confirm the findings by analysis of an independent and external aCGH 
dataset of 89 oral squamous cell carcinomas described by Snijders et al. [32]. Also in 
this material two main groups were identified (supplementary Figure 2). One group of 
oral carcinomas (N=33) was characterized by a low level of chromosomal aberrations 
(average breakpoints: 11.5 ranging from 0 to 27) and a group of oral carcinomas 
(N=56) with a high level of chromosomal aberrations (average breakpoints 28.1 
ranging from 7 to 53). Similar to our dataset, also in this external set a subgroup of 
tumors (n=18) with a much higher level of chromosomal aberrations (average 
breakpoints 34.7 ranging from 18 to 53) could be recognized. Unfortunately, no 
clinical parameters were available of these patients. The TP53 mutation status of 
most of the tumors was described by Snijders et al. [32]. Similar to our data we found 
a significant correlation between mutation status and classification as 2 out of 25 
tumors in group 1, and 15 out of 34 tumors of group 2 contained mutated TP53 
(p=0.02). It was noteworthy that all aberrations in our dataset were present in the 
dataset of Snijders et al. at high frequency as well.  
Tumors with hardly any chromosomal aberrations are also known in colorectal 
cancer. In these tumors microsatellite instability (MSI) is mostly the driving force for 
progression [10]. We evaluated this possibility on this subgroup and found no 
indications for MSI in all evaluated markers (data not shown). 
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DISCUSSION 
The present analysis of a large number of HPV-negative OOSCC by high resolution 
CGH revealed a large number of DNA copy number changes. This complex genetic 
pattern is a well known characteristic of OOSCC and confirms other CGH-studies 
[2,3,12,16,24,26,32,34,45]. Copy number changes were relatively frequent at 
chromosomes 3, 5p, 8, and 11q, involving over 50% of the tumors in group 2. 
Aberrations at these chromosomal locations have also been described in other 
studies, but at lower frequencies [2,3,12,16,24,26,32,34,45].  Three chromosomal 
regions were more pronounced and found to be altered in more than 80 percent of 
these tumors; loss at 3p, gain at 3q26 and gain at 8q24. The gain of 8q24.21 
comprising 3 MB was identified by defining the smallest region of overlap. Gain at 8q, 
in particular 8q24 has also been reported by others in an unselected group OOSCC 
[3,44]. In this region c-Myc is located, a forceful oncogene that is commonly found to 
be overexpressed by genomic amplification in OOSCC [19,14,23] and that has the 
capability to transform primary oral epithelial cells to cancer cells in vitro [15].  
By virtue of WECCA, a new classification tool for aCGH data, we were able to 
identify separate tumor groups. A group with a remarkably low and a group with a 
relatively high level of chromosomal aberrations could be discriminated; a subgroup 
within that latter group showed a very high level of chromosomal alterations. To find 
confirmation of the present findings, the data from a previously published study [32] 
was investigated in more detail with the WECCA cluster algorithm. Analysis of the 
data revealed again the presence of two major tumor groups divided on the basis of 
the number of aberrations. The average number of aberrations in the genetically 
silent group was somewhat higher than in our tumor panel and this group was 
somewhat larger (37.1% vs. 20.5% in our material). Nevertheless the high similarity 
between the two datasets, including the identification of the subgroup with the rather 
high number of aberrations, is noteworthy. Unfortunately the survival data were not 
available from that group. It has to be realized that there are geographical difference 
regarding the patient populations that were compared. In addition, the fact that only 
oral carcinomas had been included and that some cases could be HPV-positive [32], 
may explain some of the differences. 
OOSCC harboring a genome with few chromosomal aberrations were earlier 
recognized in cytogenetic studies as tumors with simple karyotypic changes [20]. In 
fact, our sensitive aCGH method confirms in a way and extends in much greater 
detail of  what was found with this ‘older’ crude method. The tumors with such a 
simple karyotype comprised approximately 36% of the study population, but were 
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never discussed as a separate tumor group and this characteristic was not correlated 
with clinical parameters like prognosis.  
When comparing the presently classified tumor groups regarding clinical and 
biological parameters it was found that survival, alcohol drinking history, gender and 
TP53 mutation status were significantly different, which can be interpreted as 
independent evidence to support the relevance of the findings. It can be appreciated 
that the tumors showing a silent genetic profile were all TP53 wild type. This notion 
was also supported by the results of the external aCGH dataset of 89 OOSCC [32]. 
The question remains whether this is a non-random association or that the TP53 
status plays a causative role on the genetic profile. An argument against the latter is 
that some tumors of group 2 with a high level of chromosomal changes also showed 
a wild type TP53 gene while the gene was sequenced from exons 2-11. 
Notwithstanding, exon deletions could have been missed and we cannot exclude that 
the p53 pathway is impaired in an alternative way. Genes modifying p53 function 
might be mutated, abrogating p53 function indirectly [4,17]. 
Six of the eight patients with a silent tumor profile, never had consumed alcohol. In 
addition, an excessive alcohol consumption appeared to be correlated with the 
presence of a TP53 mutation and thereby an increased genomic instability. Although, 
a causal relation between both tobacco and alcohol abuse and OOSCC is well 
established [9,22], there is controversy about the relationship between levels of 
tobacco and alcohol exposure vs. the number and type of genetic aberrations in the 
tumor. Koch et al. [21] found a distinct clinical and molecular entity of head and neck 
squamous cell carcinoma in non-smokers, while Singh et al. did not [29]. In addition, 
Brennan et al. found an association between excessive alcohol/ tobacco 
consumption and the presence of mutated TP53 [6]. It has recently become clear that 
alcohol can be a carcinogen on its own [28], but its role in generating a mutation in 
TP53 needs further attention.  
We found evidence that the level of DNA copy number changes is associated with 
patient outcome. The lowest level of aberrations was associated with the best and 
the highest level with the worst survival. This finding is in line with what could be 
expected: patients with carcinomas without a TP53 mutation have a better survival 
[13] and a relatively low level of genetic instability has been reported to be related to 
a better outcome, for head and neck [1] and breast cancer [8]. Although the 
difference in survival between the groups was significant, it has to be added that the 
numbers were small. A larger study on OOSCC is needed to definitively proof the 
clinical value of this classification. 
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The genetically silent group (number 1) is for a large part characterized by tumors 
that are TP53 wild type and contain hardly any chromosomal aberrations. It is 
tempting to speculate on the molecular mechanism that might drive carcinogenesis in 
these tumors. This subgroup may be the result of a defect known as microsatellite 
instability (MSI), related to a deficiency in the mismatch repair machinery. A 
proportion of colorectal carcinomas show this phenomenon as well that is reflected in 
relatively few chromosomal aberrations [10]. We evaluated this possibility on this 
subgroup, but found that all were MSI negative. It has to be added that there is a 
possibility that MSI was missed; a set of markers was tested that may not be ideal for 
OOSCC, as it is normally used for colon carcinoma. Second, other forms of DNA 
alterations, in particular loss of heterozygosity (LOH) without numerical changes and 
epigenetic alterations such as promoter hypermethylation, might play a role in these 
tumors and might even abrogate the p53 pathway. Finally, tumor heterogeneity at the 
cellular level may explain the absence of specific aberrations in these OOSCC. Gains 
in some cells could be counterbalanced by losses in other. However it seems unlikely 
that this results in normal genetic profiles, but without more detailed investigations 
this remains unclear.  
Taken together, our main finding is the identification by array CGH of a previously 
unrecognised group of OOSCC with a remarkably almost normal genome, regarding 
DNA copy numbers. Data of the current study indicate that this genomic subgroup of 
OOSCC shows a different outcome and patient profile; these findings and the 
unraveling of the possible mechanisms driving its carcinogenesis warrant additional 
studies in a larger OOSCC cohort. At this moment, at least three different OOSCC 
groups can be discriminated: 1) a HPV-positive group that was discussed in a 
previous study [31], 2) a ‘normal DNA’ group without TP53 mutation that we now 
reported on, and 3) a group with a high to very high level of chromosomal 
aberrations, characterized by loss of 3p, 5p, 11q23 and gains at 3q, chromosome 8 
and 11q13. These findings underline the clinical importance of biological 
classification of OOSCC. Stratification in groups is critical when analyzing the role of 
potential cancer genes, early detection of tumor markers, and selection of 
treatments.  
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1. WECCA heat map of 51 OOSCC, 39 without (present study) and 12 with 
HPV16-infection. Results of the HPV-infected tumors are derived from a previous publication [31]. 
Seven out of 12 HPV-positive tumors formed a separate group and five of them rearranged among the 
group of silent tumors (indicated with black bars near the x-axis). The x-axis represents tumor numbers 
and the y-axis chromosome numbers. 
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Supplementary Figure 2. WECCA heatmap of 89 OOSCCs described by Snijders et al. [32]. General 
classification is similar as in the present study; a group consisting of 33 OOSCC with in general a low 
level of chromosomal aberrations and another group of 56 tumors with many chromosomal aberrations. 
In group 2 downwards, two subgroups (a and b) can be distinguished with 2b as the group with the most 
chromosomal aberrations. The y-axis represents chromosome numbers. 
 
ACKNOWLEDGEMENTS 
This work was supported by the EU-sixth framework project: DISMAL, Contract No.: 
LSHC-CT-2005-018911.  
 
ARRAY CGH CLASSIFICATION OF OOSCC 
 
 
 93 
REFERENCES  
 
 1.  V.L. Bauer, H. Braselmann, M. Henke, D. Mattern, A. Walch, K. Unger, M. Baudis, S. Lassmann, 
R. Huber, J. Wienberg, M. Werner and H.F. Zitzelsberger, Chromosomal changes characterize 
head and neck cancer with poor prognosis. J Mol Med 86 (2008), 1353-1365. 
 2.  A. Bergamaschi, Y.H. Kim, P. Wang, T. Sorlie, T. Hernandez-Boussard, P.E. Lonning, R. 
Tibshirani, A.L. Borresen-Dale and  J.R. Pollack, Distinct patterns of DNA copy number alteration 
are associated with different clinicopathological features and gene-expression subtypes of breast 
cancer. Genes Chromosomes Cancer 45 (2006), 1033-1040. 
 3.  U. Bockmuhl, K. Schluns, I. Kuchler, S. Petersen and I. Petersen, Genetic imbalances with 
impact on survival in head and neck cancer patients. Am J Pathol  157 (2000), 369-375. 
 4.  J. Bolt, Q.N. Vo, W.J. Kim, A.J. McWhorter, J. Thomson, M.E. Hagensee, P. Friedlander, K.D. 
Brown and J. Gilbert, The ATM/p53 pathway is commonly targeted for inactivation in squamous 
cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 41 
(2005), 1013-1020. 
 5.  B.J.M. Braakhuis, P.J.F. Snijders, W.J.H. Keune, C.J.L.M. Meijer, H.J. Ruijter-Schippers, C.R. 
Leemans and R.H. Brakenhoff, Genetic patterns in head and neck cancers that contain or lack 
transcriptionally active human papillomavirus. J Natl Cancer Inst 96 (2004), 998-1006. 
 6.  J.A. Brennan, J.O. Boyle, W.M. Koch, S.N. Goodman, R.H. Hruban, Y.J. Eby, M.J. Couch, A.A. 
Forastiere and D. Sidransky, Association between cigarette smoking and mutation of the p53 
gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332 (1995 ), 712-717. 
 7.  S.F. Chin, A.E. Teschendorff, J.C. Marioni, Y. Wang, N.L. Barbosa-Morais, N.P. Thorne, J.L. 
Costa, S.E. Pinder, M.A. van de Wiel, A.R. Green, I.O. Ellis, P.L. Porter, S. Tavare, J.D. Brenton, 
B. Ylstra and C. Caldas, High-resolution aCGH and expression profiling identifies a novel 
genomic subtype of ER negative breast cancer. Genome Biol 8 (2007), R215. 
 8.  S.F. Chin, Y. Wang, N.P. Thorne, A.E. Teschendorff, S.E. Pinder, M. Vias, A. Naderi, I. Roberts, 
N.L. Barbosa-Morais, M.J. Garcia, N.G. Iyer, T. Kranjac, J.F. Robertson, S. Aparicio, S. Tavare, I. 
Ellis, J.D. Brenton and C. Caldas, Using array-comparative genomic hybridization to define 
molecular portraits of primary breast cancers. Oncogene 26 (2007), 1959-1970. 
 9.  J. Decker and J.C. Goldstein, Risk factors in head and neck cancer. N Engl J Med 306 (1982), 
1151-1155. 
 10.  S. Derks, C. Postma, B. Carvalho, S.M. van den Bosch, P.T. Moerkerk, J.G. Herman, M.P. 
Weijenberg, A.P. de Bruine, G.A. Meijer and M. van Engeland, Integrated analysis of 
chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific 
associations between promoter methylation of pivotal tumour suppressor and DNA repair genes 
and specific chromosomal alterations. Carcinogenesis 29 (2008), 434-439. 
 11.  C. Fakhry, W.H. Westra, S. Li, A. Cmelak, J.A. Ridge, H. Pinto, A. Forastiere and M.L. Gillison, 
Improved survival of patients with human papillomavirus-positive head and neck squamous cell 
carcinoma in a prospective clinical trial. J Natl Cancer Inst 100 (2008), 261-269.  
12. C. Garnis, C. Baldwin, L. Zhang, M.P. Rosin and W.L. Lam, Use of complete coverage array 
comparative genomic hybridization to define copy number alterations on chromosome 3p in oral 
squamous cell carcinomas. Cancer Res 63 (2003), 8582-8585. 
 13.  M.L. Gillison, G. D'Souza, W. Westra, E. Sugar, W. Xiao, S. Begum and R. Viscidi, Distinct risk 
factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-
negative head and neck cancers. J Natl Cancer Inst 100 (2008), 407-420. 
 14.  M.A. Ginos, G.P. Page, B.S. Michalowicz, K.J. Patel, S.E. Volker, S.E. Pambuccian, F.G. Ondrey, 
G.L. Adams and P.M. Gaffney, Identification of a gene expression signature associated with 
recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64 (2004), 55-
63. 
CHAPTER 5 
 
 
94 
 15.  G. Goessel, M. Quante, W.C. Hahn, H. Harada, S. Heeg, Y. Suliman, M. Doebele, A. von 
Werder, C. Fulda, H. Nakagawa, A.K. Rustgi, H.E. Blum and O.G. Opitz, Creating oral squamous 
cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A 102 
(2005), 15599-15604. 
 16.  S.M. Gollin, Chromosomal alterations in squamous cell carcinomas of the head and neck: 
Window to the biology of disease. Head and Neck 23 (2001), 238-253. 
 17.  S.L. Harris and A.J. Levine, The p53 pathway: positive and negative feedback loops. Oncogene 
24 (2005), 2899-2908. 
 18.  D.C. Hassane , M.L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J.L. Liesveld, M. Carroll 
and C.T. Jordan, Discovery of agents that eradicate leukemia stem cells using an in silico screen 
of public gene expression data. Blood 111 (2008), 5654-5662. 
 19.  T. Ishizuka, C. Tanabe, H. Sakamoto, K. Aoyagi, M. Maekawa, N. Matsukura, A. Tokunaga, T. 
Tajiri, T. Yoshida, M. Terada and H. Sasaki, Gene amplification profiling of esophageal 
squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun 296 (2002), 152-
155. 
 20.  C. Jin, Y. Jin, J. Wennerberg, K. Annertz, J. Enoksson and F. Mertens, Cytogenetic abnormalities 
in 106 oral squamous cell carcinomas. Cancer Genet Cytogenet 164 (2006), 44-53. 
 21.  W.M. Koch, M. Lango, D. Sewell, M. Zahurak and D. Sidransky, Head and neck cancer in 
nonsmokers: a distinct clinical and molecular entity. Laryngoscope 109 (1999), 1544-1551. 
 22.  F. Lewin, S.E. Norell, H. Johansson, P. Gustavsson, J. Wennerberg, A. Biorklund and L.E. 
Rutqvist, Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of 
the head and neck: a population-based case-referent study in Sweden. Cancer 82 (1998), 1367-
1675. 
 23.  A.M. Mandard , P. Hainaut and M. Hollstein, Genetic steps in the development of squamous cell 
carcinoma of the esophagus. Mutat Res 462 (2000), 335-342. 
 24.  C.L. Martin, S.C. Reshmi, T. Ried, W. Gottberg, J.W. Wilson, J.K. Reddy, P. Khanna, J.T. 
Johnson, E.N. Myers and S.M. Gollin, Chromosomal imbalances in oral squamous cell 
carcinoma: examination of 31 cell lines and review of the literature. Oral Oncol 44 (2008), 369-
382. 
 25.  A.B. Olshen, E.S. Venkatraman, R. Lucito and M. Wigler, Circular binary segmentation for the 
analysis of array-based DNA copy number data. Biostatistics 5 (2004), 557-572. 
 26.  H.S. Patmore, J.N. Ashman, N.D. Stafford, H.K. Berrieman, A. MacDonald, J. Greenman and L. 
Cawkwell, Genetic analysis of head and neck squamous cell carcinoma using comparative 
genomic hybridisation identifies specific aberrations associated with laryngeal origin. Cancer Lett 
258 (2007), 55-62. 
 27.  M.L. Poeta, J. Manola, M.A. Goldwasser, A. Forastiere, N. Benoit, J.A. Califano, J.A. Ridge, J. 
Goodwin, D. Kenady, J. Saunders, W. Westra, D. Sidransky and W.M. Koch, TP53 mutations and 
survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357 (2007), 2552-2561. 
 28.  H.K. Seitz and F. Stickel, Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev 
Cancer 7 (2007), 599-612. 
 29.  B. Singh, V.B. Wreesmann, D. Pfister, A. Poluri, A.R. Shaha, D. Kraus, J.P. Shah and P.H. Rao, 
Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary 
based on severity of tobacco/alcohol exposure. BMC Genet 3 (2002), 22-29. 
 30.  R.J. Slebos, Y. Yi, K. Ely, J. Carter, A. Evjen, X. Zhang, Y. Shyr, B.M. Murphy, A.J. Cmelak, B.B. 
Burkey, J.L. Netterville, S. Levy, W.G. Yarbrough and C.H. Chung, Gene expression differences 
associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin 
Cancer Res 12 (2006), 701-709. 
 
ARRAY CGH CLASSIFICATION OF OOSCC 
 
 
 95 
 31.  S.J. Smeets, B.J.M. Braakhuis, S. Abbas, P.J.F. Snijders, B. Ylstra, M.A. van de Wiel, G.A. 
Meijer, C.R. Leemans and R.H. Brakenhoff, Genome-wide DNA copy number alterations in head 
and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. 
Oncogene 25 (2006), 2558-2564. 
 32.  A.M. Snijders, B.L. Schmidt, J. Fridlyand, N. Dekker, D. Pinkel, R.C. Jordan and D.G. Albertson, 
Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral 
squamous cell carcinoma. Oncogene 24 (2005), 4232-4242. 
 33.  L.H. Sobin and C. Wittekind, TNM classification of malignant tumours. 6th edition. Wiley-Liss, 
New York, Wiley-Liss, 2002.  
 34.  A. Sparano, K.M. Quesnelle, M.S. Kumar, Y. Wang, A.J. Sylvester, M. Feldman, D.A. Sewell, 
G.S. Weinstein and M.S. Brose, Genome-wide profiling of oral squamous cell carcinoma by 
array-based comparative genomic hybridization. Laryngoscope  116 (2006), 735-741. 
 35.  A. Umar, C.R. Boland, J.P. Terdiman, S. Syngal, A. de la Chapelle, J. Ruschoff, R. Fishel, N.M. 
Lindor, L.J. Burgart, R. Hamelin, S.R. Hamilton, R.A. Hiatt, J. Jass, A. Lindblom, H.T. Lynch, P. 
Peltomaki, S.D. Ramsey, M.A. Rodriguez-Bigas, H.F. Vasen, E.T. Hawk, J.C. Barrett, A.N. 
Freedman and S. Srivastava, Revised Bethesda Guidelines for hereditary nonpolyposis 
colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004), 
261-268. 
 36.  M.A. van de Wiel, K.I. Kim, S.J. Vosse, W.N. van Wieringen, S.M. Wilting and B. Ylstra, CGHcall: 
calling aberrations for array CGH tumor profiles. Bioinformatics 23 (2007), 892-894. 
 37.  M.A. van de Wiel and W.N. van Wieringen, CGHregions: dimension reduction for array CGH data 
with minimal information loss. Cancer Informatics 2 (2007), 55-63. 
 38.  V.M. van Houten, P.J.F. Snijders, M.W. van den Brekel, J.A. Kummer, C.J.L.M. Meijer, B. van 
Leeuwen, F. Denkers, L.E. Smeele, G.B. Snow and R.H. Brakenhoff, Biological evidence that 
human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell 
carcinomas. Int J Cancer 93 (2001), 232-235. 
 39.  V.M. van Houten, M.P. Tabor, M.W. van den Brekel, J.A. Kummer, F. Denkers, J. Dijkstra, R. 
Leemans, I. van der Waal, G.B. Snow and R.H. Brakenhoff, Mutated p53 as a molecular marker 
for the diagnosis of head and neck cancer. J Pathol 198 (2002), 476-486. 
 40.  L.J. van 't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der 
Kooy, M.J. Marton, A.T. Witteveen, G.J. Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. 
Bernards and S.H. Friend, Gene expression profiling predicts clinical outcome of breast cancer. 
Nature 415 (2002), 530-536. 
 41.  W.N. Van Wieringen, M.A. Van De Wiel and B. Ylstra, Weighted clustering of called array CGH 
data. Biostatistics 9 (2008), 484-500. 
 42.  T. Wiest, E. Schwarz, C. Enders, C. Flechtenmacher and F.X. Bosch, Involvement of intact 
HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and 
perturbed pRb cell cycle control. Oncogene 21 (2002), 1510-1517. 
 43.  F.P. Worden, B. Kumar, J.S. Lee, G.T. Wolf, K.G. Cordell, J.M. Taylor, S.G. Urba, A. Eisbruch, 
T.N. Teknos, D.B. Chepeha, M.E. Prince, C.I. Tsien, N.J. D'Silva, K. Yang, D.M. Kurnit, H.L. 
Mason, T.H. Miller, N.E. Wallace, C.R. Bradford and T.E. Carey,  Chemoselection as a strategy 
for organ preservation in advanced oropharynx cancer: response and survival positively 
associated with HPV16 copy number. J Clin Oncol 26 (2008), 3138-3146. 
 44.  V.B. Wreesmann, W. Shi, H.T. Thaler, A. Poluri, D.H. Kraus, D. Pfister, A.R. Shaha, J.P. Shah, 
P.H. Rao  and B. Singh, Identification of novel prognosticators of outcome in squamous cell 
carcinoma of the head and neck. J Clinical Oncol 22 (2004), 3965-3972. 
 45.  V.B. Wreesmann and B. Singh, Chromosomal aberrations in squamous cell carcinomas of the 
upper aerodigestive tract: biologic insights and clinical opportunities. J Oral Pathol Med 34 
(2005), 449-459. 
CHAPTER 5 
 
 
96 
 
 CHAPTER 6 
 
Genomic profiling identifies common HPV-associated 
chromosomal alterations in squamous cell 
carcinomas of cervix and head and neck 
 
Submitted for publication 
 
 
Saskia M. Wilting & Serge J. Smeets 
Peter J.F. Snijders 
Wessel N. van Wieringen 
Mark A. van de Wiel 
Gerrit A. Meijer 
Bauke Ylstra 
C. René Leemans 
Chris J.L.M Meijer 
Ruud H. Brakenhoff 
Boudewijn J.M. Braakhuis &  
Renske D.M. Steenbergen 
CHAPTER 6 
 
 
98 
ABSTRACT 
It is well known that a persistent infection with high-risk human papillomavirus 
(hrHPV) is causally involved in the development of squamous cell carcinomas of the 
uterine cervix (CxSCCs) and a subset of squamous cell carcinomas of the head and 
neck (HNSCCs). The latter differ from hrHPV-negative HNSCCs at the clinical and 
molecular level.  
To determine whether hrHPV-associated SCCs arising from different organs have 
specific chromosomal alterations in common, we compared genome-wide 
chromosomal profiles of 10 CxSCCs (all hrHPV-positive) with 12 hrHPV-positive 
HNSCCs and 30 hrHPV-negative HNSCCs. Potential organ-specific alterations and 
alterations shared by SCCs in general were investigated as well.    
Unsupervised hierarchical clustering resulted in one mainly hrHPV-positive and one 
mainly hrHPV-negative cluster. Interestingly, loss at 13q and gain at 20q were 
frequent in HPV-positive carcinomas of both origins, but uncommon in hrHPV-
negative HNSCCs, indicating that these alterations are associated with hrHPV-
mediated carcinogenesis. Within the group of hrHPV-positive carcinomas, HNSCCs 
more frequently showed gains of multiple regions at 8q whereas CxSCCs more often 
showed loss at 17p. Finally, gains at 3q24-29 and losses at 11q22.3-25 were 
frequent (>50%) in all sample groups.  
In this study hrHPV-specific, organ-specific, and pan-SCC chromosomal alterations 
were identified. The existence of hrHPV-specific alterations in SCCs of different 
anatomical origin, suggests that these alterations are crucial for hrHPV-mediated 
carcinogenesis. 
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INTRODUCTION 
In the pathogenesis of uterine cervical cancer the necessary and causal involvement 
of high-risk types of the human papillomavirus (hrHPV) is widely accepted and 
supported by strong epidemiological and molecular evidence [1]. HrHPV is present in 
virtually all cervical carcinomas and the viral oncogenes E6 and E7 are consistently 
expressed in cervical cancers and precancers. Deregulated expression of these 
oncogenes in the basal, dividing cells of the epithelium interferes with cell cycle 
control due to their ability to induce degradation of the tumour suppressor proteins 
p53 and pRb, respectively. This results in uncontrolled cell proliferation and 
accumulation of specific (epi)genetic changes in the host cell genome, driving 
progression to a malignant phenotype [2,3]. In a previous study we have used array-
based comparative genomic hybridisation (array CGH) to determine frequent 
chromosomal alterations in cervical cancer, which included gains at 1q, 3q and 20q 
and losses at 8q, 10q, 11q, and 13q [4]. The necessity of these and other additional 
(epi)genetic alterations in the carcinogenic process is illustrated by the fact that their 
frequency increases with increasing severity of cervical disease.  
On the other hand, head and neck squamous cell carcinoma (HNSCC) is known to 
be mainly caused by well-established life-style related habits, such as tobacco and 
excessive alcohol consumption. However, besides the influence of these life-style 
carcinogens, high risk human papillomavirus (hrHPV) is present in 15-35% of 
HNSCCs and has been suggested to be a separate aetiological factor in head-and-
neck carcinogenesis [5-8]. Several studies have shown that hrHPV-positive HNSCCs 
are associated with a better clinical outcome [7-9]. Moreover, molecular differences 
were found between hrHPV-positive and hrHPV-negative HNSCCs, supporting the 
idea of two separate carcinogenic pathways to HNSCC, one determined by life-style 
carcinogens and the other by hrHPV [5,6,10-13].  
In a previous study, using array CGH, we identified a number of chromosomal 
alterations specific for hrHPV-negative HNSCCs that were absent in hrHPV-positive 
HNSCCs, including loss at 3p, 5q, and 9p, and amplifications at 11q [13]. The 
hrHPV-positive HNSCCs were characterised by a lower level of chromosomal 
alterations, none of which were hrHPV-specific. To investigate potential organ-
independent, hrHPV-associated chromosomal alterations, genomic profiles of 
cervical SCCs (CxSCCs), hrHPV-positive and hrHPV-negative HNSCCs were 
compared using sophisticated clustering and statistical approaches [4,13]. In 
addition, we also investigated the presence of organ-specific alterations and 
alterations shared by all SCCs included in this study.  
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METHODS 
 
CGH microarrays 
We used chromosomal profiles of 30 hrHPV-negative HNSCCs, 12 hrHPV-positive 
HNSCCs and 10 CxSCCs all of which were previously described (Table 1) [4,13] 
(Smeets et al., in press Cell Oncol 2009). To avoid possible confounding of our 
results, we excluded a subset of hrHPV-negative HNSCCs described in Smeets et 
al., which showed little to no alterations and should therefore be considered a 
separate group (Smeets et al., in press, Cell Oncol 2009). 
CGH BAC microarrays produced at the Microarray facility of the VU Medical Center 
were used. These arrays included the 1Mb resolution Sanger BAC clone set and a 
subset of clones from the Children’s Hospital Oakland Research Institute (CHORI). 
Spots were quantified using ImaGene 5.6.1 software (BioDiscovery Ltd, Marina del 
Rey, CA, USA) with default settings for the flagging of bad quality spots.  
The entire dataset described here is available from the Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/projects/geo/) through series accession numbers 
GSE6473 (CxSCC) and GSE12020 (HNSCC). 
This study followed the ethical guidelines of the Institutional Review Board of the VU 
University Medical Center and informed consent was obtained from all patients 
included. 
 
Array CGH analysis 
Calling of gains and losses 
BAC clones were positioned along the genome according to the May 2004 freeze. 
After exclusion of clones with one or more flagged spots, the average of the triplicate 
spots was calculated for each BAC clone. Log2 ratios were normalised per spotted 
sub-array by subtraction of the median value of all BAC clones spotted within that 
sub-array. Segmentation and subsequent calling of gained, amplified and lost regions 
was done using CGHCall, an automated calling algorithm. Segments with a 
probability score of ≥0.5 were considered gained, amplified or lost [14].  
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Table 1. Summary of clinical data of carcinomas included in this study. 
Sample ID origin hrHPV (+/-) age (yrs) sex 
CxSCC2 cervix + 39 female 
CxSCC4 cervix + 62 female 
CxSCC12 cervix + 44 female 
CxSCC15 cervix + 47 female 
CxSCC27 cervix + 49 female 
CxSCC28 cervix + 48 female 
CxSCC32 cervix + 37 female 
CxSCC36 cervix + 72 female 
CxSCC38 cervix + 51 female 
CxSCC39 cervix + 40 female 
HNSCC9741 oropharynx - 53 female 
HNSCC9762 oral cavity - 76 female 
HNSCC9773 oral cavity - 49 male 
HNSCC9830 oral cavity - 42 male 
HNSCC9848 oropharynx - 59 male 
HNSCC9892 oral cavity - 67 male 
HNSCC9897 oral cavity - 72 male 
HNSCC9902 oral cavity - 53 female 
HNSCC9942 oral cavity - 55 female 
HNSCC9952 oral cavity - 61 female 
HNSCC9956 oral cavity - 38 male 
HNSCC2014 oral cavity - 68 female 
HNSCC2034 oral cavity - 45 female 
HNSCC9738 oral cavity - 60 male 
HNSCC9745 oropharynx - 52 male 
HNSCC9750 oral cavity - 65 male 
HNSCC9812 oral cavity - 65 female 
HNSCC9827 oropharynx - 57 male 
HNSCC9829 oral cavity - 74 female 
HNSCC9831 oral cavity - 55 male 
HNSCC9841 oropharynx - 55 female 
HNSCC9847 oropharynx - 57 male 
HNSCC9880 oral cavity - 71 female 
HNSCC9907 oral cavity - 46 male 
HNSCC9914 oropharynx - 78 male 
HNSCC9926 oropharynx - 60 male 
HNSCC9957 oral cavity - 51 male 
HNSCC9970 oral cavity - 49 female 
HNSCC9981 oropharynx - 55 female 
HNSCC9987 oral cavity - 79 male 
HNSCC9881 oral cavity + 51 male 
HNSCC9729 oropharynx + 52 male 
HNSCC9838 oropharynx + 60 male 
HNSCC9860 oropharynx + 67 female 
HNSCC9901 oropharynx + 57 female 
HNSCC9948 oropharynx + 70 male 
HNSCC9951 oropharynx + 46 male 
HNSCC9808 oral cavity + 46 male 
HNSCC9859 oral cavity + 40 male 
HNSCC9924 oral cavity + 41 female 
HNSCC9947 oral cavity + 72 male 
HNSCC2015 oral cavity + 65 male 
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Reduction of dataset into chromosomal regions 
We used the CGHregions algorithm to reduce our dataset to chromosomal regions, 
accepting maximally 0.1% information loss (Threshold=0.001). It was shown by Van 
de Wiel et al. that the use of regions instead of single BAC clones improved the 
effectiveness of subsequent statistical analyses and facilitated interpretation of the 
results [15]. 
 
Clustering analysis 
The samples were clustered by means of a modified version of WECCA [16]. 
WECCA is a hierarchical clustering method tailor-made for called aCGH data. The 
modified version accommodates the use of call probabilities instead of calls. The use 
of the call probabilities in the unsupervised analysis will give a more subtle picture of 
the similarities and differences between the samples. The modified version of 
WECCA defines the distance between two features as the symmetric Kullback-
Leibler divergence. The distance between the call probability profiles of two samples 
is then defined as the average of these divergences over all features. In the 
construction of the dendrogram we used Ward's linkage as it yields compact and 
well-separated clusters.  
 
Statistical analysis 
The association between clustering results and HPV status was determined by chi-
square testing. The average total number of altered regions was compared between 
HPV-positive and HPV-negative carcinomas using the non-parametric Mann Whitney 
test. Two-sided p-values below 0.05 were considered statistically significant. 
Alteration patterns between HPV-positive (HNSCCs and CxSCCs) and HPV-negative 
tumors as well as between HNSCCs and CxSCCs were compared using a binomial 
differential proportion test. The test procedure includes a permutation-based false 
discovery rate (FDR) correction for multiple testing, needed to discriminate real 
differences from chance effects [17]. An FDR below 0.10 was considered statistically 
significant. 
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Gene ontology analysis 
To interpret the biological significance of the genes that are located at altered 
chromosomal regions of interest, a gene ontology analysis was performed using 
Ingenuity Pathways Analysis (Ingenuity Systems®, Redwood City, USA). 
Biological/molecular functions were considered to be significantly overrepresented if 
they contained more than 1 gene and the Benjamini-Hochberg corrected p-value was 
p<0.10 [18].   
 
Figure 1. Result from the unsupervised hierarchical clustering analysis. Cluster 1 contains in majority 
hrHPV-positive carcinomas, as is indicated by the black boxes in the legend underneath the heatmap 
(p<0.0001).  
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RESULTS 
 
hrHPV-positive carcinomas cluster together 
To obtain an overview of the similarities between samples, unsupervised hierarchical 
clustering was performed. This method enabled us to determine in an unbiased 
manner whether chromosomal profiles of hrHPV-positive HNSCCs were more closely 
related to hrHPV-negative HNSCCs or hrHPV-positive CxSCCs.  
As is shown in Figure 1, two clusters emerged. Cluster 1 contained 24 samples, 18 of 
which were hrHPV-positive (75%) and 6 were hrHPV-negative. Cluster 2 contained 
28 samples of which 4 samples were hrHPV-positive and 24 were hrHPV-negative 
(86%). This association between cluster assignment and hrHPV status was 
statistically significant (p<0.0001). The hrHPV-positive cluster 1 included both 
samples of cervical (n=8) and head and neck origin (n=10), indicating similarities 
between the chromosomal profiles of hrHPV-induced carcinomas of different 
anatomical origins. Within cluster 1, however, 7 out of 8 cervical samples formed a 
separate sub-cluster. This suggests that organ-specific alterations exist as well in 
hrHPV-positive HNSCCs and CxSCCs.  
 
hrHPV-associated loss at chromosome 13q and gain at 20q 
To assess the differences between all three sample groups, the frequency of gains 
(including amplifications) and losses was analysed for all chromosomal regions 
(Figure 2). In general, hrHPV-negative carcinomas showed significantly more altered 
regions than hrHPV-positive carcinomas (p=0.022).  
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Figure 2. Frequency plots for all 3 sample groups. The frequency of gains (positive axis) and losses 
(negative axis) are shown for A. hrHPV-negative HNSCCs, B. hrHPV-positive HNSCCs and C. CxSCCs 
for chromosome 1-22.  
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Table 3. Significantly different chrom
osom
al alterations betw
een hrH
P
V-positive H
N
S
C
C
s and C
xS
C
C
s. 
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To determine hrHPV-specific chromosomal alterations, the frequency of alterations 
was compared between hrHPV-positive (12 HNSCCs and 10 CxSCCs) and hrHPV-
negative tumors (30 HNSCCs) for all chromosomal regions. Regions showing a 
significant difference (FDR<0.10) in this comparison are shown in Table 2. 
Interestingly, loss of 13q21.1-21.33 and gain of 20p12.1-q13.33 were significantly 
more frequent in HPV-positive SCCs compared to hrHPV-negative HNSCCs (66.7% 
and 58.5% in hrHPV-positive SCCs compared to 33% and 24% in hrHPV-negative 
SCCs, respectively). As was also shown in our previous study, loss of regions at 3p 
and 5q, and gains/amplifications of a small region at 11q (CCND1 locus) were 
specific for hrHPV-negative HNSCCs [13]. A region at 8p showed loss in hrHPV-
negative HNSCCs, gain in hrHPV-positive HNSCCs and no alteration in CxSCCs. 
Gain at chromosome 8q was more frequent in hrHPV-negative HNSCCs, which was 
due to absence of this alteration in CxSCCs.  
Our unsupervised classification results indicated that, within our hrHPV-positive 
cluster, CxSCCs formed a separate group. To identify potential organ-specific 
alterations, we therefore also compared the frequency of alterations for all regions 
between hrHPV-positive HNSCCs (n=12) and CxSCCs (n=10) (Table 3). Gains at 3q 
and losses at 17p were significantly more frequent in CxSCCs than HNSCCs 
(FDR<0.10). On the other hand, HNSCCs showed frequent gains at chromosome 8q 
and losses at 11q. It is important to note that even though gain at 3q and loss at 11q 
were significantly different between hrHPV-positive HNSCCs and CxSCCs, these 
alterations were frequent in all sample groups (>50%). Significant differences for 
these regions can mainly be explained by the fact that the size of the exact altered 
region differed between groups. Therefore, the smallest regions of overlap between 
all samples, namely 3q24-29 and 11q22.3-25, may represent general alterations in 
carcinomas derived from squamous epithelium. 
All results described above are summarised in a Venn diagram, showing a general 
overview of the frequently altered chromosomal arms specific to or common between 
the (sub) groups (Figure 3).  
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Figure 3. Summary of common and specific chromosomal alterations in the different sample groups. 
Chromosome arms showing frequent alterations (>50%) in one or more sample groups (hrHPV-positive 
HNSCCs; hrHPV-negative HNSCCs; CxSCCs) are shown in a Venn diagram.  indicates gain;  
indicates loss. 
 
Biological functions of genes located within hrHPV-specific chromosomal alterations 
As described above gain at 20p12.1-q13.33 and loss at 13q21.1-21.33 were 
significantly more frequent in hrHPV-positive SCCs compared to hrHPV-negative 
ones. In fact, a 4.5 megabase (Mb) region on chromosome 20 (20q11.21-q11.23), 
and a 2Mb region on chromosome 13 (13q21.1) formed the smallest regions of 
overlap (SRO) at these respective loci when all hrHPV-positive carcinomas were 
considered (Figure 4A and B). All genes located within the SROs found at 
chromosome 20q (78 genes) and 13q (6 genes) are listed in Supplementary Table 1. 
Within the SRO at chromosome 20, two genes reside, i.e. NCOA6 and RBM39, 
which showed elevated expression in hrHPV16 E7 expressing cells in vitro [19]. 
Other cancer-related genes located within this SRO include PIGU, E2F1, and 
DNMT3B. The SRO on chromosome 13 encompasses the PCDH17 gene and a 
cluster of five identical loci all of which are predicted to encode proline-rich proteins 
that contain several dopamine D4 receptor signatures.  
Subsequent gene ontology analysis of all genes located in these SROs identified a 
number of significantly overrepresented GO biological/molecular functions, including 
cell cycle, cell-to-cell signalling and interaction, cellular growth and proliferation, and 
a number of cellular maintenance functions (i.e. DNA replication, recombination and 
repair, gene expression, cellular function and maintenance, cellular assembly and 
organisation, cellular compromise, cell death, cell morphology, cellular development, 
nucleic acid metabolism, and lipid metabolism).  
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Figure 4. Genomic coordinates of A. losses at chromosome 13 and B. gains at chromosome 20 are 
shown for all hrHPV-positive carcinomas. Chromosomal alterations in CxSCCs are shown by dashed 
lines and alterations in hrHPV-positive HNSCCs by solid lines. In C. the smallest regions of overlap 
(SROs) between hrHPV-positive carcinomas at chromosome 13 and 20 are summarised.   
 
GENOMIC PROFILING OF HRHPV-INDUCED CARCINOMAS OF CERVIX AND HEAD AND NECK  
 
 
 111 
DISCUSSION 
In the present study we compared genome-wide chromosomal profiles of hrHPV-
negative HNSCCs, hrHPV-positive HNSCCs and hrHPV-positive CxSCCs, to 
determine whether hrHPV-associated carcinomas of different origins have similar 
chromosomal signatures. In addition, potential organ-specific alterations were 
determined within the total group of hrHPV-positive SCCs.   
Unsupervised hierarchical clustering resulted in a separate hrHPV-positive cluster, 
indicating similarities in the chromosomal profiles of hrHPV-induced carcinomas. 
Subsequent supervised statistical analysis identified a number of hrHPV-associated 
chromosomal alterations, including gains at 20p13-q13.33 and losses at 13q21.1-
21.33, which were frequent (>50%) in hrHPV-positive carcinomas, but were only 
rarely observed in hrHPV-negative carcinomas. In contrast, lost regions at 3p and 5q 
as well as amplifications at 11q13.3 (CCND1 locus) were frequent in hrHPV-negative 
carcinomas, but not in hrHPV-positive carcinomas. In our previous study comparing 
only hrHPV-positive and hrHPV-negative HNSCCs, the same regions were identified 
as well as being specific for hrHPV-negative HNSCCs [13].  
In the present study we found that gains at 20q and losses at 13q are specific for 
hrHPV-positive carcinomas of different anatomical origins. Our previous study, 
including only hrHPV-positive and hrHPV-negative HNSCCs, did not identify these 
alterations as specific for hrHPV-positive HNSCCs. However, in the present study a 
larger number of hrHPV-negative hrHNSCCs and HPV-positive SCCs was included. 
Furthermore, a sophisticated, objective calling method was presently used to 
determine gained and lost regions [14]. Interestingly, in a number of studies 
describing hrHPV E6 and/or E7 mediated immortalisation of keratinocytes of multiple 
anatomical origins, gains of chromosome 20q and losses of chromosome 13q were 
consistently observed [19-22]. Low-level gains of chromosome 20q are suggested to 
be caused by E7 expression and consequent inactivation of the pRb pathway in 
epithelial cells [19,20,23]. Deletion of part of the long arm of chromosome 13 is 
frequently found in a number of  hrHPV-associated tumors, including cervical, anal 
and head and neck carcinomas [4,13,24]. Sabbir et al. showed that loss of 13q in 
HNSCCs was associated with the presence of hrHPV, which is in agreement with our 
findings [25].  
In a recent study Pyeon et al. showed that the gene expression patterns of hrHPV-
positive HNSCCs and CxSCCs differed yet shared many changes compared to 
hrHPV-negative HNSCCs [10]. Our study shows that the same holds true on a 
chromosomal level. Interestingly, 28% of the genes Pyeon et al. found to be 
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differentially expressed between hrHPV-positive and hrHPV-negative carcinomas is 
located within the chromosomal regions identified in this study and showed 
expression changes concordant with the chromosomal alterations [10]. Of these 
genes, 39% was located at chromosome 1p, 25% at 5q, and 14% at 3p. The other 
genes were located at 11q, 18q and 21q. Only one gene, SYCP2, was located within 
the hrHPV-specific chromosomal alterations found in this study (20q), but was not 
located within our SRO. To the best of our knowledge none of the genes are known 
to directly interact with hrHPVE6 and/or E7 [26,27]. Pathway analysis of all genes 
overlapping with our findings identified cell cycle/proliferation as most 
overrepresented biological function, which is in concordance with the observations 
made by Pyeon et al. [10].  
Pathway analysis of all genes located within the hrHPV-associated SROs at 
chromosome 20q and 13q found in this study, again underlined the importance of cell 
cycle (replication and proliferation) related genes in hrHPV-mediated carcinogenesis. 
This may be related to the continuous E7-regulated E2F1 activation and is 
accompanied by changes in overall cellular maintenance systems, such as nucleic 
acid metabolism, as was also found in HPV16 E7 expressing epithelial cells in vitro 
[19]. Two genes, NCOA6 and RBM39, overlapped between this in vitro study and our 
results, warranting further investigation of their role in hrHPV-mediated 
transformation. NCOA6 encodes a transcriptional coactivator interacting with basal 
transcription factors, histone acetyltransferases, and methyltransferases. RBM39 
encodes an RNA binding protein and possible splicing factor and may act as a 
transcriptional coactivator for the AP-1 transcription activator complex and estrogen 
receptors. Other cancer-related genes at 20q include E2F1, which is specifically 
targeted by hrHPV-mediated degradation of pRb, PIGU, which may play a role in cell 
cycle control and was identified as an oncogene in bladder cancer [28], and 
DNMT3B, a de novo DNA methyl transferase. We previously showed that DNMT3B 
is amplified in the cervical cancer cell line SiHa and found a correlation between 
increased DNMT3B gene copy numbers and elevated mRNA expression in 78% of 
CxSCCs [4]. The increased DNMT3B levels are most likely related to the high 
frequency of tumour suppressor gene promoter hypermethylation events during 
hrHPV-mediated carcinogenesis [29-31]. The SRO at chromosome 13q includes one 
known gene, PCDH17, a member of the protocadherin family, which is a subfamily of 
the cadherin superfamily. At present no reports are available describing interactions 
between hrHPV and protocadherins. However hrHPV presence has been related to 
decreased E-cadherin and subsequent impaired immune response [32-34]. 
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Next to the hrHPV-related common events, organ-specific alterations for CxSCCs 
and HNSCCs were identified as well. CxSCCs more frequently showed loss at 17p, 
while HNSCCs were characterised by frequent gains at chromosome 8q, harbouring 
the oncogene c-Myc [35].  
Gains at 3q and losses at 11q were found frequently in all SCCs included in this 
study, suggesting their involvement in carcinogenesis of squamous epithelial cells in 
general. Interestingly, we previously showed that gains of 3q were highly frequent in 
CxSCCs but not in adenocarcinomas of the same organ, further emphasising that 
this alteration may be specific for squamous epithelium [4]. 
 
CONCLUSIONS 
Together with results from previous studies, our findings support a causal role for 
hrHPV in the development of a subset of HNSCCs. Consequently, hrHPV-positive 
and hrHPV-negative HNSCCs should be regarded as different disease entities 
requiring different diagnostic and therapeutic approaches. The fact that hrHPV-
associated SCCs of different organs have chromosomal alterations in common, 
suggests that these alterations are crucial for hrHPV-induced carcinogenesis. 
Diagnostic and/or therapeutic targets based on these alterations may therefore be 
relevant to hrHPV-associated SCCs of all anatomical origins.  
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Supplementary Table 1. BAC clones and genes included in the SROs of the hrHPV-specific 
chromosomal alterations at chromosomes 13q and 20q. 
Cytoband Start position 
(bp) 
End position 
(bp) 
BAC clones Genes 
20q11.21-
q11.23 29779091.5 34257710.5 
RP5-857M17; 
RP1-310O13; 
RP5-854E16; 
RP11-410N8; 
RP5-1018D12; 
RP5-1093G12; 
RP5-1085F17; 
RP4-733O23; 
RP5-1137F22; 
RP5-1184F4; 
RP4-553F4; 
RP1-18C9; 
RP11-234K24 
TPX2; MYLK2; FOXS1; 
DUSP15; TTLL9; PDRG1; 
XKR7; C20orf160; HCK; 
TM9SF4; TSPYL3; PLAGL2; 
POFUT1; KIF3B; ASXL1; 
C20orf112; LOC284805; 
COMMD7; DNMT3B; MAPRE1; 
EFCAB8; SPAG4L; BPIL1; 
BPIL3; C20orf185; C20orf186; 
C20orf70; BASE; C20orf71; 
PLUNC; C20orf114; 
CDK5RAP1; SNTA1; CBFA2T2; 
NECAB3; C20orf144; 
C20orf134; E2F1; PXMP4; 
ZNF341; CHMP4B; RALY; 
EIF2S2; ASIP; AHCY; ITCH; 
DYNLRB1; MAP1LC3A; PIGU; 
TP53INP2; NCOA6; HMGB3L1; 
GGT7; ACSS2; GSS; MYH7B; 
TRPC4AP; EDEM2; PROCR; 
MMP24; EIF6; FAM83C; UQCC; 
GDF5; CEP250; C20orf173; 
ERGIC3; FER1L4; SPAG4; 
CPNE1; RBM12; NFS1; 
ROMO1; RBM39; PHF20; 
SCAND1; C20orf152; EPB41L1 
13q21.1 55718989 57862597.5 
RP11-640E11; 
RP11-205J24; 
RP11-516G5; 
RP11-204N9; 
RP11-435P18; 
RP11-98F3; 
RP11-111C7; 
RP11-522F22; 
RP11-334O13; 
RP11-538C21; 
RP11-168J5 
LOC729233; LOC729240; 
LOC729246; LOC729250; 
PRR20; PCDH17 
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ABSTRACT 
Abrogation of the p53 and pRb pathways is critical in head and neck squamous cell 
carcinogenesis. TP53 is mostly inactivated by mutation and the pRb pathway either 
by downregulation of p16 (methylation or gene loss) and/or overexpression of cyclin 
D1. In head and neck tumors that arise by infection with the human papillomavirus 
(HPV) these pathways are abrogated by the viral oncogenes E6 and E7, 
respectively. Aim of our study was to establish the functional and molecular 
consequences of p53 and pRb pathway inactivation irrespective whether this might 
occur by HPV infection or a genetic event. We applied a model with conditionally 
transformed oral squamous cells that allows studying the effect of gene manipulation 
on immortalization and down-stream gene expression. We show that abrogation of 
the p53 pathway by either shRNA mediated knock-down of the TP53 gene 
(mimicking a nonsense mutation), overexpression of dominant-negative missense 
mutant p53R(175)H or overexpression of the HPV16 oncoprotein E6, led to an 
extended life span. Despite a seemingly identical phenotype, gene expression 
profiles considerably varied in relation to the type of p53 inactivation. The dominant-
negative mutant p53R(175)H showed highly significant different molecular changes 
associated with an activation of the hypoxia signalling (HIF1) and WNT signaling 
pathways. Knock-down of p16, overexpression of cyclin D1 or overexpression of 
HPV16 E7 had no direct effect on the lifespan, but all led in combination with p53 
pathway abrogation to an immortal phenotype. Our data show the critical role of p53 
and pRb pathway abrogation in early squamous carcinogenesis by either HPV 
infection or genetic events, and indicate that these are the earliest changes in the 
carcinogenic process. The way by which the p53 pathway is inactivated has 
functional consequences at the molecular level.  
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INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) comprises about 5% of all newly 
diagnosed cancer cases in the Northern and Western European countries and the 
United States, and is the fifth most common cancer worldwide [1]. Despite advances 
in local tumor control, the five-year survival rates have only moderately improved 
during the last 20 years. Identification of the cancer genes or pathways causally 
involved in carcinogenesis seems crucial to enable development of new diagnostic 
tools and targeted therapies.  
Based on epidemiological data and in vitro transformation experiments, it has been 
estimated that four to six genetic events are required to transform a normal human 
cell into a malignant cell [2;3]. In various tumor types these events entail the 
impairment of the p53 and the pRb pathways, which are involved in cell cycle 
regulation and apoptosis [4]. In some tumor types such as colorectal cancer, p53 
abrogation is considered a late event, while in other types this seems an early 
change [5;6]. Also in HNSCC carcinogenesis, the p53 pathway appears to be 
abrogated in more than 60% by mutations of the TP53 gene, often accompanied by 
allelic loss at the 17p13 region [5]. Evidence has been provided suggesting that 
these genetic changes belong to the earliest events [5;7]. TP53 inactivating 
mutations are either nonsense mutations or deletions and insertions that lead to a 
truncated protein. In addition, missense mutations are frequently found resulting into 
a protein with impaired DNA binding. Many missense mutants exert a dominant-
negative effect in a heterozygous cell by forming mixed tetramers with wild type p53; 
this effective reduction of the cellular levels of wild-type homotetramers contributes to 
p53 inactivation. Recently, it was shown that the type of TP53 mutation seem to have 
clinical consequences in HNSCC, and that tumors with so called disruptive mutations 
show a less favorable outcome [8].  
Besides TP53 mutations, chromosomal loss of 9p21 and amplification of 11q13 are 
found in 60-80% of the HNSCC, also in precursor stages, suggesting early 
impairment of the pRb pathway by p16 down- and cyclin D1 upregulation. Although 
there is compelling evidence for p16, the supportive role of cyclin D1 is less clear 
[9;10]. Moreover, the precise timing of the different events has not been elucidated 
and is still debated. 
The hypothesis that abrogation of the p53 and pRb pathways are key events in 
HNSCC carcinogenesis is supported by the etiological role of the human 
papillomavirus (HPV). A subgroup of HNSCC, particularly those in the oropharynx, 
are caused by HPV infection [11-13], the virus known to be involved in 100% of 
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cervical cancers. The virus produces two oncoproteins encoded by the E6 and E7 
genes, which inactivate the p53 and pRb proteins, respectively. These two viral 
oncoproteins are crucial in the carcinogenic process, but are not sufficient to induce 
malignant transformation into an invasive carcinoma as in HPV-positive head and 
neck tumors specific additional genetic changes are found in the cancer cell genome 
[11;14]. 
It is at present unknown whether the inactivation of the p53 and pRb pathways by 
both HPV E6 and E7 is functionally equivalent to mutational inactivation of p53 or 
changes in p16 and/or cyclin D1. A compelling approach to identify and characterize 
cancer genes involved in squamous carcinogenesis is to asses the transforming 
ability of these genes in normal mucosal keratinocytes in vitro, but experimental 
transformation of primary human oral keratinocytes is very difficult due to the rapid 
premature senescence of keratinocytes in culture [15;16]. In a few passages the cells 
stop proliferation and die, a biological phenomenon seriously hampering functional 
experiments. Here we present a conditionally immortalized model of oral squamous 
cells of a normal healthy individual. With this model we performed a detailed 
investigation of p53 and pRb pathway abrogation in oral carcinogenesis, and the 
functional consequences at the molecular level.  
 
RESULTS 
Establishment of the in vitro model of conditionally transformed oral keratinocytes. 
We cultured keratinocytes isolated from the oral mucosa and transduced the cells at 
their first passage with amphotropic retroviral vectors carrying a temperature-
sensitive mutant of the SV40 large T-antigen (tsLT) and the telomerase subunit 
hTERT. Before we generated these cultures, we checked that primary oral 
keratinocytes grow well at both 32 °C and 39 °C. In total 17 different clones 
developed; the remaining cells stopped proliferation and died. The clones were 
individually expanded to cell lines. Three of these SV40 transformed cell lines have 
been cultured for more than 150 population doublings at 32°C confirming their 
immortal state at the temperature at which tsLT is active. The 17 lines were further 
characterized for their sensitivity to calcium, a strong differentiation inducer of 
primary keratinocytes, and their ability to grow on soft agar, a phenotype associated 
with invasive growth, at the permissive temperature of 32 °C. These are typical 
characteristics of established malignant squamous carcinoma cell lines. None of the 
tsLT-hTERT-keratinocyte lines showed growth in soft-agar or calcium containing 
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medium (data not shown), which suggested that these cells are still in an early state 
of carcinogenesis.  
All cell lines were shifted to 39°C to test the effect of temperature induced inactivation 
of tsLT. After the temperature shift cells immediately went into proliferation arrest 
(less than one additional doubling), and died during the following one to three weeks.  
To confirm that these lines express telomerase (hTERT), a TRAP assay measuring 
telomerase activity was performed on the three cell lines that were chosen for further 
study. All tested SV40-LT-hTERT keratinocyte cell lines, but not primary oral 
keratinocytes, were positive in the TRAP assay (Table I).  
 
Table I. Results of the TRAP-assay measuring telomerase activity  
Sample RTA 
SiHa (+) 3245 
tsLT-OK 165 
OK (-) 17 
RTA= Relative telomerase activity. A lysate of the conditionally immortalized oral keratinocytes (tsLT-
OK) transduced by p53R(175)H and cultured at 39 °C for 2 weeks was analyzed for telomerase activity. 
These cells show an enhanced telomerase activity as compared to primary keratinocytes. SiHa cells 
were used as positive control. 
 
Abrogation of p53 leads to an extended lifespan 
We determined the effect of p53 abrogation on the proliferation arrest that occurred 
after temperature shift to 39°C. We inhibited p53 expression by using a p53 shRNA 
construct [17], mimicking a nonsense mutation. In addition, we expressed the 
dominant-negative missense mutant p53R(175)H. Finally, we introduced the HPV16 
oncogene E6. Knockdown of TP53 gene expression by introduction of shRNA as well 
as blocking the wild type p53 protein by either overexpression of p53R(175)H or 
HPV16 viral oncogene E6, resulted all in an extended lifespan of approximately 15 
cell doublings in a 2-month period (Figure 1A). After this extended lifespan all cells 
simultaneously entered a proliferation arrest within a week. These experiments were 
repeated with three different lines in duplicate. In one of these experiments we 
analyzed the p53 protein level in the cultures four weeks after gene manipulation by 
Western blot. In Figure 1B the effect of the various gene manipulations on the level of 
p53 expression is shown, as well as the effect on the level of the downstream protein 
p21. For p53R(175)H enhanced expression of the mutant protein is detected and for 
the other two manipulations, the relative levels of p53 protein were much lower. The 
protein level of p21, a well-known protein of which the expression is regulated by 
p53, was low in all manipulated cells lines, a molecular confirmation that p53 is not 
active. Both p53 and p21 were not downregulated at 32 °C when the SV40 large T 
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antigen is active. Although this seems somewhat unexpected, it confirms previous 
observations that the exact working mechanism of SV40 large T remains elusive [18].  
 
Figure 1. Lifespan of SV40-LT-hTERT keratinocytes at 39°C. Values are averaged over three cell lines. 
A: Effect of p53 pathway abrogation. Number of population doublings (PDs) are depicted after 
introduction of empty vector ((-) negative control), TP53 shRNA (17.3±2.3 PDs), p53R(175)H cDNA 
(20.1±0.5 PDs) or HPV16 E6 cDNA (17.0±2.4 PDs). B: Downregulation of p53 and p21 protein levels 
after genetic manipulation assayed by Western blot. Cell lysates of tsLT oral keratinocytes cultured at 
32°C were used as control. Manipulated cells were cultured at 39 °C for four weeks before harvest. For 
p53R(175)H the (mutant) protein is detected but the low expression of p21 indicates that the detected 
p53 protein is not active. Inactivation of p53 by HPV16-E6 and p53 shRNA causes a low level of p53 
and downstream p21 proteins. C: Effect of pRB pathway abrogation: Number of PDs after introduction 
of empty vector (negative control), HPV16 E6 cDNA (positive control) (12±0.5 PDs), cyclin D1 cDNA, 
p16 shRNA, a combination of both, or E7 cDNA. None of the cells with a pRb pathway abrogation 
showed an extended lifespan. 
 
 
Abrogation of the pRb pathway has no effect on life span 
To investigate pRb pathway abrogation, we manipulated the pathway in four different 
ways: by 1) overexpression of cyclin D1, 2) downregulation of p16, 3) a combination 
of both, or 4) overexpression of HPV-E7. None of these pRb pathway abrogations 
caused a change in the lifespan of SV40-LT-hTERT keratinocytes, compared to cells 
transduced with an empty vector. All cells died within one to three weeks after the 
temperature shift (Figure 1C), which also hampered analysis of the effect of the gene 
manipulations at the molecular level. 
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Combination of p53 and pRb pathway abrogation causes immortalization 
Based on all existing descriptive data collected from the genetic analysis of HNSCC 
and its precursor lesions as well as the fact that HPV contains two oncogenes that 
block both pathways simultaneously we raised the hypothesis that pRb pathway 
abrogation only has effect in combination with functional inactivation of p53. 
Therefore, we inactivated p53 by overexpression of the viral oncogene HPV-E6, 
followed by perturbation of the pRb pathway, using the same manipulations as 
indicated above. This resulted in four different SV40-LT-hTERT keratinocyte variants: 
E6/p16 shRNA; E6/cyclin D1; E6/p16 shRNA and cyclin D1, as well as E6/E7. All 
combinations of p53 and pRb pathway perturbation led to an immortal phenotype as 
the cells could be grown for more than 100 Population Doublings (PDs) at 39°C 
(Figure 2A) with a similar proliferation rate (Figure 2B). 
To proof that HPV16-E6 was successfully transcribed, the expression of E6 was 
determined by RT-PCR, and an Enzyme Immuno Assay (EIA). The cells that were 
transduced by the E6 containing vector were all highly positive in the EIA (Figure 
2C). The effect of overexpression of HPV16-E6 on p53 protein level was investigated 
by Western blot, and a clear downregulation was observed (Figure 2C). Cyclin D1 
was investigated at the RNA level using qRT-PCR and an increased mRNA 
expression level was detected (data not shown). P16 protein levels were also 
investigated by Western blot. All cells harboring the p16-specific shRNA displayed a 
lowered expression of p16 protein when compared to the control cells (Figure 2D).  
CHAPTER 7 
 
 
124 
 
 
Figure 2. A: P53 inactivation in combination with pRb pathway abrogation: Number of Population 
Doublings after introduction of respectively empty vector (-), E6 cDNA, E6 cDNA in combination with 
p16 shRNA, cyclin D1 cDNA (CD1), a combination of both, or E7 cDNA. Values are averaged over three 
cell lines. In contrast to the negative control (-) and E6 cDNA, all manipulations abrogating the pRb 
pathway in the context of p53 downregulation by HPV16 E6 led to immortalization (>100 PD’s). B: 
Proliferation rates between the various conditions described in A. C: Levels of p53 protein under the 
conditions indicated in A analyzed by Western blotting using monoclonal antibody DO-7. SV40-tsLT 
keratinocytes grown at 39°C were used as control. ß-actin was included as a loading control. Presence 
of HPV16 E6 transcripts was measured by Enzyme Immuno Assay (EIA); (+) = EIA OD value that 
reached at least 3x the background, (-) = EIA OD value is below 3x background. D: Analysis of p16 
expression levels by Western Blotting. Cell lysates of tsLT-keratinocytes with and without E6 
overexpression and p16 downregulation, cultured at 39°C were analyzed. Cell lines SiHa and UM-SCC-
22A were included as positive and negative controls, respectively. Equal amounts of protein were 
separated by 12 % SDS/PAGE, blotted and p16 detected with a p16-specific monoclonal antibody. ß-
actin was included as a loading control. 
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Expression profiling of cells with different ways of p53-pathway abrogation  
We observed that the various methods of p53 pathway abrogation showed a 
comparable extended lifespan without apparent differences in growth rate. This was 
unexpected as several lines of evidence suggest that dominant-negative TP53 
mutations like R(175)H, can lead to a gain-of-function tumorigenic activity in vivo [19-
21]. Also HPV16 E6 interacts with a variety of cellular proteins [22], of which the 
targeting for proteasome-mediated degradation of the p53 protein is best 
characterized [23]. To investigate potential differences between the three methods of 
TP53 inactivation at the molecular level, we used microarray expression profiling. 
Our hypothesis was that introduction of the dominant-negative mutant p53R(175)H or 
HPV16-E6 might have additional molecular effects when compared to the knock-
down of TP53 by short hairpin RNA. Therefore we used cells manipulated by shRNA 
transfection as reference condition. P53 inactivation by the dominant-negative mutant 
R(175)H or HPV16-E6 resulted in respectively 2467 or 2399 significantly (p<0.05, 
corrected for the false discovery rate (FDR) differentially expressed genes compared 
to the shRNA reference (Figure 3A; Supplementary Table 1). Some of these genes 
were shared (n=784), but a larger number seemed specific for either p53R(175)H or 
HPV16-E6. To interpret the biological significance of the lists of differentially 
expressed genes, a gene ontology analysis was performed by Ingenuity Pathways 
Analysis. As the expression of TP53 was manipulated in the reference condition, we 
removed this gene from the dataset prior to the analysis. Cells with a p53 pathway 
abrogation by HPV16 oncoprotein E6 did not reveal any significant additional 
pathway changes as compared to the shRNA reference condition. However, 
abrogation of p53 function by overexpression of the R(175)H mutant showed 
significant specific involvement of 2 canonical pathways, i.e. ‘Hypoxia signaling 
(HIF1)’ and ‘WNT/ beta-catenin signaling’ (p<0.05, FDR corrected) (Figure 3B; 
Supplementary Figure 1). Significant involvement of only these two pathways were 
confirmed using Panther Gene Ontology [24].   
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Figure 3. Genes that showed differential expression in keratinocytes with an extended lifespan induced 
by either overexpression of HPV16-E6 or p53R(175)H. Knockdown of TP53 by shRNA was used as 
reference condition. A: Venn diagram showing the differentially expressed genes (p<0.05, FDR 
corrected [39]) specific for and shared by HPV16-E6 and p53R(175)H. B: Significant canonical 
pathways discovered by Ingenuity Pathway Analysis (IPA) using the differentially expressed genes 
indicated under A. Expression of cells with HPV16 E6 (black) or mutant p53R(175)H (grey) were 
compared to p53 knockdown by shRNA as reference. The threshold line represents the p-value 0.05 
(corrected for multiple testing according to Benjamini-Hochberg [39]). 
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DISCUSSION 
The functional consequences of various p53 and pRb pathway abrogations found in 
HNSCC by either HPV infection or specific genetic events, has not been investigated 
before. To allow these studies we have established an in vitro model of early 
carcinogenesis using conditionally transformed oral keratinocytes. All different 
approaches used for p53 pathway inactivation; overexpression of dominant-negative 
mutant p53R(175)H, overexpression of HPV16-E6, or knockdown of the TP53 gene 
by shRNA, caused an extended lifespan of about 15 cell doublings. Abrogation of the 
pRb pathway by cyclin D1 overexpression, p16 knockdown or HPV16-E7 
overexpression had no effect, but in combination with p53 inactivation led to an 
immortal phenotype, albeit in the context of telomerase expression. These results 
implicate in our view that p53 and pRb pathway abrogation are early genetic hits in 
HNSCC carcinogenesis as had already been hypothesized by Braakhuis et al. in 
their progression model [5]. Our data are in line with those from previous studies 
showing that p53 and pRb pathway manipulations are necessary to transform 
primary oral keratinocytes [25;26]. It should be stressed, however, that although the 
large majority of HNSCCs show a clear manifestation of p53 pathway abrogation, 
there are tumors that are TP53-wild type and do not contain HPV [11;27]. It is unclear 
whether the p53 pathway is functionally impaired in these tumors by other 
mechanisms, or that there are p53 independent routes of HNSCC carcinogenesis. 
Our current data strongly support the role of p53 (and pRb) pathway abrogation in 
the malignant transformation of oral keratinocytes, but do not exclude alternative 
routes.  
With respect to the proliferation arrest, it seems of no importance how the p53- or 
pRb pathways are abrogated. Every manipulation tested for p53 abrogation led to the 
same extended lifespan, and every manipulation of the pRb pathway in the context of 
E6 overexpression led to immortalization. In this respect it is remarkable that loss of 
9p21 and amplification of 11q13, chromosomal regions containing the p16 and cyclin 
D1 genes, respectively, are frequently found together in the same tumor [9]. Detailed 
analysis of the various key players in this same model might help to elucidate 
whether cyclin D1 is indeed always the driving gene at the 11q13 locus [28], or that 
other candidate genes within this amplicon like FADD could also be involved [29]. 
It has previously been shown that different p53 mutations lead to different cancer-
associated phenotypes. In transgenic mouse models it was shown that 
overexpression of the mutant p53R(175)H (in mouse R(172)H) shows a cancer 
phenotype different from that in p53-/- mice [20;21]. Evidence was provided that 
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deregulation of the p63/p73 proteins by the R(175)H mutant might explain at least 
part of the different cancer phenotypes observed [20]. We investigated the 
downstream effects of the various ways of p53 inactivation in our model by 
microarray expression profiling using p53 shRNA as reference condition. When we 
compared the molecular effects of the dominant-negative missense mutation 
R(175)H to TP53 gene knock-down we noted that two pathways were specifically 
identified: the hypoxia signalling (HIF1) and the WNT signaling pathway. The 
reliability of this finding is supported by the fact that all the determinant genes 
indicating these pathways are in the non-overlapping differential gene set of 2,467 
genes in Figure 3A. The apparent link between p53 and HIF1 has been reported 
previously. The triad of p53, Myc and HIF1 appears to be the key regulator of the 
glycolysis, as in many cancers with changes in the activity of these genes the 
glucose metabolism is deregulated. This phenomenon is known as the “Warburg” 
effect and recently even called the “Seventh hallmark of cancer” [30]. In this context 
the function of p53 is considered to be downregulated and those of Myc and HIF1 
upregulated. Metabolic profiling of cells with different functional abrogations of p53 
might reveal whether this is indeed associated with the type of mutation as 
suggested by our data. 
The second pathway that was significantly associated with overexpression of 
p53R(175)H, was the WNT signaling. Activation of the WNT signaling pathway is the 
initial step in the development of colorectal cancer, and seems to play an important 
role in the epithelial stem cell homeostasis of the colon. There is no compelling 
evidence at present that the WNT signaling pathway is involved in head and neck 
carcinogenesis. However, there is strong evidence for a role of the WNT signaling 
pathway in HPV-mediated cellular transformation [31]. Introduction of HPV in primary 
foreskin keratinocytes leads to immortalization, but without transformation to a 
malignant phenotype. Only by subsequent activation of the WNT signaling pathway a 
transformed phenotype is obtained, an observation that was confirmed in clinical 
material. This indicated that WNT activation might be an important second hit in 
HPV-mediated squamous cancer progression [31]. Our data suggest that this might 
be true for tumors with a TP53 nonsense mutation as well. Tumors with a TP53 
missense mutation comparable to p53R(175)H might already have a change in the 
WNT signaling pathway caused by the oncogenic mutation. Whether this effect on 
gene expression profiles leads to other cancer-associated phenotypes or might be 
specific for this particular TP53 mutation awaits further investigation.  
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In summary, our study provides evidence for TP53 downregulation as an early hit in 
HNSCC carcinogenesis, and leads to immortalization of mucosal keratinocytes when 
the p16-cyclin D1-pRb pathway becomes abrogated as well, albeit in the context of 
telomerase expression. Based on these data we postulate that HNSCC 
carcinogenesis starts with TP53 mutation and pRb pathway abrogation, an 
observation that fits with the genetic changes found in precursor lesions [5;7]. The 
apparent different molecular and clinical effects of different p53 mutant proteins 
inactivation might be exploited to select patients for other treatment regimens and for 
the development of specific targeted therapies. 
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MATERIALS AND METHODS 
Cell culture and vector constructs 
Normal human oral keratinocytes were isolated from an excised uvula of a non-
smoking individual who never had consumed alcoholic beverages. Isolation and 
culturing of the primary oral keratinocytes was performed as previously described 
[32], except that the cells were cultured at 32°C and that 0.1% of bovine serum 
albumin (BSA) was added to the medium to inactivate trypsin after passaging the 
cells.  
Amphotropic retroviral supernatants were produced by transient transfection of 
Phoenix packaging cells with retroviral vector constructs [33] using Fugene 6 (Roche 
Diagnostics, Woerden, The Netherlands). Phoenix cells were cultured in DMEM 
supplemented with 5% heat-inactivated fetal calf serum (LONZA, Basel, Switzerland) 
at 37°C. Viral supernatants were filtered through a 0.45 mm filter and infections were 
carried out at three following days for 4 hours in the presence of 3 µg/ml polybrene 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). After infection the viral supernatant 
was discarded, and cells were washed thoroughly with phosphate buffered saline 
(PBS) to remove the Ca2+ residues from the viral supernatant to avoid keratinocyte 
differentiation and proliferation arrest. 
Vector constructs used were pBabe-hTERT-hygro and pMESVts-neo [17;34], 
containing the telomerase catalytic subunit and a temperature-sensitive allele of the 
SV40-Large T antigen (tsLT), respectively. Drug selection was performed with 50 
µg/ml Neomycin (Invitrogen, Breda, The Netherlands).  
Control transfections were performed with retroviral vectors without insert. LZRS-
GFP, a retroviral vector marked with the Green Fluorescence Protein (GFP) gene, 
was used to check the transfection efficiency by UV-microscopy. 
Culturing of the tsLT-keratinocytes was performed according to the same procedure 
as primary keratinocytes at incubation temperatures of 32°C or 39°C. Media were 
refreshed twice a week and cells were passaged when 70% confluence was 
reached.  
 
Calcium sensitivity and soft agar growth 
The tsLT-keratinocytes were monitored for two hallmarks of transformation; their 
resistance to calcium-induced differentiation and their capability to grow in soft agar. 
Calcium sensitivity was analyzed by adding 2.5 mM Ca2+ to the culture medium 
during a culturing period of two weeks at 32°C. Cells were considered sensitive to 
 P53 AND PRB PATHWAY INACTIVATION IN ORAL KERATINOCYTES 
 
 
 131 
Ca2+ when the cells differentiated, stopped proliferating and reached premature 
senescence. 
For the analysis of anchorage independent soft agar growth, 5,000 cells were mixed 
in 0.35% TOP agarose in Keratinocyte Growth Medium (KGM) (Invitrogen, Breda, 
The Netherlands) [32] and plated onto a bottom of 0.6% agarose in KGM. Cells were 
cultured for 20 days before colonies were counted. As a positive and negative control 
UM-SCC-22A cells and primary oral keratinocytes were taken, respectively. 
 
P53 and pRb pathway abrogation: vector-constructs and lifespan analysis   
Vector constructs used for p53 abrogation were pWZL-p53DN-hygro (encoding the 
human p53 dominant-negative mutant Arg(175)His or R(175)H, pRS-p53shRNA-puro 
containing a short hairpin RNA specific for TP53 as described in [17] and LZRS-E6-
GFP (containing the HPV16-E6 oncogene: kindly provided by Dr. E. Hooijberg, 
Amsterdam, Netherlands).  
Vector constructs used for pRb-pathway abrogation were pRS-p16shRNA-puro 
containing a p16 specific short hairpin sequence [17], pBabe-cyclinD1 and pBabe 
HPV16-E7-puro (kindly provided by Dr. K. Münger, Bethesda, United States). Cells 
were counted by microscope and population doublings (PD) calculated with the 
formula: PD = 2log (nc/n0); nc stands for the number of counted cells and n0 for the 
initial number of cells seeded. The total number of PDs was taken as lifespan. 
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Molecular analysis of gene manipulations 
RNA and DNA isolation 
RNA and DNA isolation from cell pellets was performed using RNAbee and DNAstat 
as previously described [35].  
 
Detection of cyclin D1 expression by real-time quantitative RT-PCR 
Real time quantitative RT-PCR was performed using the ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Nieuwerkerk AD IJssel, The Netherlands) as 
was previously described [35]. Intron-spanning primers were chosen to avoid 
amplification of contaminating genomic DNA. Primers and probes specific for cyclin 
D1 were selected using PrimerExpress software (Applied Biosystems, Nieuwerkerk 
AD IJssel, The Netherlands). Selected sequences of primers and probes (Isogen, 
IJsselstein, The Netherlands) are listed in Table II. RNA input was determined by 
using the housekeeping gene BGUS as a reference.  
 
Detection of HPV16 E6 mRNA. 
Primers to detect HPV E6 are listed in Table II. PCR products were detected on 
agarose gel and confirmed using an enzyme immunoassay (EIA) as described 
previously [36;37] with a HPV16-E6 specific probe (Table II). The EIA for E6 was only 
considered positive when the EIA OD value reached at least 3x the background 
value. 
 
Table II. Primer and probe sequences for HPV16-E6 and CCND1 mRNA detection. 
Gene Amplicon size (bp) Primer/ probe 5’-Sequence-3’ 
Forward TTACTGCGACGTGAGGTGTA 
Reverse GGAATCTTTGCTTTTTGTCC HPV16-E6 86 
Probe AAGCCACTGTGTCCTGAAGAAAAGCAA 
Forward TACTACCGCCTCACACGCTTC 
Reverse TTCGATCTGCTCCTGGCAG CCND1 81 
Probe ATCAAGTGTGACCCAGACTGCCTCCG 
 
 
TRAP assay  
For quantitative determination of telomerase activity, the TeloTAGGG Telomerase 
PCR ELISA plus kit (Roche Diagnostics, Mannheim, Germany) was used. The 
procedure was performed according to the manufacturer’s protocol, with an input of 
250 ng protein. All samples were analysed in duplicate. The tumor cell line SiHa was 
included as a positive control. Primary oral keratinocytes were included as a negative 
control.  
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Western Blotting 
Cells were lysed using a buffer of 10 mM Tris, 0.65% NP40 and 150 mM NaCl (pH 
8.0) and protein concentrations were measured using a nanodrop spectrophotometer 
(Isogen). Western Blot was performed as previously described [38]. Cell lines SiHa 
and UM-SCC-22A were used as controls. Proteins were detected with antibodies 
specific for p16INK4A (clone DCS50.1; Pharmigen 1:500) and p53 (clone DO7; DAKO, 
1:800). beta-actin (clone 150 1R; Chemicon, 1:3,000) was used as a loading control.  
 
Gene expression profiling of cells with different p53-pathway abrogation  
In two different tsLT keratinocyte lines, p53 was inactivated in triplicate by either 
TP53 shRNA, HPV16-E6 or p53R(175)H, allowing six replicates per manipulated 
condition. Cells were transduced at 32°C as described above and checked for 
transduction efficiency by LZRS-GFP control. Cells were harvested synchronously 
after three weeks of culturing at 39°C. Microarray hybridization, using the Agilent Low 
RNA Input Fluorescent Linear Amplification Kit and 4x44K Whole Human Genome 
Arrays, was carried out according to the manufacturer (Agilent Technologies, 
Amstelveen, The Netherlands). We assumed that overexpression of dominant-
negative mutant p53R(175)H and viral oncogene HPV16-E6 would have increased 
activity as compared to TP53 shRNA inactivation, and therefore analyzed the data 
using the shRNA manipulated cells as reference. The gene expression data have 
been deposited in the NCBIs Gene Expression Omnibus (GEO), with series 
accession number GSE12553. 
For interpretation of the biological processes and canonical pathways, we used 
Ingenuity Pathways Analysis 6.0 (Ingenuity Systems®, Redwood City, USA). Gene 
lists containing the significant genes (FDR corrected p-value p<0.05), of the two 
conditions used for p53 abrogation (HPV16-E6 and p53R(175)H) versus TP53 
shRNA as reference condition, were uploaded into the application. The significance 
of a canonical pathway is controlled by a Benjamini-Hochberg corrected p-value [39], 
considering p<0.05 as significant. The same analysis was repeated using Panther 
Gene Ontology analysis [24]. 
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Supplementary Figure 1. Ingenuity pathway analysis schemes of the hypoxia signalling (HIF1) and the 
Wnt/ß-catenin signalling pathway, respectively. Increased RNA levels are indicated in red, decreased 
levels in green and unaffected levels in white. The color intensity correlates to the fold change. When 
multiple ‘family-members’ of one particular gene shows both increased and decreased expression, a 
mixture of green and red is used. As we manipulated the TP53 transcript levels by shRNA knockdown, 
we removed the gene from the dataset. 
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CHAPTER 1 
 
 
Figure 2. HNSCC progression model. Braakhuis et al. suggested an adapted progression model for 
cancer in the head and neck. A stem cell acquires one or more genetic alterations and forms a patch, a 
small cluster of less than 200 cells in diameter that can be detected by p53 immunostaining. Eventually 
the stem cell escapes normal growth control. A precursor lesion arises and laterally displaces the 
normal mucosa. Additional genetic hits give rise to different subclones within a field and eventually a 
subclone evolves into invasive cancer [61]. 
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CHAPTER 1 
Figure 3. Principle of array CGH. This figure shows the steps in BAC array CGH. (A) BAC clones are 
selected from a physical map of the genome. (B) DNA samples are extracted from selected BAC clones 
and their identity is confirmed by DNA fingerprinting or sequence analysis. (C) A multi-step amplification 
process generates sufficient material from each clone for array spotting. Each clone is spotted in 
replicate onto a solid support. (D) Reference DNA and test DNA are differentially labeled with cyanine 3 
and cyanine 5 respectively. (E) The two labeled products are combined and hybridized onto the spotted 
slide. (F) Images from hybridized slides are obtained by scanning in two channels. Signal intensity ratios 
from individual spots can be displayed as a simple plot (G) or by using more complex software such as 
Imagene, which can display copy number alterations throughout the whole genome [88]. 
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CHAPTER 2 
Figure 2. Typical examples of HPV16 FISH on sections of paraffin embedded HNSCC specimens. All 
three tumors were positive for HPV DNA and E6/E7 expression. The images A and B show punctuate 
nuclear FISH signals indicating HPV16 DNA integrated into the host genome. Image C shows an area 
with diffuse nuclear FISH staining indicative for episomal HPV16 DNA. 
 
 
 
Figure 3. Representative examples of p16 immunostaining on three tumors of the HPV D+/R+ group (A-
C) and one of the HPV-negative group (D). A = Tumor 1 (table 2) with 100% of the cells stained with 
high intensity in both nucleus and cytoplasm; B = Tumor 5 (table 2) with approximately 50% of the cells 
positively stained with high intensity; C = Tumor 11 (table 2) with 100% of the cells stained, but with a 
lower intensity; D = Tumor 26 (table 2) negative for p16 immunostaining. 
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Figure 2. A genetic progression model of multi-step head and neck carcinogenesis is proposed. The 
two etiological factors, smoking and HPV16 are incorporated into the “patch-field-cancer” model that in 
essence has previously been published [9]. In this model the development of a field with genetically 
altered cells play a central role. In the initial phase a “patch” develops, a clonal unit in which the stem 
cell and its daughter cells acquire a genetic alteration. Some evidence point to an alteration in 
p53/MDM2 pathway as a likely first event. This pathway is disrupted by a mutation of TP53 in case of 
smoking as a causative factor, or alternatively, by the HPV effect of E6, that results in a degradation of 
p53. The conversion of a patch into a field is the next step in this progression model, and this field 
expands at the expense of normal epithelium. An important event in the field phase is the impairment of 
the p16/CDK/pRb pathway [22]. In case of smoking this pathway is disrupted by inactivating CDKN2A, 
the gene encoding p16, by mutation, chromosomal loss or promoter hypermethylation. Alternatively, this 
pathway can be impaired by E7, a protein that is produced by HPV. Next, clonal divergence leads to the 
development of one or more tumors within the contiguous field of preneoplastic cells. Considering the 
two etiological factors, the common and differential chromosomal events possibly involved in the 
progression from field to carcinoma are shown. At this moment it is difficult to point out the pathways 
that are involved in this stage of carcinogenesis. CCND1 (Cyclin D1) is likely involved in smoking-related 
HNSCC, since the 11q13 region is found to be highly significantly amplified; cyclin D1 is part of the 
p16/CDK/pRb pathway, a component of the CDK/Cyclin complex that phosphorylates pRb causing S-
phase entry. 
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CHAPTER 5 
Figure 1. WECCA heatmap of 39 OOSCCs without HPV involvement. At the top of the tree two tumor 
groups can be distinguished: a group consisting of 8 OOSCC with in general genetically silent profiles 
and another group of 31 tumor with many genetic aberrations. In group2 downwards, two subgroups (a 
and b) can be distinguished with 2b as the group with the most genetic aberrations. The x-axis 
represents tumor numbers and the y-axis chromosome numbers. 
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Supplementary Figure 1. WECCA heatmap of 51 OOSCC, 39 without (present study) and 12 with 
HPV16-infection. Results of the HPV-infected tumors are derived from a previous publication [31]. seven 
out of 12 HPV-positive tumors formed a separate group and five of them rearranged among the group of 
silent tumors (indicated with black bars near the x-axis). The x-axis represents tumor numbers and the 
y-axis chromosome numbers. 
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CHAPTER 5 
Supplementary Figure 2. WECCA heatmap of 89 OOSCCs described by Snijders et al. [32]. General 
classification is similar as in the present study; a group consisting of 33 OOSCC with in general a low 
level of chromosomal aberrations and another group of 56 tumors with many chromosomal aberrations. 
In group 2 downwards, two subgroups (a and b) can be distinguished with 2b as the group with the most 
chromosomal aberrations. The y-axis represents chromosome numbers. 
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CHAPTER 6 
 
Figure 1. Result from the unsupervised hierarchical clustering analysis. Cluster 1 contains in majority 
hrHPV-positive carcinomas, as is indicated by the black boxes in the legend underneath the heatmap 
(p<0.0001). 
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Figure 3. Genes that showed differential expression in keratinocytes with an extended lifespan induced 
by either overexpression of HPV16-E6 or p53R(175)H. Knockdown of TP53 by shRNA was used as 
reference condition. A: Venn diagram showing the differentially expressed genes (p<0.05, FDR 
corrected [39]) specific for and shared by HPV16-E6 and p53R(175)H. B: Significant canonical 
pathways discovered by Ingenuity Pathway Analysis (IPA) using the differentially expressed genes 
indicated under A. Expression of cells with HPV16 E6 (purple) or mutant p53R(175)H (blue) were 
compared to p53 knockdown by shRNA as reference. The threshold line represents the p-value 0.05 
(corrected for multiple testing according to Benjamini-Hochberg [39]). 
 
 
Supplementary Figure 1. Ingenuity pathway analysis schemes of the hypoxia signalling (HIF1) and the 
Wnt/ß-catenin signalling pathway, respectively. Increased RNA levels are indicated in red, decreased 
levels in green and unaffected levels in white. The color intensity correlates to the fold change. When 
multiple ‘family-members’ of one particular gene shows both increased and decreased expression, a 
mixture of green and red is used. As we manipulated the TP53 transcript levels by shRNA knockdown, 
we removed the gene from the dataset. 
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SUMMARY AND FUTURE PERSPECTIVES 
Despite major improvements in surgical techniques and radiotherapy in the clinical 
management of squamous cell carcinoma in the head and neck (HNSCC), the long 
term survival of HNSCC patients has only moderately improved during the last 20 
years [1]. Significant improvements may be reached when the mechanisms 
underlying HNSCC carcinogenesis would be better characterized and the causative 
genes identified. The main risk factors for the development of HNSCC are tobacco 
smoking and excessive alcohol consumption [2]. Recently, also the involvement of 
the human papillomavirus (HPV) in a subset of HNSCC cases was firmly established 
[3-8]. The reported frequencies of HNSCC with high-risk HPV involvement vary 
tremendously, ranging from 0 to 100% [9;10]. Part of the variation in HPV prevalence 
could be explained by differences in the location of the tumor, i.e. the prevalence is 
relatively low in the oral cavity and high in the tonsil [5;6;11]. More importantly, 
variations in the type of tissue material studied and the HPV detection method used, 
may have a major impact on the discrepancy in the reported prevalence rates 
[5;9;12;13]. In Chapter 2, an explanation is provided for the discrepancy in the 
literature about HPV prevalence in HNSCC. We evaluated commonly used HPV 
detection methods and used that experience to find a combination of techniques to 
reach the most reliable HPV detection. This HPV detection algorithm had to be 
applicable for archival formalin-fixed paraffin-embedded (FFPE) material, since the 
preparation of FFPE specimens is routine in histopathological diagnostics worldwide.  
We compared quantitative reverse transcriptase polymerase chain reaction (RT-
PCR), fluorescence in-situ hybridization (FISH), general primer PCR (GP-PCR), HPV 
protein detection in sera, and p16-immunostaining. As a golden standard we used 
the presence of viral transcripts (oncogenes E6/E7) in frozen tissue samples of the 
same tumors, a method that reflects active virus involvement. None of the tested 
methods was optimal with respect to sensitivity and specificity, but an algorithm 
based on a combination of two frequently used diagnostic techniques reached 100% 
for both parameters. All HNSCC tumors should be tested first for p16 overexpression 
by immunostaining, followed by a GP5+/6+ DNA PCR on the p16-positive cases.  
In this thesis we also focused on a genetic fingerprint of HNSCC in relation to clinical 
and molecular variables. For this purpose, a micro-array CGH platform with a 
genomic resolution of 1 mega base (Mb) was established. This platform allows 
mapping of the genome-wide numerical genetic alterations in a high throughput 
manner. When genomic data is generated in a high-throughput manner good 
bioinformatics becomes necessary. In Chapter 3 a ’bioinformatics’-tool is described 
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which enables calculation of significance for genetic alterations that differ between 
tumor groups [14]. Specific statistical approaches need to be applied for ordinal data 
as produced by array CGH. Furthermore, a correction for multiple testing was 
incorporated by defining a false discovery rate (FDR) according to Benjamini and 
Yekutieli [15].  
The established array CGH platform and developed bioinformatics were applied to 
genetically characterize HNSCC that are positive or negative for transcriptionally 
active HPV16 (Chapter 4). The main question was if genetic differences between 
HPV-positive and HPV-negative HNSCC could be detected, which would be 
indicative for two different routes of carcinogenesis. Furthermore, this study also 
defined the relevant genetic regions that differ and are shared between these two 
groups of tumors. A gain of 18q was shown to be specific for HPV-positive HNSCC. 
HPV-negative tumors showed more specific genetic alterations such as loss of 9p21, 
amplification of 11q13.1 and TP53 mutations. These changes all relate to the 
abrogation of the p53 and pRb-pathways, and are consistent with and provide further 
evidence for the hypothesis that HNSCCs develop by two different etiologies [16-18]; 
one driven by exposure to environmental carcinogens (i.e. tobacco and alcohol) 
without HPV involvement, and one involving infection with transcriptionally active 
HPV16. On the other hand, it seems that the two carcinogenic routes also partly 
overlap. The alterations in common may be necessary events in HNSCC irrespective 
of the etiological factor, and a comprehensive genetic progression model of multi-
step head and neck carcinogenesis was proposed. 
In Chapter 5, we studied the hypothesis if additional subgroups within HPV-negative 
oral and oropharyngeal squamous cell carcinoma (OOSCC) could be distinguished 
on basis of the pattern of chromosomal aberrations, which might be relevant for 
further stratification. Thirty-nine OOSCCs were classified on basis of their genetic 
pattern determined by array CGH using a recently developed cluster algorithm. The 
tumors clustered in three groups, one (n=8) characterized by a low chromosomal 
instability index (low CIN), another by a relatively high chromosomal instability index 
(n=26), and one with a very high chromosomal instability index (n=5). This 
classification was significantly (p=0.003) associated with survival, with the best 
survival in the low CIN group and the worst survival in the group with very high CIN. 
Low CIN was also significantly (p<0.05) associated with the presence and type of 
TP53 mutation, absence of alcohol consumption and a female gender. In addition, 
we excluded that these tumors showed microsatellite instability, and they were 
shown to be diploid. We confirmed this classification of OOSCC on basis of low CIN 
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and high CIN with an independent set of 89 oral carcinomas [19]. To elucidate the 
biological basis of the low CIN genotype, these tumors were tested for microsatellite 
instability, but this could not be detected. The discovery of these new classes of 
OOSCC with unique genetic and clinical characteristics might have important 
consequences for future biological and clinical studies. The most important 
conclusion is, taking also HPV-positive HNSCC in consideration, that at least three 
and possibly four genetically distinct subgroups of HNSCC exist which might each 
have their own different route of carcinogenesis. It is too early to speculate on the 
role of this classification for clinical management. There is a consensus in the field 
that at least HPV-positive HNSCC should be considered separately in clinical trials, 
but even for this specific group adjustment of clinical management is not yet 
implemented. An important problem at present is that there is no consensus on the 
most reliable assay to assess HPV, which has consequences for the claims on the 
more favorable prognosis of HPV-positive tumors. Our algorithm might help to 
assess the involvement of HPV in large retrospective series.  
Currently, the role of HPV in a subset of HNSCC is under intensive research. In 
contrast to the well established causal role of transforming hrHPV infections in 
carcinomas of the uterine cervix [20], less is known about the precise role of hrHPV 
infections in HNSCC. We hypothesized that the genomic patterns of HPV-positive 
HNSCC might show similarity to that of cervical cancers, irrespective the difference in 
anatomical site. In Chapter 6 genomic profiles of HNSCC, positive and negative for 
transcriptionally active HPV16 (described in Chapters 4 and 5) were compared to 
those of cervical carcinomas (all HPV-positive). This comparison showed that a 
number of alterations common to HPV-negative head and neck carcinomas were 
rarely detected in HPV-positive carcinomas either from the cervix or the head and 
neck, which included losses at 3p, 5q, and 8p as well as amplifications at 11q13.3 
(CCND1 locus). On the other hand gains of chromosome 20 and losses at 13q 
seemed specific for HPV-induced tumors, irrespective the anatomical site. Frequently 
shared changes between all tumors encompassed 3q gains and 11q losses, 
suggesting critical cancer genes at these loci. Finally, a number of organ-specific 
alterations were found, including a gain at 8q in HNSCCs and losses at 17p in 
cervical carcinomas. The high frequencies in which these alterations are detected in 
these tumor types suggest that they are crucial in carcinogenesis.  
HNSCC carcinogenesis is driven by a few genetic events that entail the impairment 
of the p53 and the pRb pathways, which are involved in cell cycle regulation and 
apoptosis [21]. Based on epidemiological data and in vitro transformation 
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experiments, it has been estimated that four to six genetic events are required in 
humans to transform a normal cell into a malignant cell [22;23]. The current high-
throughput methods that allow genome wide analysis of genetic changes with high 
resolution such as array CGH described in this thesis, but also the increasing body of 
sequencing data, have tremendously accelerated the identification of candidate 
cancer genes and chromosomal regions harboring candidate cancer genes [24]. Of 
many of these genes, the role and importance in the pathogenesis is unclear. 
Tumors are intrinsically genetically unstable and many DNA changes or aberrantly 
expressed genes should be considered a consequence and not as a cause of 
carcinogenesis. It is therefore of utmost importance to discriminate the carcinogenic 
‘driving’ from the ‘passenger’ events.  
At present suitable transgenic mouse models are absent for HNSCC carcinogenesis, 
and functional characterization of candidate cancer genes in established HNSCC cell 
lines only allows analysis of phenotypes in the highly deregulated cellular 
environment of an established invasive carcinoma cell line. We therefore generated 
an in vitro model of conditionally immortalized primary oral squamous keratinocytes. 
Establishment of this model system and its application to investigate the phenotypes 
associated with p53 and pRb pathway abrogation in HNSCC are described in 
Chapter 7. The abrogation of the p53 pathway, either by knock-down of the p53 
gene by overexpression of dominant-negative p53, or by the human papillomavirus 
oncoprotein E6, led to an extended life span. Despite the seemingly identical 
phenotypes, dominant-negative mutant p53 showed most severe molecular changes 
including upregulation of the hypoxia signaling (HIF1) and WNT pathways. Knock-
down of p16, overexpression of cyclin D1 or HPV E7 alone did not seem to have 
effect on the life span. In combination with abrogation of the p53 pathway this led to 
an immortal phenotype. Our data suggest a critical order of genetic hits in squamous 
carcinogenesis with abrogation of pRb and p53 pathways as essential and likely 
primary hits. This in vitro model of conditionally immortalized primary oral squamous 
keratinocytes further allows the functional analysis of other candidate cancer genes, 
as well as high-throughput functional genetic screens. 
 
FUTURE PERSPECTIVES 
The Human Genome Project has provided an enormous amount of knowledge about 
the human DNA sequence. This allowed the global profiling of copy number 
imbalances in tumors and the precise determination of the breakpoints of regions that 
are gained and/or lost. During the last few years, micro-array and sequencing 
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technology rapidly became the main techniques for studying chromosomal 
aberrations. Array CGH has proven valuable for a better understanding of the biology 
of human cancer [25;26] and has the potential to improve diagnosis, outcome 
prediction and treatment response. Diagnostic genomic signatures, as are already 
present for gene expression [27], will soon be at hand [28] and will improve tailored 
therapy in the near future. Also for HNSCC we have shown by array CGH analysis 
the existence of subgroups of tumors with distinct genomic profiles. These subgroups 
with different genomic entities may also have specific underlying mechanisms of 
progression and patient prognosis. For instance, HPV-positive HNSCC have distinct 
genomic alterations similar to those found in cervical cancers, in which HPV has a 
confident causal role, and should therefore be investigated as a separate tumor 
group. Use of reliable detection methods as RT-PCR, FISH or the algorithm provided 
in this thesis, are necessary to select the true HPV-positive patients and to estimate 
the world-wide prevalence for HPV in HNSCC. The question remains if HPV-induced 
HNSCC can be prevented by vaccination. Currently prophylactic HPV vaccination is 
carried out for cervical carcinoma prevention and in theory could be implemented for 
the prevention of HPV-induced HNSCC as well. To date, there is only evidence that 
the vaccine prevents infection and it will take years before beneficial effects on the 
cervical carcinoma incidence will become clear. Nevertheless, no serious side effects 
have been reported so far, supporting the view to start vaccination studies in the near 
future in both girls and boys.  
Within the group of HPV-negative HNSCC additional subgroups can be distinguished 
on basis of the genetic profile. This classification seems associated with p53 
mutation status, the number of genomic alterations, etiological risk factors, and 
prognosis. Investigation of larger cohorts should substantiate this initial observation. 
Prognostic separation of patients in different subgroups based on different aetiology, 
genomic classification and other parameters clearly has major clinical implications. If 
unequivocally proven, these subgroups of patients need to be analyzed as separate 
groups in future studies for several reasons. First, the effect of targeted drugs could 
be very different and this needs to be considered in future clinical trials. Second, the 
current clinical management could be adapted either for the tumors that show a clear 
favorable prognosis (treatment less intense) or for the tumors that show with current 
treatment regimen a more unfavorable prognosis (more intense: shift to primary 
surgical treatment with adjuvant chemo- or bioradiation). Thirdly, novel therapies 
could be developed directed to the cell signaling pathways involved in the different 
subgroups of tumors (e.g. directed to HPV as causative factor). 
 SUMMARY AND FUTURE PERSPECTIVES 
 
 
163 
Our array CGH studies were of value for tumor classification, but did not improve our 
understanding of the underlying mechanisms driving cancer because of its 
descriptive nature. The genomic resolution of the array CGH platform we established 
and used had a limited resolution of 5 Mbs. The identified genomic aberrations were 
therefore too large to pinpoint candidate driver genes. Nevertheless, the differential 
analysis showed the genomic regions that we have to focus on in the future, mainly 
3q26, 8q24 and 11q. At present, the resolution and accuracy of array CGH platforms 
are improving enormously and will soon enable us to detect genomic aberrations at 
the gene level. Furthermore, sophisticated data analysis tools facilitate the integration 
of array CGH with expression, single nucleotide polymorphism (SNP), methylation 
and proteomics data. This and other upcoming high resolution applications like 
massive parallel sequencing will lead to an excess of candidate cancer genes 
[24;29;30]. Functional characterization of all these genes and their relevance to 
HNSCC development necessitates in vitro models. The in vitro model we established 
will be of importance in understanding the underlying gene interactions and 
pathways. Large high-throughput genetic screens using cDNA, short hairpin RNA or 
microRNA libraries are at hand to identify novel candidate cancer genes. The 
elucidation of the driving cancer genes and signaling pathways causing head and 
neck cancer, taking the HNSCC subgroups into account, will be a major step to the 
identification of novel drug targets and to the improvement of the clinical outcome of 
this disease in the future.   
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SAMENVATTING EN TOEKOMSTPERSPECTIEF 
De laatste 20 jaar is er veel vooruitgang geboekt in de behandeling van 
plaveiselcelcarcinomen in het hoofd-halsgebied (HHPCC). Desalniettemin is de kans 
op overleving op de lange termijn slechts beperkt verbeterd. Grote verbeteringen 
kunnen alleen worden bereikt als de onderliggende biologie van het ontstaan van 
deze tumoren wordt opgehelderd. Hiervoor moeten de verantwoordelijke 
kankergenen en signaalpaden waarin ze actief zijn worden geïdentificeerd. De 
belangrijkste risicofactoren voor het ontwikkelen van HHPCC zijn het roken van 
tabak en overmatig alcoholgebruik. Recentelijk is ook beschreven dat het humaan 
papillomavirus (HPV) HHPCC kan veroorzaken. Het exacte percentage van tumoren 
waarbij HPV een rol speelt is onduidelijk. Dit komt doordat de gerapporteerde 
prevalenties van HPV-positieve HHPCCs sterk uiteenlopen. Deze variatie kan 
gedeeltelijk verklaard worden doordat verschillende tumorlocaties onderzocht zijn; 
het virus wordt namelijk vaker gevonden in tumoren van de keelholte dan in die van 
de mondholte. Een andere belangrijke oorzaak van de variatie in prevalentie is het 
soort monster dat wordt geanalyseerd (ingevroren of formaline-gefixeerd paraffine-
ingebed weefselmateriaal) en de methode waarmee HPV wordt gedetecteerd. Dit 
laatste wordt onderzocht in hoofdstuk 2. Hier worden de meest gebruikte HPV 
detectie methoden met elkaar vergeleken en zijn de verkregen resultaten 
gecombineerd om de meest gevoelige en specifieke HPV bepaling te verkrijgen die 
eenvoudig werkt op formaline-gefixeerd paraffine-ingebed weefselmateriaal. Dit 
laatste is van belang omdat weefsel wereldwijd zo opgeslagen wordt en zal worden. 
Wij hebben in deze studie kwantitatieve “reverse transcriptase-polymerase chain 
reaction” (RT-PCR), fluorescentie in situ hybridisatie (FISH), General Primer PCR 
(GP-PCR), p16-immunokleuring en detectie van HPV specifieke eiwitten in bloed met 
elkaar vergeleken. De aanwezigheid van viraal mRNA (expressie van de oncogenen 
E6/E7 bepaald met RT-PCR) in vers ingevroren materiaal werd als afspiegeling van 
de aanwezigheid van actief HPV beschouwd, de gouden standaard voor deze 
vergelijking. Geen enkele test bereikte een specificiteit en gevoeligheid van 100%. 
Dit kon alleen worden bereikt door een combinatie van twee standaard diagnostische 
technieken; alle HHPCCs worden dan eerst getest op p16 overexpressie, gevolgd 
door een GP5+/6+ DNA-PCR op de p16-positieve tumoren. Kanker ontstaat door 
een verzameling van genetische veranderingen in het DNA van de cel. De 
genetische veranderingen beïnvloeden de activiteit van genen die betrokken zijn bij 
onder andere celgroei, invasie, uitzaaiing en celdood. Genen die tumorgroei 
bevorderen zijn oncogenen en genen die een remmende werking hebben op de 
SAMENVATTING EN TOEKOMSTPERSPECTIEF 
 
 
 169 
tumorgroei noemt men tumorsuppressorgenen. Dit proefschrift richt zich op het 
identificeren van de genetische veranderingen in HHPCC in relatie tot klinische en 
moleculaire variabelen. Voor dit doel werd array CGH met een genomische resolutie 
van ~1 Megabase (Mb) opgezet. Met array CGH is het mogelijk om op een snelle 
wijze de numerieke genetische veranderingen over het gehele genoom van een 
tumor in kaart te brengen. Met behulp van array CGH wordt in een korte tijd een 
enorme hoeveelheid data geproduceerd die goede bioinformatica noodzakelijk maakt 
voor de analyses. In hoofdstuk 3 wordt een analyse-methode beschreven waarmee 
kan worden berekend welke genetische veranderingen tussen twee tumorgroepen 
significant verschillend zijn. Deze analyse is specifiek voor geordende data, zoals die 
door array CGH worden gegenereerd. Bovendien is een statistische correctie voor 
meervoudige testen, zoals beschreven door Benjamini en Yekutieli, in het 
programma verwerkt. Deze methode is vervolgens toegepast op array CGH data van 
een groep HHPCCs die wel of geen HPV16 bevatten (hoofdstuk 4). HPV-negatieve 
tumoren bleken zeer specifieke chromosomale veranderingen te hebben, zoals het 
verlies van 9p21, amplificatie van 11q13.1 en de aanwezigheid van TP53 mutaties. 
Deze DNA veranderingen zijn geassocieerd met een blokkering van de p53 en pRb 
signaalpaden en zijn in overeenstemming met onze hypothese dat HHPCC zich 
ontwikkelt langs twee verschillende routes; één gedreven door de blootstelling aan 
kankerverwekkende stoffen (bijvoorbeeld tabak en alcohol) zonder HPV, en één 
gedreven door infectie met HPV16. Tevens ontdekten we dat de twee routes naar 
kanker genetisch ook gedeeltelijk overlappen. Deze gemeenschappelijke genetische 
veranderingen kunnen genen bevatten die betrokken zijn bij het ontstaan van 
HHPCC, ongeacht de etiologische factor. Deze resultaten zijn tevens schematisch 
weergegeven in een genetisch progressie model voor ‘hoofd-hals carcinogenese’. In 
hoofdstuk 5 hebben we de hypothese onderzocht of er nog extra subgroepen binnen 
de HPV-negatieve carcinomen kunnen worden onderscheiden op basis van 
chromosomale afwijkingen. Van negenendertig HHPCCs werden de chromosomale 
veranderingen in kaart gebracht met behulp van array CGH en vervolgens in 
groepen ingedeeld met behulp van een recentelijk ontwikkeld cluster algoritme. Er 
konden drie groepen tumoren onderscheiden worden: (I) één gekarakteriseerd door 
zeer weinig chromosomale veranderingen (n = 8), (II) een ander door een relatieve 
hoge hoeveelheid chromosomale veranderingen (N = 26) en (III) een met een zeer 
hoge hoeveelheid chromosomale veranderingen (N = 5). Deze indeling correleerde 
significant met een aantal klinische en moleculaire variabelen. De patiënten met 
tumoren met zeer weinig chromosomale veranderingen hadden de beste 
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overlevingskans (p = 0,003). Verder bleek dat afwezigheid van chromosomale 
veranderingen in het tumorgenoom gerelateerd is aan het vrouwelijke geslacht, het 
ontbreken van een TP53 mutatie en het ontbreken van alcoholgebruik in de 
voorgeschiedenis. Tevens werd uitgesloten dat microsatelliet instabiliteit een factor 
van belang is in deze tumoren en ze waren ook allemaal diploid. Het bestaan van 
groepen HHPCC met zulke grote verschillen in aantal chromosomale veranderingen 
hebben we bevestigd met behulp van classificatie analyse van een eerder 
beschreven onafhankelijke set van 89 orale carcinomen. De ontdekking van deze 
nieuwe indeling van HHPCC met unieke genetische en klinische kenmerken kan 
belangrijke gevolgen hebben voor toekomstige biologische en klinische studies. De 
belangrijkste conclusie is, met inachtneming van de groep van HPV-positieve 
HHPCC, dat minstens drie genetisch verschillende subgroepen van HHPCC bestaan 
met mogelijk hun eigen specifieke route naar kanker. Het is nog te vroeg om te 
speculeren over het precieze belang van deze classificatie voor het klinisch 
handelen. Er is in ieder geval consensus over het feit dat HPV-positieve HHPCC als 
verschillend moeten worden beschouwd en voor deze specifieke groep is de 
discussie omtrent een specifieke behandeling in volle gang. Er is helaas nog geen 
consensus over de meest betrouwbare HPV-detectie methode. Hierna kan namelijk 
pas de juiste prevalentie en de veronderstelde gunstigere prognose van patiënten 
met HPV positieve tumoren met zekerheid bepaald worden. Onderzoek op grote 
retrospectieve series HHPCC met behulp van ons detectie algoritme zou kunnen 
helpen om de rol van HPV en de klinische gevolgen hiervan nauwkeurig te bepalen.  
In tegenstelling tot tumoren van de cervix uteri (baarmoederhals) waar de causale rol 
van hrHPV duidelijk is vastgesteld, is de precieze rol van HPV in HHPCC nog 
onduidelijk. Indien de werking van het virus in HHPCC vergelijkbaar is aan die in 
baarmoederhals tumoren, dan zouden de chromosomale veranderingen van HPV 
positieve HHPCC veel gelijkenis met die van baarmoederhals tumoren moeten 
vertonen. Om deze hypothese te toetsen werd in hoofdstuk 6 de array CGH data van 
HPV-positieve en -negatieve HHPCC (beschreven in hoofdstuk 4 en 5) vergeleken 
met die van baarmoederhalscarcinomen (allen HPV positief). Uit deze vergelijking 
werd bevestigd dat een aantal chromosomale veranderingen gevonden in HPV-
negatieve HHPCC zelden werden aangetroffen in HPV-positieve carcinomen 
(baarmoederhalsPCC en HHPCC), waaronder verlies van de chromosomale regio’s 
3p, 5q, en 8p evenals toename van 11q13.3 (CCND1 locus). Verlies van 
chromosoom 20 en 13q bleek specifiek voor HPV-positieve tumoren ongeacht de 
anatomische herkomst. Tenslotte is binnen de groep van HPV-positieve carcinomen, 
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ook een aantal weefsel-specifieke chromosomale veranderingen gevonden, zoals 
vermeerdering van 8q in HHPCCs en verlies van 17p in baarmoederhalstumoren. De 
hoge frequentie waarin deze HPV-specifieke chromosomale veranderingen voor 
komen, suggereren dat zij belangrijk zijn naast de kanker initiërende rol van HPV 
zelf. Het identificeren van deze chromosomale veranderingen zal nuttig blijken om de 
verantwoordelijke genen op te sporen.  
HHPCC carcinogenese wordt gedreven door enkele genetische veranderingen die 
leiden tot blokkade van de p53 en de pRb signaalpaden. Deze signaalpaden zijn 
betrokken bij de regulatie van o.a. de celcyclus en geprogrammeerde celdood 
(apoptose). Op basis van epidemiologische gegevens en onderzoek naar 
celtransformatie in in vitro modelsystemen is bepaald dat vier tot zes genetische 
gebeurtenissen nodig zijn om een normale humane cel in een kwaadaardige 
kankercel te veranderen. De huidige snelle methoden, waarmee zeer precies 
minimale chromosomale veranderingen en mutaties in kaart worden gebracht, 
hebben de identificatie van kandidaat kankergenen enorm versneld. Voor veel van 
deze genen is de rol en betekenis in het ontstaan van kanker nog onduidelijk. 
Tumoren zijn genetisch instabiel en vele DNA veranderingen moeten worden 
beschouwd als een gevolg van het carcinogenese proces en niet als een oorzaak. 
Het is daarom van het allergrootste belang om de 'bestuurder' van de 'passagier' 
genetische veranderingen functioneel te onderscheiden. Op dit moment zijn er geen 
geschikte transgene muismodellen beschikbaar voor HHPCC om kandidaat 
kankergenen te onderzoeken. De functionele karakterisering van kandidaat genen 
wordt daarom vooral gedaan in HHPCC cellijnen die alleen een vergevorderd 
stadium van kanker nabootsen. Om die reden hebben wij een celkweekmodel van 
conditioneel onsterfelijke primaire orale plaveiselcellen ontwikkeld. De ontwikkeling 
van dit model en het onderzoek naar het effect van p53 en pRb signaalpad blokkade 
in HHPCC is beschreven in hoofdstuk 7. Blokkade van de p53-pathway, hetzij door; 
(I) specifiek short hairpin RNA (shRNA) van het p53-gen, (II) overexpressie van een 
dominant-negatieve p53 mutant, of (III) overexpressie van het HPV oncoprotein E6, 
leidde alle tot een langere levensduur van de cellen. Ondanks de ogenschijnlijk 
identieke effecten op de levensduur van de cellen, toonde cellen met de dominant-
negatieve p53 mutant grotere moleculaire veranderingen, waaronder aktivatie van de 
hypoxia (HIF1) en WNT signaalpaden. Blokkade van het pRb signaalpad door 
vermindering van p16 expressie, vermeerdering van cyclin D1 of HPV E7 expressie 
bleken allen geen effect te hebben op de levensduur van de cellen. Echter, in 
combinatie met blokkade van het p53-pad leidde dit tot immortalisatie, een van de 
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belangrijke kanker-geassocieerde kenmerken. Onze resultaten suggereren eveneens 
dat de volgorde van genetische veranderingen in de HHPCC carcinogenese kritisch 
is, met blokkade van de pRB en p53 pathways als essentiële en waarschijnlijk eerste 
veranderingen. Dit celkweek model van conditioneel geïmmortaliseerde primaire 
orale plaveiselcellen vereenvoudigt de functionele analyse van andere 
kandidaatgenen, en maakt ook het uitvoeren van grootschalige functionele 
genetische screens mogelijk. 
 
TOEKOMSTPERSPECTIEF 
Het Human Genome Project heeft enorm veel kennis over het menselijk DNA 
opgeleverd. Hierdoor werd het mogelijk de basenvolgorde van kankergenomen te 
bepalen en methoden te ontwikkelen voor grootschalige analyse van chromosomale 
veranderingen en genexpressie. Micro-array technologie en grootschalige 
basenvolgorde bepaling zijn daar nu de belangrijkste technieken voor. Deze 
methodieken hebben hun toegang tot de kliniek al gevonden, enerzijds in het beter 
voorspellen van de prognose, en anderzijds om gerichter te kiezen voor een 
behandeling waar de tumor gevoelig voor is. Verder heeft deze methodologie er toe 
geleid dat verschillende subgroepen van tumoren kunnen worden onderscheiden op 
basis van moleculaire verschillen, hetgeen belangrijke consequenties heeft voor het 
onderzoek naar de oorzakelijke kankergenen. Ook voor HHPCC hebben we door 
middel van array CGH analyse laten zien dat er subgroepen van tumoren bestaan. 
De identificatie van deze subgroepen en de gevonden associaties met specifieke 
klinische karakteristieken zijn een belangrijke waarneming in dit proefschrift. HHPCC 
die geïnfecteerd zijn met HPV hebben specifieke chromosomale veranderingen en 
specifieke genexpressie profielen. Dit inzicht in combinatie met de literatuurgegevens 
dat deze tumoren ook klinisch een gunstiger beloop lijken te hebben, maken duidelijk 
dat deze tumoren als een afzonderlijke groep dienen te worden beschouwd. Gebruik 
van betrouwbare detectiemethoden zoals RT-PCR, of het detectie algoritme uit dit 
proefschrift, zijn nodig om de HPV-positieve patiënten te identificeren. De vraag is of 
HPV-geïnduceerde HHPCC voorkomen zou kunnen worden door vaccinatie. 
Preventie door profylactische HPV vaccins wordt al toegepast om 
baarmoederhalskanker te voorkomen en zou in theorie ook toegepast kunnen 
worden om HPV-positieve HHPCC te voorkomen in de gehele populatie. De 
introductie van grootschalige HPV vaccinatie bij meisjes in Nederland verliep echter 
bepaald niet zonder slag of stoot en de vraag is of op dit moment het draagvlak 
bestaat om ook jongens te gaan immuniseren. Het zal ook nog jaren gaan duren 
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voordat een effect van vaccinatie op de baarmoederhalskanker incidentie kan 
worden aangetoond. Tot op heden is alleen bewezen dat infectie wordt voorkomen. 
Omdat er op dit moment geen bijwerkingen van het vaccin worden gerapporteerd lijkt 
het toch in de rede te liggen om niet langer te wachten. 
Ook binnen de HPV-negatieve HHPCC blijken er nog additionele subgroepen met 
specifieke patronen van chromosomale veranderingen te bestaan. Verder onderzoek 
met grotere aantallen tumoren is echter nodig om deze eerste resultaten te 
bevestigen. Het onderscheiden van de patiënten in verschillende subgroepen naar 
etiologische factoren, specifieke chromosomale veranderingen en de relatie die deze 
hebben met de prognose heeft een belangrijke klinische implicatie. Ten eerste kan 
het effect van een bepaald geneesmiddel verschillen per subgroep. Ten tweede 
zouden de tumoren met een duidelijk gunstige prognose minder intensief behandeld 
kunnen worden in verhouding tot tumoren met een ongunstige prognose. Een op het 
eerste gezicht logische consequentie die echter niet zo snel ingang zal vinden om 
mogelijke onderbehandeling te voorkomen. Eerder zal men geneigd zijn zwaardere 
behandelingen zoals postoperatieve chemoradiatie te beperken tot de 
patiëntengroep met de meest ongunstige prognose. Ten derde kunnen nieuwe 
therapieën worden ontwikkeld gericht op de afwijkende signaalpaden die specifiek 
zijn voor een bepaalde subgroep. Verder zullen in klinisch vervolgonderzoek deze 
variabelen moeten worden bepaald omdat ze net als de TNM stadiëring van invloed 
kunnen zijn op het beloop en dus moeten worden meegewogen in de analyse. 
In het onderzoek beschreven in dit proefschrift zijn nog geen nieuwe kandidaat 
kankergenen geïdentificeerd. Een van de oorzaken is de beperkte resolutie van het 
toegepaste array CGH platform, dat slechts grote chromosomale afwijkingen 
detecteert en dus niet zomaar tot de ontdekking van specifieke kandidaat 
kankergenen leidt. Niettemin geven de differentiële analyses wel aan op welke 
chromosomale gebieden we ons voorlopig moeten concentreren, in het bijzonder op 
3q26, 8q24 en 11q. Momenteel is de resolutie en de nauwkeurigheid van de array 
CGH enorm verbeterd en is het detecteren van zeer kleine chromosomale 
veranderingen mogelijk. Bovendien maakt geavanceerdere data analyse de 
integratie van array CGH data met expressie profielen, single nucleotide 
polymorfismen (SNPs), methylatie patronen en proteomics data mogelijk. Deze en 
andere aankomende toepassingen met hoge resolutie, zoals massale parallelle 
sequencing (MPS), zullen leiden tot de identificatie van kandidaat kankergenen. 
Functionele karakterisering van al deze genen en hun relevantie voor HHPCC vereist 
goede functionele modellen. Het door ons opgezette celkweekmodel van 
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conditioneel geïmmortaliseerde plaveiselcellen uit de mondholte is hiervoor zeer 
geschikt. Grote functionele genetische screens met behulp van cDNA, shRNA of 
microRNA, zijn hiermee eveneens mogelijk om nieuwe kandidaat genen te 
identificeren. De ontregeling van de signaalpaden in een tumor zijn tegelijkertijd ook 
hun achilleshiel, en we zullen derhalve moeten proberen de relevante signaalpaden 
voor hoofdhalskanker te ontrafelen. Daarmee zullen we beschikken over de meest 
betrouwbare biomerkers voor diagnostische toepassingen en een ingang voor 
nieuwe behandelingen. 
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DANKWOORD 
Pfff, ik heb heel wat ‘opbeurende’ spreekwoorden langs horen komen en aan ‘De 
laatste loodjes wegen het zwaarst’ hecht ik nu veruit de meeste waarde. Maar nu is 
het af en ben ik hartstikke trots op alles wat hierin staat. En daarvoor wil ik vele 
mensen bedanken, want anders was dit nooit gelukt. Helaas kan ik onmogelijk 
iedereen aanspreken, maar ik wil graag toch de belangrijkste spelers noemen. 
Laat ik beginnen met mijn beide promotoren. Prof. Dr. R.H. Brakenhoff. Beste Ruud, 
hierbij wil ik je allereerst bedanken voor het geloof in mijn kunnen. Je gaf me op het 
Integraal Moleculair Biologisch Laboratorium (IMBL) alle vrijheid om nieuwe 
technieken op te zetten en vervolgens een belangrijk deel van de organisatie op me 
te nemen. Later als promovendus veranderde dit in het opzetten van een model 
systeem in samenwerking met Dr. Katrien Berns, Prof. Dr. René Bernards en Dr. 
Reuven Agami op het NKI, waar ik hen zeer erkentelijk voor ben. Ook het uitvoeren 
van kostbare micro arrays werd onderdeel van mijn takenpakket. Iets waar ik tot de 
dag van vandaag nog altijd de vruchten van pluk. Je bevlogenheid en kritische blik 
werden me wel eens te veel, maar je enorme enthousiasme en ‘drive’ weet je als 
geen ander over te brengen. Je hebt je overigens aan je belofte; ‘Als AIO gaan we je 
wel even anders aanpakken’, zeker gehouden. Ook buiten het VUMC, zoals op de 
Jaap Eden baan, zijn we nog steeds actief en ik hoop dat dit voorlopig nog zal 
blijven. Ik heb je ooit in het zonnetje mogen zetten met een sketch op jouw 
oratiefeest. Ik hoop dat jij mij ook zal sparen op mijn feestje… Prof. Dr. C.R. 
Leemans, beste René, ook jij bedankt voor je interesses in dit onderzoek en de 
mogelijkheden die mij geboden zijn. 
Dan natuurlijk mijn beide co-promotoren. Dr. B.J.M. Braakhuis, beste Boudewijn, ik 
leerde je pas echt kennen toen ik als promovendus ‘uitverkorene’ werd om met jou 
de kamer te gaan delen. Sinds die tijd ging mijn “know-how” met sprongen vooruit. 
Jouw enorme kennis van de literatuur, jouw relativering van wetenschappelijke 
frustraties en functie als rustgevende buffer van Ruud heb ik altijd enorm 
gewaardeerd. Dr. B. Ylstra, beste Bauke. Eerst samen aan de BAC arrays en nu aan 
de ultra high resolution arrays! Lange tijd heb ik de afronding van dit onderzoek en 
proefschrift in de avond-uren moeten combineren met het mijn werk op de micro-
array faciliteit. Iets wat regelmatig leidde tot begrijpelijke wederzijdse frustraties. Ik wil 
je danken voor de kritische blik en waardevolle discussies in de laatste fase van dit 
onderzoek en hoop op een goede voortzetting in de toekomst. 
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De leden van de promotie commissie, Prof. Dr. Frank Speleman, Prof. Dr. René 
Bernards, Dr. Katrien Berns, Prof. Dr.  Rob J Baatenburg de Jong, Prof. Dr. Henk 
MW Verheul, Prof. Dr.  Elisabeth Bloemena en Prof. Dr. Peter JF Snijders, wil ik 
danken voor de tijd en aandacht die ze aan mijn werk hebben besteed.  
Al mijn collega AIO’s bij de KNO, met in het bijzonder mijn paranimfen Hester en 
Lars. Hester, bedankt voor al je meedenken en meeleven met alle keratinocyten in 
voor en tegenspoed. Jij begreep als geen ander dat kera’s alleen meewerken als je 
ze vertroetelt en met ze praat. Lars, ook al heb je een totaal andere 
onderzoeksrichting, meepraten over micro arrays ging al snel goed door je lieve 
vriendin en zeer aanstaande vrouw Esther. We hebben ook buiten het lab een hoop 
lol gehad en ik hoop dat we binnenkort in rustiger tijden het sporten weer op kunnen 
pakken. Uiteraard zullen we met het hele ploegje blijven schaatsen, zodat we in de 
Skeeve skaets weer een ‘werkbespreking’ kunnen houden. We zouden die biertjes 
eigenlijk moeten declareren. Ook alle andere collega KNO-AIO’s: Pontus, Asaf, 
Jantien, Tieneke, Bernard, Peggy, Lisa en Maria. Bedankt voor alles en ik wens jullie 
allen heel veel succes met de afronding van jullie eigen promotie.  
Ook dank aan al mijn hard werkende labmaatjes en toenmalige collega’s Arjen, 
Henrique, Thijs, Michiel, Marianne, met in het bijzonder Janny voor alle p16 
kleuringen en Aafke en Marijke voor het afronden van mijn ‘never-ending’ 
kweekproeven en het behalen van de 100 celdelingen!  
Al mijn studenten: Saman, Geert, Nadia, Johan en Eva. Bedankt voor jullie 
onnoemlijke inzet en het zetten van jullie tanden in het model-systeem. Ik heb met 
veel plezier met jullie gewerkt en hopelijk houden we contact. De meeste van jullie 
zijn in het onderzoek gebleven en ik hoop jullie later nog als groot onderzoeker te 
treffen.  
Mijn collega’s bij de Pathologie, Renske, Peter, Saskia, Bart en Debbie. Jullie zijn de 
beste HPV-speurders ter wereld en gelukkig hebben jullie veel van die HPV “know-
how” met mij willen delen. Ik ben blij dat onze samenwerking tot meerdere 
hoofdstukken heeft geleid. Hopelijk in de toekomst nog meer. Renske, ik betreur het 
nog steeds dat je bent verhuisd naar Aalsmeer. Ondanks dat we vaak stevig 
moesten doortrappen om op tijd bij de kinderopvang te zijn, hadden we toch nog 
adem genoeg voor goede gesprekken.  
Dan mijn vroegere en huidige collega’s bij de Micro-array Core Faciliteit (MACF) en 
Tumor Profiling Group (TP). In den beginne met Bauke, Paul Eijk, Paul van den 
IJssel, Sandra, Beatriz, Cindy en Marianne. Bedankt voor jullie hulp met het opzetten 
van de 5K BAC array en de eerste array experimenten. Tegenwoordig zijn Danielle, 
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Josien, François, Dirk, Jolanda, Ulrike met nog altijd Paul en Bauke de MACF 
kernploeg. Jullie ook bedankt voor jullie interesse en vele adviezen bij de laatste 
loodjes. Onlosmakelijk verbonden aan de arrays zijn natuurlijk ook de heren van de 
‘sophisticated analysis’; Mark, Wessel en Sjoerd. Bedankt voor al jullie hulp met 
analyseren en leerzame samenwerking. Ik hoop nog lang met jullie te kunnen 
werken.  
Ook nog mijn collegae bij de Hematologie, met in het bijzonder Pauline, Jacqueline 
en mijn goede vriend en vervolg BVF-er Fedor. Het was leuk om met jullie de labs te 
delen. Ik wil jullie danken voor alles en nog wat, zoals het doornemen van SOP’s, het 
ontwerpen en inrichten van de CCA laboratoria en nog veel meer. 
Vrienden en kennissen vragen zich wel eens af. Leeft die jongen nog? Al was ik 
sowieso nooit goed in het onderhouden van contacten, nu heb ik me de laatste jaren 
toch echt verstopt. Aan iedereen die ik de laatste jaren verwaarloosd heb, bij dezen 
mijn excuses. Ik hoop het nu weer helemaal goed te gaan maken.  
Lieve pa en ma, wat ben ik jullie dankbaar voor jullie ondersteuning en alle 
donderdagen dat jullie helemaal uit Venlo zijn komen rijden om op jullie kleinkinderen 
te passen. Allemaal zodat ik in de bibliotheek van Osdorp mijn laatste hoofdstukken 
kon schrijven. Jullie deden het zichtbaar graag en de kinderen hadden altijd een 
gouden dag. Lieve Tiny en Wiel, ook jullie bedankt voor alle keren dat jullie 
ingesprongen zijn als er zich in eens een kindergriepje de kop op stak. Vooral de 
vele treinreizen van Tiny vanuit Venlo naar Amsterdam om eventjes te kunnen 
genieten van je kleinkinderen, en dan diezelfde avond weer terug te gaan, spreken 
boekdelen. Bart en Tanja en Bob en Sabine, hartelijk dank voor jullie interesse, steun 
en begrip. Bart, jouw promotie was een prachtig voorbeeld en bedankt voor de 
peptalk. 
Iedereen weet dat kinderen krijgen en een promotieonderzoek doen een onmogelijke 
combinatie is. Of je promotie legt het loodje of je relatie krijgt een dreun. Lieve 
Nicolle, wat ben ik blij met jou en wat heb ik me vaak schuldig gevoeld, omdat ik je 
weer moest teleurstellen. Of ik kwam laat thuis of ik zat tijdens de kerst mijn andere 
kinderen (de keratinocyten) te vertroetelen. Ik ben ongelofelijk blij dat je in mij bent 
blijven geloven, ondanks dat je altijd tegen een labtop moest praten of me verwenste 
als de kinderen midden in de nacht wakker werden van mijn geratel op het 
toetsenbord. Gelukkig, aan alles komt een eind, al duurt het soms iets langer dan 
gehoopt. Zonder jou had ik dit nooit kunnen doen en je bent de basis van ons 
gezinnetje. Lieve Ghislaine en Philine. Wat zijn jullie mooie meiden! Mijn trots is 
werkelijk onbeschrijfelijk. Ghislaine, je hebt vanaf jouw eerste dag een rol gespeeld in 
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mijn onderzoek. Je kwam namelijk op de dag dat ik eigenlijk mijn “VICI-evening 
lecture” moest presenteren. Daarna heb je heel wat proefjes in het weekend 
meegedaan. Eerst vanuit de kinderwagen spelend met kweekflesjes, later crossend 
met een rolstoel door de verlaten gangen van de poli of CCA. Het kan niet anders of 
ik heb wat onderzoeker-genen in je losgemaakt. Lieve Philine, ook jij bent een 
onderzoekster pur sang. Wat jij thuis al niet bij elkaar weet te gooien…., ik hou mijn 
hart vast voor de toekomst. Dank jullie wel voor het direct te laten vergeten waar ik 
allemaal mee bezig ben, zodra ik de deur thuis binnenstap. Jullie drieën zijn mijn 
alles!  
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